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1 GENERAL INTRODUCTION TO THE THESIS 
1.1 General Background 
The prevention of diseases by vaccination is one of the most significant medical 
achievements of mankind. More than 3 million deaths per year are currently prevented 
by vaccines [Ulmer et al., 2006]. Antiviral vaccines garner the largest share of the 
market with nineteen billion dollars and a positive economic impact of about a billion 
dollars per year [Fox, 2007].  
The most potent vaccines used in the past decades consisted of live attenuated 
or inactivated forms of whole pathogens [Russo et al., 1997;  
Vollmar et al., 2005]. Although inactivated and attenuated vaccines are relatively safe, 
there is a small but present risk of reversion to virulent, aggressive phenotypes in vivo 
which can cause disease [Russo et al., 1997]. This was observed for the Sabin 
attenuated poliovirus vaccine [Murdin et al., 1996]. Additionally, non-infectious 
subunits of pathogens might be poorly immunogenic and might have to be formulated 
with immune-stimulating adjuvants [Kaufmann, 2004]. Unfortunately, many potent 
adjuvants are rather toxic or at least painful and are not allowed in human use  
[Singh et al., 1999].  
Thus, significant efforts have been taken to develop more potent but safer 
vaccines and adjuvants with improved compatibility to humans. A new class of 
vaccines of growing interest are virus-like particles (VLP). They consist of one or 
several viral proteins, recombinantly expressed in cell culture systems, which 
spontaneously assemble into supramolecular, highly repetitive, icosahedral or rod-like 
structures. Of capital importance is that VLP do not contain any genetic information of 
the virulent phenotype which renders the replication in the host impossible  
[Kaufmann, 2004].  
Due to their particular structure with highly repetitive, organised epitopes on their 
surface, VLP are able to induce strong and long-lasting humoral and cell-mediated 
immune responses in the absence of adjuvants [Lechner et al., 2002;  
Kaufmann, 2004].  Several viral antigens have been expressed as VLP and have 
been tested in clinical trials, including some that were recently approved for human 
use (Table 1.1.1). The high economic value of this new class of vaccines was 
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demonstrated by Gardasil® (Merck & Co., Inc.), a vaccine for the prophylaxis of 
human papillomavirus (HPV) infection, which achieved blockbuster status within the 
first year of approval°.  
Table 1.1.1 Commercialized VLP based vaccines and selection of VLP vaccines recently tested in 
clinical trials. 
Vaccine Indication 
Stage of 
clinical 
development 
Company or 
institute 
HBsAg VLP (Engerix-B®) Prophylactic B cell vaccine for HBV infection Approved GlaxoSmithKline* 
HPV L1 capsid VLP: 
6 / 11 / 16 / 18 (Gardasil®) 
Prophylactic B cell vaccine 
for HPV infection Approved Merck & Co., Inc.
# 
HPV L1 (16 / 18) 
capsid VLP (Cervarix®) 
Prophylactic B cell vaccine 
for HPV infection Approved GlaxoSmithKline* 
Norwalk virus capsid protein 
VLP (NVCP-VLP) 
Prophylactic B cell vaccine 
for NV infect. gastroenteritis 
Phase I 
completed 
Baylor College of 
Medicine& 
Nicotine derivative covalently 
linked to ImmunodrugTM carrier 
Qbeta (bacteriophage Qb 
capsid VLP) (NIC002) 
Therapeutic B cell vaccine 
for smoking addiction 
Phase I and II 
completed 
Cytos 
Biotechnology AG+ 
(in collaboration 
with Novartis) 
Chemically synthesized 
angiotensin II coupled to 
ImmunodrugTM carrier Qbeta 
(CYT006-AngQb) 
Therapeutic B cell vaccine 
for treatment of hypertension 
Combined 
phase I / II 
completed 
Cytos 
Biotechnology AG+ 
Peptide of TNF-α covalently 
linked to ImmunodrugTM carrier 
Qbeta (CYT007-TNFQb) 
Therapeutic B cell vaccine 
for treatment of psoriasis 
Combined 
phase 
I / II ongoing 
Cytos 
Biotechnology AG+ 
ImmunodrugTM carrier QbG10 
(Qb capsid VLP filled with 
immunostimulatory DNA 
sequence G10)  
(CYT003-QbG10) 
Therapeutic T cell vaccine 
for treatment of perennial 
allergy to house dust mite 
and / or cat 
Phase I and II 
completed 
Cytos 
Biotechnology AG+ 
Melan-A/MART-1 protein 
coupled to the ImmunodrugTM 
carrier QbG10 
(CYT004-MelQbG10) 
Therapeutic T cell vaccine 
for treatment of malignant 
melanoma 
Phase I and II 
completed 
Cytos 
Biotechnology AG+ 
ImmunodrugTM carrier QbG10 
together with grass pollen 
allergen 
(CYT005-AllQbG10) 
Therapeutic T cell vaccine 
for treatment of grass pollen 
allergy 
Phase I and II 
completed 
 
Cytos 
Biotechnology AG+ 
 
______________________________________________________________ 
° http://blog.vaccineethics.org/2007/10/gardasil-rotateq-sales-top-merck.html 
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Vaccine Indication 
Stage of 
clinical 
development 
Company or 
institute 
Fragment of the β-amyloid-
protein coupled to 
ImmunodrugTM carrier Qbeta 
(CAD106) 
Therapeutic B cell vaccine 
for treatment of Alzheimer’s 
disease 
Phase I 
ongoing 
Cytos 
Biotechnology AG+ 
(in collaboration 
with Novartis) 
HIV p17 / p24:Ty VLP 
Therapeutic T cell vaccine 
for the treatment of HIV 
infections 
Phase I 
completed 
National Institute of 
Allergy and 
Infectious  Diseases 
(NIAID)~ 
HPV 16 L1 / E7 VLP: chimeric 
HPV capsid / cytotoxic T cell 
(CTL) epitope VLP (CVLP) 
Therapeutic T cell vaccine 
for cervical dysplasias 
Phase I and II 
completed 
MediGene AG§ (in 
collaboration with 
Virionics Corp.) 
H5N1 VLP influenza vaccine 
 
Prophylactic B cell vaccine 
for H5N1 clade 2 influenza 
virus infection 
Phase I and II 
ongoing Novavax
$ 
HPV L1 capsid VLP: 
6 / 11 /16 / 18 
Prophylactic B cell vaccine 
for HPV infection in HIV 
infected children 
Phase I 
completed 
phase II 
ongoing 
NIAID~ 
*   http://www.gsk.com   #   http://www.merckvaccines.com  +   http://www.cytos.com  
§   http://www.medigene.de  ~   http://www.niaid.nih.gov  &   http://www.bcm.edu 
$   http://www.novavax.com 
 
Additionally, VLP not only act as carriers of immunological epitopes derived from 
microbial pathogens, but they have also been successfully used to present  
self-antigens or non-immunogenic small molecular weight molecules to the immune 
system and to overcome B cell tolerance [Lechner et al., 2002]. Based on this 
principle, Cytos Biotechnology AG developed several therapeutical vaccines based on 
VLP built from recombinantly expressed coat proteins of the bacteriophage Qb. For 
example, the therapeutical treatment of chronic diseases such as hypertension  
(e.g. angiotensin as antigen) [Ambuehl et al., 2007] and drug addiction like smoking 
(e.g. nicotine as hapten) [Maurer et al., 2006], two of the most important preventable 
causes of premature death worldwide [Mackay, 2004], are attained.  
However, for commercialization, the development of stable and convenient 
formulations is essential. In this context two major challenges of VLP vaccines have to 
be addressed: (1) VLP as highly complex protein drugs might be prone to many 
chemical and physical degradation pathways which can lead to ineffectiveness of the 
drug and / or side reactions [Manning et al., 1989; Brandau et al., 2003;  
Hermeling et al., 2004; Wang, 2005]; (2) To reach adequate immune responses 
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vaccines have to be applied at least two to three times which might lead to poor 
patient compliance [Aguado, 1993; Sinha et al., 2003].  
Although a liquid formulation is preferred in terms of cost and convenience for the 
end user, many vaccines are not stable enough in liquid solutions to meet shelf-life 
requirements. Thus, in order to overcome stability issues often dried forms are 
produced. Freeze-drying is the most widely used technique for this purpose. [Scott  
et al., 1976; Adebayo et al., 1998; Rexroad et al., 2002; Sarkar et al., 2003; Zhai  
et al., 2004; Abdul-Fattah et al., 2007]. However, during freeze-drying the drug is 
exposed to diverse stress factors, ascribed to freezing and drying, which can cause 
significant loss of activity. Thus, the proper choice of the freeze-drying process and 
the accurate selection of stabilizing excipients is inevitable [Franks, 1998; Nail et al., 
2002; Tang et al., 2004].  
With the intention to improve the effectiveness of a vaccine and patient 
compliance tremendous efforts have been taken during the last decades to develop 
single dose vaccine devices. Although, plenty of promising systems like implants, 
microspheres, and in-situ forming systems have been investigated [Cohen et al., 
1994; Sanchez et al., 1996; O'Hagan et al., 1998; Cleland, 1999; Dorta et al., 2002; 
Eliaz et al., 2002; Jaganathan et al., 2005; Katare et al., 2006], no controlled release 
vaccine formulation has been marketed so far. The limited success can be related to 
stress factors occurring during manufacture of the specific devices, storage 
instabilities, and the environmental changes during release. Nevertheless, due to the 
strong demand for stable, single dose vaccines further work in this field is valuable. 
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1.2 Aim and Organization of the Thesis 
One main objective of the thesis was the development of stable, freeze-dried 
formulations for a specific VLP based vaccine, NicQb, meeting the standard 
requirements necessary for large scale clinical studies and commercial use.  
In this context the development of an asymmetrical flow field-flow fractionation 
(AF4) method, as a new powerful tool, in the investigation of the physical stability of 
VLP is described (Chapter 3). 
In order to determine adequate formulations all steps of a complete formulation 
development study, i.e. preformulation, freeze-drying and long-term stability studies 
were conducted. The effect of parameters like pH and salt concentration, and various 
excipients on the stability of the drug were investigated. Additionally, the biological 
activity of the drug in the final freeze-dried form was assessed (Chapter 4). 
The second goal of the thesis was the development of sustained release devices 
for VLP. For this purpose, preliminary studies with PLGA and lipid based implants as 
surrogate formulations were carried out and their efficacy in vivo was assessed. Due 
to the inconvenient route of application and unsatisfactory stability of the target VLP in 
these devices PLGA microcapsules with an oily inner core as potentially improved 
formulation were scrutinized (Chapter 5). 
 
General Introduction 
___________________________________________________________________________ 
 
6 
 
1.3 References 
Adebayo, A. A., Sim-Brandenburg, J. W., Emmel, H., Olaleye, D. O., and Niedrig, M.; 
Stability of 17D yellow fever virus vaccine using different stabilizers; Biologicals, 
1998, 26(4), 309-316 
Aguado, M. T.; Future approaches to vaccine development: Single-dose vaccines 
using controlled-release delivery systems; Vaccine, 1993, 11(5), 596-597 
Ambuehl, P. M., Tissot, A. C., Fulurija, A., Maurer, P., Nussberger, J., Sabat, R., Nief, 
V., Schellekens, C., Sladko, K., Roubicek, K., Pfister, T., Rettenbacher, M., 
Volk, H. D., Wagner, F., Mueller, P., Jennings, G. T., and Bachmann, M. F.; A 
vaccine for hypertension based on virus-like particles: preclinical efficacy and 
phase I safety and immunogenicity; Journal of Hypertension, 2007, 25(1), 63-72 
Abdul-Fattah, A. M., Truong-Le, V., Yee, L., Pan, E., Ao, Y., Kalonia, D. S., and Pikal, 
M. J.; Drying-Induced Variations in Physico-Chemical Properties of Amorphous 
Pharmaceuticals and Their Impact on Stability II: Stability of a Vaccine; 
Pharmaceutical Research, 2007, 24(4), 715-727 
Brandau, D. T., Jones, L. S., Wiethoff, C. M., Rexroad, J., and Middaugh, C. R.; 
Thermal stability of vaccines; Journal of Pharmaceutical Sciences, 2003, 92(2), 
218-231 
Cleland, J. L.; Single-administration vaccines: controlled-release technology to mimic 
repeated immunizations; Trends in Biotechnology, 1999, 17(1), 25-29 
Dorta, M. J., Santovena, A., Llabres, M., and Farina, J. B.; Potential applications of 
PLGA film-implants in modulating in vitro drugs release; International Journal of 
Pharmaceutics, 2002, 248(1-2), 149-156 
Eliaz, R. E., and Szoka, F. C., Jr.; Robust and prolonged gene expression from 
injectable polymeric implants; Gene Therapy, 2002, 9(18), 1230-1237 
Fox, J. L.; Antivirals become a broader enterprise; Nature Biotechnology, 2007, 
25(12), 1395-1402 
Franks, F.; Freeze-drying of bioproducts: putting principles into practice; European 
Journal of Pharmaceutics and Biopharmaceutics, 1998, 45(3), 221-229 
Hermeling, S., Crommelin, D. J. A., Schellekens, H., and Jiskoot, W.; Structure-
Immunogenicity Relationships of Therapeutic Proteins; Pharmaceutical 
Research, 2004, 21(6), 897-903 
Jaganathan, K. S., Rao, Y. U. B., Singh, P., Prabakaran, D., Gupta, S., Jain, A., and 
Vyas, S. P.; Development of a single dose tetanus toxoid formulation based on 
polymeric microspheres: a comparative study of poly (-lactic-co-glycolic acid) 
versus chitosan microspheres; International Journal of Pharmaceutics, 2005, 
294(1-2), 23-32 
Katare, Y. K., and Panda, A. K.; Influences of excipients on in vitro release and in vivo 
performance of tetanus toxoid loaded polymer particles; European Journal of 
Pharmaceutical Sciences, 2006, 28(3), 179-188 
 
General Introduction 
___________________________________________________________________________ 
7 
 
Kaufmann, S. H. E.; Novel Vaccination Strategies; WILEY-VCH Verlag GmbH & 
Co.KGaA, 2004 
Lechner, F., Jegerlehner, A., Tissot, A. C., Maurer, P., Sebbel, P., Renner, W. A., 
Jennings, G. T., and Bachmann, M. F.; Virus-like particles as a modular system 
for novel vaccines; Intervirology, 2002, 45(4-6), 212-217 
Mackay, J., and Mensah, G. A.; The Atlas of Heart Disease and Stroke; WHO Press, 
2004 
Manning, M. C., Patel, K., and Borchardt, R. T.; Stability of protein pharmaceuticals; 
Pharmaceutical Research, 1989, 6(11), 903-918 
Maurer, P., and Bachmann, M. F.; Therapeutic vaccines for nicotine dependence; 
Current Opinion in Molecular Therapeutics, 2006, 8(1), 11-16 
Murdin, A. D., Barreto, L., and Plotkin, S.; Inactivated poliovirus vaccine: past and 
present experience; Vaccine, 1996, 14(8), 735-746 
Nail, S. L., Jiang, S., Chongprasert, S., and Knopp, S. A.; Fundamentals of 
freeze-drying; Pharmaceutical Biotechnology, 2002, 14, 281-360 
O'Hagan, D., Singh, M., and Gupta, R. K.; Poly(lactide-co-glycolide) microparticles for 
the development of single-dose controlled-release vaccines; Advanced Drug 
Delivery Reviews, 1998, 32(3), 225-246 
Rexroad, J., Wiethoff, C. M., Jones, L. S., and Middaugh, C. R.; Lyophilization and the 
thermostability of vaccines; Cell Preservation Technology, 2002, 1(2), 91-104 
Russo, S., Turin, L., Zanella, A., Ponti, W., and Poli, G.; What's going on in vaccine 
technology?; Medicinal Research Reviews, 1997, 17(3), 277-301 
Sanchez, A., Gupta, R. K., Alonso, M. J., Siber, G. R., and Langer, R.; Pulsed 
controlled-release system for potential use in vaccine delivery; Journal of 
Pharmaceutical Sciences, 1996, 85(6), 547-552 
Sarkar, J., Sreenivasa, B. P., Singh, R. P., Dhar, P., and Bandyopadhyay, S. K.; 
Comparative efficacy of various chemical stabilizers on the thermostability of a 
live-attenuated peste des petits ruminants (PPR) vaccine; Vaccine, 2003, 
21(32), 4728-4735 
Scott, E. M., and Woodside, W.; Stability of pseudorabies virus during freeze-drying 
and storage: effect of suspending media; Journal of Clinical Microbiology, 1976, 
4(1), 1-5 
Singh, M., and O'Hagan, D.; Advances in vaccine adjuvants; Nature Biotechnology, 
1999, 17(11), 1075-1081 
Sinha, V. R., and Trehan, A.; Biodegradable microspheres for protein delivery; Journal 
of Controlled Release, 2003, 90(3), 261-280 
Tang, X., and Pikal, M. J.; Design of freeze-drying processes for pharmaceuticals: 
practical advice; Pharmaceutical Research, 2004, 21(2), 191-200 
Ulmer, J. B., Valley, U., and Rappuoli, R.; Vaccine manufacturing: challenges and 
solutions; Nature Biotechnology, 2006, 24(11), 1377-1383 
 
General Introduction 
___________________________________________________________________________ 
 
8 
 
Vollmar, A., and Dingermann, T.; Immunologie; Wissenschaftliche Verlagsgesellschaft 
mbH, Stuttgart, 2005 
Wang, W.; Lyophilization and development of solid protein pharmaceuticals; 
International Journal of Pharmaceutics, 2000, 203(1-2), 1-60 
Wang, W.; Protein aggregation and its inhibition in biopharmaceutics; International 
Journal of Pharmaceutics, 2005, 289(1-2), 1-30 
Zhai, S., Hansen, R. K., Taylor, R., Skepper, J. N., Sanches, R., and Slater, N. K. H.; 
Effect of Freezing Rates and Excipients on the Infectivity of a Live Viral Vaccine 
during Lyophilization; Biotechnology Progress, 2004, 20(4), 1113-1120 
 
  
 
Materials and Methods 
___________________________________________________________________________ 
9 
 
2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Virus-Like Particles (VLP) 
All VLP used in this work were provided by Cytos Biotechnology AG, Schlieren, 
Switzerland, as liquid, frozen and stored at -80 °C until use.  
The VLP are derived from the coat protein of the bacteriophage Qb. The coat 
protein is recombinantly expressed in E. coli and assembles spontaneously in the 
bacterial cytoplasm to RNA stabilized VLP of about 30 nm diameter  
[Kozlovska et al., 1993]. Each VLP consists of 180 highly organized repetitive 
subunits of approximately 14 kDa which results in a theoretical molecular weight (MW) 
of the VLP of 2.5 MDa. The amino acid sequence and a model of the assembled 
Qb VLP based on the structure dissolved by crystallography  
[Golmohammadi et al., 1996] are depicted in Figure 2.1.1 and Figure 2.1.2, 
respectively.  
AKLETVTLGNIGKDGKQTLVLNPRGVNPTNGVASLSQAGAVPALEKRVTVSVSQPSRNRKNY
KVQVKIQNPTACTANGSCDPSVTRQAYADVTFSFTQYSTDEERAFVRTELAALLASPLLIDAID
QLNPAY 
Figure 2.1.1 Amino acid sequence of Qb VLP coat protein.  
 
 
Figure 2.1.2 Model of Qb VLP. 
 
Materials and Methods 
___________________________________________________________________________ 
 
10 
 
Each of the 180 VLP subunits comprises 7 lysine residues (Figure 2.1.1). Using 
chemical cross-linkers, antigens can be coupled covalently to the Qb VLP surface via 
the lysine residues (Qb platform, Figure 2.1.3 A). By presenting antigens in highly 
repetitive order to the immune system B-cells can be directly activated and strong 
antibody responses can be induced even against small, low molecular weight (lmw) 
haptens [Bachmann et al., 1993; Jegerlehner et al., 2002; Lechner et al., 2002]. 
Based on this immunological principle VLP based drugs can be used for example for 
the therapeutical treatment of chronic diseases such as hypertension (e.g. angiotensin 
as antigen) [Ambuehl et al., 2007] and drug addiction like smoking (e.g. nicotine as 
hapten) [Maurer et al., 2006].  
Furthermore, by packaging immunostimulatory nucleic acid sequences, so called 
cytosine-phosphate-guanosine motifs (CpGs), into antigen-decorated VLP cytotoxic  
T-cell induction in addition to the above described B-cell activation can be achieved 
(QbG10 platform, Figure 2.1.3 B) . The CpGs activate dendritic cells via stimulation of 
Toll-like receptor 9 consequently leading to a more pronounced activation of cytotoxic 
T-cells.  This second feature can be used to treat diseases such as cancer and 
chronical viral infections [Storni et al., 2004].  
 
 
Figure 2.1.3 Scheme of Qb (A) and QbG10 (B) platform. 
In this work four different types of VLP were used. Three were based on the 
above described Qb VLP platform, namely NicQb, AngQb and QbSAMSA, and one, 
QbG10p33, based on the VLP carrier vaccine platform QbG10.  
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NicQb 
NicQb is a therapeutic vaccine for the treatment of nicotine addiction. Nicotine is 
coupled to the VLP of RNA bacteriophage Qb via a succinyl linker to the lysine side 
chains of the Qb coat proteins [Maurer et al., 2005]. Vaccination with NicQb leads to 
the induction of nicotine specific antibodies. The antibodies bind nicotine (from inhaled 
tobacco smoke) in the blood and inhibit its passage to the brain, as antibodies 
normally cannot pass the blood brain barrier. Phase II clinical trials with NicQb have 
demonstrated that this vaccine is efficacious for smoking cessation and relapse 
prevention [Maurer et al., 2006].  
AngQb 
AngQb is a therapeutic vaccine for the treatment of hypertension. It consists of 
chemically synthesized angiotensin II (identical to human form) which is chemically 
cross-linked onto the surface of Qb VLP. The drug is designed to instruct the patient’s 
immune system to produce a specific anti-angiotensin II antibody response*. 
Angiotensin II is a potent vasoconstrictor and part of the renine-angiotensin-
aldosteron system, the main regulator of blood pressure [Mutschler et al., 2001]. 
Vaccination with AngQb is anticipated to induce antibodies that bind angiotensin II 
and thus blood pressure should be down regulated. In a phase IIa clinical trial the 
efficacy of the drug was proved [Ambuehl et al., 2007].  
QbG10p33 
QbG10p33 is a model VLP which consists of a model peptide p33 covalently 
bound to Qb VLP packed with CpG oligonucleotides [Storni et al., 2004]. QbG10p33 
was used as model VLP to investigate antibody response and T-cell induction.   
QbSAMSA 
QbSAMSA is a fluorescence labeled VLP. SAMSA fluorescein is covalently 
bound to the surface of Qb VLP. In this work the labeled VLP were used as model 
VLP for encapsulation into microcapsules. 
 
______________________________________________________________ 
* htttp://www.cytos.com 
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2.1.2 Fine chemicals 
Significant chemicals used in this work are listed in Table 2.1.1. All other 
chemicals were of at least analytical grade. 
Table 2.1.1 Significant fine chemicals. 
Reagent Producer Article number 
L-Histidine Merck KGaA (Darmstadt, Germany) 1.04352 
D-Mannitol Sigma-Aldrich Laborchemikalien GmbH (Seelze, Germany) 33440 
Mineral oil Sigma-Aldrich Chemie GmbH  (Steinheim, Germany) M1180 
Poly(vinyl alcohol) 
80 % hydrolyzed 
Sigma Aldrich Chemie GmbH  
(Steinheim, Germany) 360627 
Polyethylene glycol 3,350 Sigma Aldrich Chemie GmbH  (Steinheim, Germany) 88276 
Polyethylene glycol 6,000 Clariant GmbH (Sulzbach, Germany) 107926 
Polysorbate 20 Fluka Chemie GmbH (Buchs, Switzerland) 44112 
Resomer® RG 502 Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany) 60640667 
Resomer® RG 502 H Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany) 60640802 
Resomer® RG 503 Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany) 60640661 
Sesame oil 
refined 
Henry Lamotte GmbH  
(Bremen, Germany) 84260 
α, α-Trehalose  
dihydrate 
Ferro Pfanstiehl Lab., Inc.  
(Waukegan, IL, USA) T-104-1-MC 
Tristearin 
(Dynasan 118) 
Sasol GmbH 
(Witten, Germany) 106582 
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2.2 Methods 
2.2.1 Processing 
Handling of VLP solutions 
All VLP solutions were stored at -80 °C until use. Thawing was performed at 
25 °C in agitated water baths. Before using the active pharmaceutical ingredient (API) 
bulk material VLP solutions were generally filtered through 0.22 µm polyvinylidene 
difluoride (PVDF) syringe-driven filter units. 
Freeze-thawing (FT) 
VLP solutions were filled into standard Eppendorf reaction tubes (Eppendorf AG, 
Hamburg, Germany). Samples were frozen by placing the tubes in a refrigerator at 
-80 °C.  After a minimum of 3 hours the samples were thawed at ambient 
temperature. Freeze-thaw cycles were repeated for 5 times. 
Freeze-drying (FD) of VLP formulations and microcapsule formulations 
VLP formulations were prepared by mixing API bulk material with excipient stock 
solutions. After preparation, VLP formulations were sterile filtered through 
syringe-driven 0.22 µm PVDF filter units. Generally, aliquots of 600 µl of the final 
composition were transferred into 2R class I glass vials (Schott AG, Mainz, Germany) 
for freeze-drying.  The samples were freeze-dried either in an EPSILON 2-6D pilot 
scale freeze-drier or an EPSILON 2-12D freeze-drier (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode, Germany) (Figure 2.2.1) using three 
different protocols, A, B and C (Figure 2.2.2).  
A B
 
Figure 2.2.1 Freeze-driers: Epsilon 2-6D (A) and Epsilon 2-12D (B). 
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Figure 2.2.2 Freeze-drying cycles – VLP formulations. 
 
Materials and Methods 
___________________________________________________________________________ 
15 
 
Samples were frozen to -50 °C with a cooling rate of 1 °C / min if the freeze-drier 
EPSILON 2-12D was used. When using freeze-drier EPSILON 2-6D samples were 
first frozen to -40 °C at a freezing rate of 1 °C /min. Due to technical limitation the 
samples were then frozen to -50 °C at a cooling rate of 0.16 °C / min. Subsequently, 
the temperature was held at -50 °C for 3 hours. Protocol A comprises two primary 
drying steps, 20 hours at -35 °C and 10 hours at -20 °C, and a 10 hour secondary 
drying step at 20 °C at a pressure of 0.045 mbar. In protocol B, primary drying was 
conducted at -15 °C for 20 hours at 0.045 mbar and secondary drying at 40 °C for 
10 hours at 0.007 mbar. Protocol C was alike protocol 2 with a 2 hour annealing step 
at -15 °C. After annealing the samples were again frozen to -40 °C with a cooling rate 
of 1 °C / min and to -50 °C at a freezing rate of 0.16 °C / min. The temperature was 
held at -50 °C for further 3 hours before primary drying. After freeze-drying the 
chamber was vented with nitrogen and the vials were stoppered with 
polydimethylsiloxane (PDMS) and ethylenetetrafluoroethylen (ETFE) coated 
lyophilization stoppers (West Pharmaceutical Services, Inc., Lionville, PA, USA) under 
vacuum at 800 mbar. The samples were rehydrated with highly purified water to a 
volume being equivalent to the volume prior to lyophilization. 
 
Microcapsule formulations were freeze-dried with the EPSILON 2-6D pilot scale 
freeze-drier according to freeze-drying protocol D (Figure 2.2.3). Aliquots of about 
0.5 mL were transferred into 2R class I glass vials (Schott AG, Mainz, Germany), 
frozen to -30 °C at a cooling rate of 1 °C / min and held at -30 °C for 1 hour. Primary 
drying was conducted at -30 °C and 0.100 mbar for 6 hours and secondary drying at 
20 °C and 0.05 mbar for 10 hours. After freeze-drying the chamber was vented with 
nitrogen and the samples were stoppered with PDMS and ETFE coated lyophilization 
stoppers at 800 mbar.  
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Figure 2.2.3 Freeze-drying cycle – microcapsule formulations. 
Stability studies 
Stability studies were carried out at controlled temperature levels. The conditions 
applied were 2-8 °C, 25 °C / 60 % relative humidity (RH) and 40 °C / 75 % RH. VLP 
lyophilizates were stored in 2R class I glass vials either open or sealed with PDMS 
and ETFE-coated lyophilization stoppers. VLP solutions and oily suspensions were 
stored either in LoBind Eppendorf reaction tubes or in 2R class I glass vials, open or 
sealed with the above mentioned stoppers. 
In vivo study - NicQb lyophilizates  
(performed by Cytos Biotechnology AG, Schlieren, Switzerland) 
For bioactivity testing reconstituted lyophilizates and API bulk material were 
assessed. Groups of 10 female balb / c mice were immunized subcutaneously with a 
dose of 100 μg of vaccine. Mice were boosted after seven days with the same amount 
of drug. Sera were collected after another seven days and analyzed by Enzyme-linked 
Immunosorbent Assay (ELISA). ELISA analysis was carried out by measuring the 
specific anti-nicotine IgG titers of individual mice on RNase-nicotine conjugate. In 
brief, ELISA plates were coated overnight at 5 ± 3 °C with 4.25 µg / ml RNase-nicotine 
conjugate. After blocking, mouse serum dilutions were added to the plate and 
incubated for 2 hours at room temperature. Binding of  
NicQb-antibodies was detected by goat anti-mouse IgG-horseradish 
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peroxidase-conjugate after 1 hour incubation time. A pooled standard mouse serum 
was used to establish an anti-nicotine antibody standard curve. Data fitting of the 
standard curve was performed using a 4-parameter Marquardt fit. Titers of individual 
mice were determined from triplicate analysis of different dilutions. Individual 
measurements within the linear range of the ELISA curves were used for calculations. 
Manufacture of implants 
VLP loaded, PLGA or tristearin based implants with a total weight of each 25 mg 
were produced as follows: VLP lyophilizate (10 % of total mass), matrix materials 
PLGA or tristearin (80 - 86 % of total mass) and varying amount of further excipients 
(PEG and magnesium hydroxide, in sum 4 - 10 % of total mass) were ground in an 
agate mortar. Preparation was performed in a dry-nitrogen-purged glove box to 
prevent moisture uptake from the ambient atmosphere.  25 mg of this mixture were 
transferred into a compaction tool (3 mm diameter) and compressed for 15 seconds 
with a 5 ton hydraulic press (Maassen, Eningen, Germany) (Figure 2.2.4) at 2.0 kN.  
 
 
Figure 2.2.4 Hydraulic press and compacting equipment. 
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Release studies 
The implants were placed into LoBind Eppendorf reaction tubes together with 
1 mL release buffer. The samples were incubated at 37 °C at an agitation speed of 
40 rpm in a B. Braun Biotech International Certomat® IS chamber (Melsungen, 
Germany). After defined time intervals, release media were exchanged with fresh 
release buffer. The Qb coat protein content in the release medium was determined via 
RP-HPLC. Therefore, the VLP were first disassembled with dithiothreitol (DTT) and 
guanidine hydrochloride (GuaHCl). Specific samples were analyzed via SE-HPLC for 
VLP integrity. The release buffer consisted of 20 mM sodium phosphate buffer,  
0.01 % polysorbate 20 and 0.05 % sodium azide, pH 7.2. 
In vivo study – QbG10p33 implants  
(performed by Cytos Biotechnology AG, Schlieren, Switzerland) 
For bioactivity testing different PLGA and tristearin implant formulations 
containing 300 µg VLP and placebo implants (negative control) were assessed. 
Additionally, liquid VLP formulations (reconstituted QbG10p33 lyophilizates) 
containing 50 µg VLP were applied either 1 x or 3 x (weekly application) as positive 
control. The different formulations were administered to groups of 3 - 5 female  
C57BL / 6 mice. The implants were placed under isofluorane anesthesia after surgical 
incision in the subcutaneous neck tissue. The liquid formulation was applied 
subcutaneously. Sera were collected after 1, 2, 3, 4, 6, 9 and 12 weeks. Samples 
were analyzed either by ELISA to measure the specific anti-p33 IgG titers or by 
fluorescence-activated cell sorting (FACS) to investigate the activation of p33-specific 
CD8+ T cells. 
ELISA measurements were performed by using a robotic liquid handling system 
(Hamilton Bonaduz AG, Bonaduz, Switzerland). In brief, Elisa plates were coated for 
12 hours with 10 µg / ml p33-antigen coupled to RNase. Mouse serum dilutions were 
added to the plate and incubated for 2 hours. Binding of anti-p33-antibodies was 
detected by goat anti-mouse IgG-Fc-horseradish peroxidase-conjugate after 1 hour 
incubation time. ELISA titers from individual mouse sera were calculated using a 
4-parameter Marquardt fit. The titer corresponds to the dilution needed to achieve half 
maximal optical density (OD). 
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For FACS analysis samples were incubated for 20 min at 4 °C with Strep-Tactin 
PE-labeled (IBA, Göttingen, Germany) p33-H-2b tetrameric complexes and 
subsequently 30 min with anti-mouse CD8a APC Abs (BD PharMingen, San Diego, 
CA, USA). CD8+ p33 specific T cells were acquired in a FACSCalibur device and 
analyzed by using CellQuest software (BD PharMingen, San Diego, CA, USA). 
Manufacture of microcapsules 
Oil-Based PLGA microcapsule formulations were prepared by a solvent 
extraction / solvent evaporation process introduced by Sanchez et al.  
[Sanchez et al., 1996]. The microcapsules consisted of VLP-loaded oily droplets 
coated with PLGA. 
  VLP lyophilizate was suspended in mineral oil using a SpeedMixerTM DAC 150 
FVZ (Hauschild Engineering, Hamm, Germany). The resulting suspension was 
dispersed by vortexing in acetonitrile, ethyl acetate or mixtures of both solvents 
containing PLGA. Subsequently, the suspension was slowly added through a capillary 
with an inner diameter of 0.8 mm to 10 mL of a PVA solution (0.75 % w/v) under 
vigorous magnetic stirring. After stirring for 3 minutes additional 10 mL of the PVA 
solution were slowly added for extraction of the organic solvents. After stirring for 
further 10 minutes 30 mL water were added. Then, the emulsion was stirred for 30 
minutes to enable evaporation of the organic solvents and hardening of the 
microcapsules (Figure 2.2.5).  Afterwards, the microcapsules were collected by 
vacuum filtration and rinsed with hexane. The final microcapsule formulations were 
washed with water and lyophilized as described in “Freeze-drying (FD) of VLP 
formulations and microcapsule formulations”. 
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VLP lyophilizate Mineral oil
Lyophilizate suspension PLGA solution
PLGA Organic solvent
Dispersion of lyophilizate 
suspension in PLGA solution PVA solution
Intermediate microcapsules with
„unhardened“ PLGA shells
Further addition of PVA solution
Addition of water
Microcapsules with „hardened“
PLGA shells  
Figure 2.2.5 Schematic display of manufacture process of microcapsules. 
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2.2.2 Analytics 
Asymmetrical flow field-flow fractionation (AF4) 
AF4, a quasi chromatographic fractionation technique, is gaining more and more 
interest in protein and nanoparticle analytics. It is described to be capable of 
separating particles from a few nm up to several µm. By coupling AF4 to UV and 
multiangle laser light scattering (MALLS) detectors it became possible to quantify and 
determine the molecular weight of the specific fractions [Fraunhofer et al., 2004; 
Zillies, 2007]. 
AF4 measurements were performed using either the Wyatt standard separation 
channel (25 cm) or the short channel (18 cm) equipped with a 350 µm spacer, an 
Eclipse2 separation system (Wyatt Technology Europe GmbH, Dernbach, Germany), 
Agilent 1100 HPLC series isocratic pump, autosampler, degasser, UV detector 
(Agilent Technologies, Palo Alto, CA, USA) and the Wyatt DAWN EOS MALLS 
detector. Regenerated cellulose (MWCO of 10 kDa) was used as ultrafiltration 
membrane.  
NicQb samples were analyzed by applying separation method A (Figure 2.2.6) 
and using the standard channel. The running buffer consisted of sodium phosphate 
buffer (pH 7.0) and 150 mM sodium chloride. 
AngQb and QbG10p33 samples were analyzed by applying separation method B 
(Figure 2.2.6) and using the small channel. The running buffer used for AngQb 
analysis was composed of sodium phosphate buffer (pH 7.2) with 50 mM sodium 
chloride. For QbG10p33 samples sodium phosphate buffer (pH 7.2) was used.  
The VLP concentration was determined at 260 nm via UV detection. The MALLS 
detector was used for the determination of the average molecular weight of the VLP 
fractions.  
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Figure 2.2.6: AF4 cross-flow profiles for NicQb (A), CYT006-AngQb and QbG10p33 (both B).  
Size exclusion – high performance liquid chromatography (SE-HPLC) – VLP 
integrity 
SE-HPLC is an analytical method typically applied for the investigation of soluble 
protein impurities such as degradation products and low molecular weight aggregates 
[Skoog et al., 1992; Rodriguez-Diaz et al., 2005]. In this context VLP degradation and 
aggregation was determined by SE-HPLC on a Summit HPLC System  
(Dionex GmbH, Idstein, Germany) using a TSKgel G5000PWXL SE-HPLC column 
(Tosoh Biosience GmbH, Stuttgart, Germany). The running buffer was composed of 
20 mM sodium phosphate and 150 mM sodium chloride (pH 7.2). The analytics were 
performed at a flow rate of 0.8 mL / min with UV detection at 260 nm.  
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Dynamic light scattering (DLS) 
DLS is a standard analytical tool applied for the investigation of VLP impurities 
[Brandau et al., 2003; Shi et al., 2005]. Measurements were performed using a 
Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK). The 
polydispersity index (PI) and the hydrodynamic diameter were determined by using a 
NNLS (Non-Negatively Constrained Least Squares) fitting algorithm. The size 
distributions by intensity and volume were calculated form the correlation function by 
using the multiple narrow mode of the Dispersion Technology Software version 4.00 
(Malvern Instruments Ltd., Worcestershire, UK). 
Determination of zeta potentials 
Zeta potentials state electrostatic properties of particles in a dispersion medium 
[Leuenberger, 2002]. They were assessed with a Malvern Zetasizer Nano ZS 
(Malvern Instruments Ltd., Worcestershire, UK). Malvern DTS 1060 disposable cells 
were filled with VLP solutions and analyzed at 25 °C via the automatic measurement 
mode. 
Laser diffraction - particle size distribution 
The size of the PLGA microcapsules was determined by laser diffraction using a 
Horiba LA-950 (Retsch Technology GmbH, Haan, Germany) particle size distribution 
analyzer equipped with a 10 mL fraction cell. Values of RI = 1.49 and 
absorption = 0.000 were used as optical model. 
Light obscuration analysis – particulate matter  
The particulate matter was analyzed with a PAMAS SVSS-C40 light blockage 
system (PAMAS GmbH, Rutesheim, Germany). Particles were counted due to their 
obscuration of light and were classified into 16 different size ranges from > 1 µm up to 
> 200 µm. Briefly, measurements were carried out as follows: The measurement cell 
was flushed with particle free water and rinsed with 0.3 mL sample. Subsequently, two 
independent measurements of 0.1 mL were performed, respectively. Particles larger 
than 1 and 10 µm were counted, and the mean values of the referring particle 
numbers per mL were displayed.  
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Transmission electron microscopy (TEM)  
(performed by Prof. P. Wild at the Institute of Veterinary Anatomy and Virology, 
University of Zurich, Switzerland) 
VLP samples were analyzed in a transmission electron microscope CM12 
(Philips, Eindhoven, Netherlands) at 100 kV. Therefore, parlodion films mounted on 
300 mesh / inch were carbon coated by electron gun evaporation at 10-5 mbar in a 
vacuum unit BAE 121 (BalTec Maschinenbau AG, Pfäfficon, Switzerland). The VLP 
were adsorbed onto these coated films and negatively stained with uranylacetate 
(Sigma Aldrich Chemie GmbH, Buchs, Switzerland). Images were taken using a CCD 
low scan camera (Gatan Inc., Pleasanton, CA, USA). 
 Reversed phase-HPLC (RP-HPLC) - determination of free nicotine derivatives 
(performed by Cytos Biotechnology AG, Schlieren, Switzerland) 
The free nicotine derivatives hydroxymethyl-nicotine and succinyl-hydroxy-
methyl-nicotine were separated from NicQb by filtration at 14000 rcf in Nanosep 3K 
Omega spin filters from PALL Corporation (Dreieich, Germany). The filtrate was 
analyzed by RP-HPLC on a Summit HPLC System (Dionex GmbH, Idstein, Germany) 
using a Hypersil BDS-C18, 4.0 x 125 mm, 5 µm column (Agilent Technologies 
Deutschland GmbH, Böblingen,  Germany).  A flow rate of 1.0 mL / min with UV 
detection at 260 nm was applied. An elution gradient was used, applying acetonitrile 
and a sodium dihydrogen phosphate / triethylamine buffer (pH 7.0) as eluents. The 
concentration of the nicotine derivatives was calculated from the regression of a 
nicotine standard curve. The values for free nicotine derivatives were given as 
percentage of total nicotine.  
RP-HPLC - determination of total nicotine  
(performed by Cytos Biotechnology AG, Schlieren, Switzerland) 
The nicotine moiety covalently linked to Qb VLP was quantitatively cleaved 
during 3 h incubation at 40 °C and pH > 11. Subsequently, proteins were precipitated 
with hydrochloric acid and removed by centrifugation. The concentration of the 
hydrolysis product hydroxymethyl-nicotine in the supernatant was determined as 
described above. 
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RP-HPLC – quantification of Qb coat proteins 
For the quantification of Qb coat proteins in liquid samples VLPs were first 
disassembled by reducing disulfide bonds with DTT (50 mM) and disrupting 
non-covalent interactions with guanidine hydrochloride (2 M). Disassembled samples 
were centrifuged to remove particulate matter. The supernatant was analyzed by 
RP-HPLC on a Summit HPLC System (Dionex GmbH, Idstein, Germany) using a 
Jupiter C4, 300 A, 150 x 4.6 mm, 5 µm column (Phenomenex,  Aschaffenburg, 
Germany). A flow rate of 1.0 mL / min with UV detection at 215 nm was applied. An 
elution gradient was used, introducing acetonitril (40 % v/v) and acetonitril (60 % v/v) 
as eluents under acidic conditions. The concentration of Qbeta coat protein was 
determined by external calibration with a VLP standard. 
Bioanalyzer – RNA integrity  
(performed by Cytos Biotechnology AG, Schlieren, Switzerland) 
The integrity of RNA in Qb VLP was analyzed either by Bioanalyzer or by 
SE-HPLC. For sample preparation VLP formulations were first homogenized with 
TRI-Reagent® (Lucerna Chem AG, Luzern, Switzerland), a combination of phenol and 
guanidine thiocyanate in a monophase solution used to inhibit RNase activity. After 
incubation for 5 minutes at ambient temperature BCP Phase Separation Reagent 
(Lucerna Chem AG, Luzern, Switzerland) was added. Thereby, the homogenate is 
separated into aqueous and organic phases. Afterwards the mixture was centrifuged. 
RNA remains exclusively in the aqueous phase, DNA in the interphase and proteins in 
the organic phase. RNA was precipitated from the aqueous phase by addition of 
isopropanol, washed with ethanol and dissolved in diethyl pyro-
carbonate (DEPC) - water. RNA was analyzed by using a 2100 Bioanalyzer (Agilent 
Technologies AG, Basel Switzerland) together with the RNA 6000 Nano assay 
(Agilent Technologies AG, Basel Switzerland).  The Agilent 2100 Bioanalyzer uses a 
combination of microfluidics, capillary electrophoresis, and fluorescent dyes that bind 
to nucleic acid to simultaneously evaluate both RNA concentration and integrity. The 
RNA pattern of the samples was compared to a corresponding standard.   
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SE-HPLC – RNA integrity  
(performed by Cytos Biotechnology AG, Schlieren, Switzerland) 
The VLP samples were prepared as described in “Bioanalyzer – RNA integrity”. 
RNA degradation was determined by SE-HPLC on a Summit HPLC System  
(Dionex GmbH, Idstein, Germany) using a TSKgel G5000PWXL SE-HPLC column 
(Tosoh Biosience GmbH, Stuttgart, Germany). The running buffer was composed of 
20 mM sodium phosphate and 150 mM sodium chloride (pH 7.2). The analytics were 
performed at a flow rate of 0.8 mL / min with UV detection at 260 nm. The retention 
time of the extracted RNA was determined relative to a tRNA standard analyzed in the 
same sequence.  
Gel electrophoresis (LDS-PAGE) – VLP degradation  
(performed by Cytos Biotechnology AG, Schlieren, Switzerland) 
LDS-PAGE and SDS-PAGE (lithium / sodium dodecylsulfate polyacrylamide gel 
electrophoresis) is a standard tool to separate different fractions of a protein sample. 
After denaturing the protein with LDS / SDS, protein species are separated according 
to their mass on a polyacrylamide gel. In general, protein species with low molecular 
weight diffuse faster through the gel than those with larger molecular weight. 
LDS / SDS-PAGE can be carried out under non-reducing or reducing conditions 
(addition of DTT resulting in the break-up of covalent disulfide bonds) [Dunn, 2000; 
Wang et al., 2006]. 
This method was used for the determination of degradation products of Qb coat 
proteins. VLP samples and a Qb standard were incubated with DTT solution 
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) and NuPage® LDS sample buffer 
(Invitrogen Life Technologies Ltd, Paisley, UK). Thus, disassembling of VLP is 
enabled by the cleavage of disulfide bonds and non-covalent bonds. Invitrogen 
NuPage® 12% Bis-Tris gels and NuPage® MES LDS running buffer were used for 
separation of the samples in an Novex Xcell SureLock Mini-Cell (Invitrogen Life 
Technologies Ltd, Paisley, UK) connected to a BioRad Power Pac 300 power supply 
(Bio-Rad AG, Glattbrugg, Switzerland). Detection was carried out by silver staining 
with silver nitrate solution. SigmaMarker™ low range (6,500-66,000 Da) MW standard 
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(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) was run on each gel for 
estimation of molecular weights. Low molecular weight impurities and degradation 
products were detected. The intensity of bands of an apparent molecular weight 
smaller than the molecular weight of Qb coat protein monomer was compared to a Qb 
standard, applied at different concentrations to the same gel.  
Osmolality 
Osmolality measurements were conducted by using a Knauer Semimicro 
Osmometer Automatik (Knauer Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer 
GmbH, Berlin, Germany). The osmolality of liquid formulations and reconstituted 
lyophilisates was determined via reduction of the freezing point of the solution in 
comparison to pure water.  
Karl Fisher (KF) titration - determination of residual water content 
Residual moisture contents of the lyophilizates were determined by coulometric 
Karl Fischer (KF) titration using an Aqua 40.00 titrator with a headspace module 
(Analytic Jena AG, Halle, Germany). In brief, samples were heated in 2R glass vials to 
80 °C for at least 5 minutes. The vaporised water was transferred with nitrogen into 
the titration solution (Hydranal®-Coulomat AG, Sigma-Aldrich GmbH, Seelze, 
Germany), where its amount was determined. 
X-Ray powder diffraction (XRD) 
The morphology of lyophilizates was analyzed by XRD from 5-40 °2-θ, with steps 
of 0.05 °2-θ (2 s per step) on an XRD 3000TT X-ray diffractometer (Seiffert, 
Ahrenburg, Germany), equipped with a copper anode (40 kV, 30 mA, wavelength 
154.17 pm).  
Differential scanning calorimetry (DSC) 
DSC is used to study the glass transition of the maximally freeze-concentrated 
solutions (Tg’), the glass transition (Tg) and / or melting temperature of lyophilizates, 
and the crystallization behavior of amorphous excipients [Nail et al., 2002;  
Hawe, 2006]. Samples were analyzed on a Differential Scanning Calorimeter 204 
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Phoenix (Netzsch-Geraetebau GmbH, Selb, Germany) in cold-sealed aluminum 
crucibles. 
For the investigation of the Tg’ of liquid samples heating and cooling rates of 
10 °C / min were applied, in a range of -70 °C up to 20 °C. About 20 mg of the 
samples were analyzed. Tg’ (point of inflection) of the compositions was determined 
during the heating scan.   
For the investigation of dried samples 2-15 mg were used. Preparation was 
performed in a dry-nitrogen-purged glove box to prevent moisture uptake from the 
ambient atmosphere. In a first heating scan samples were heated from -20 to 90 °C at 
10 °C / min, cooled to -20 °C at 10 °C / min and again heated in a second heating 
scan from -20 °C to 170 °C at 10 °C / min. Tg (point of inflection) of trehalose, melting 
temperature (peak) of mannitol and crystallization of amorphous mannitol were 
determined from the heating scans.  
Light microscopy 
Aliquots of 10 to 20 µL microcapsule formulations were pipetted on a glass object 
holder plate and were covered with a glass cover slide. The samples were assessed 
using a Nikon Labophot microscope (Nikon Instruments Inc., Melville, NY, USA), 
equipped with CFW 10x oculars and 4x, 10x, 20x and 40x objectives, respectively. 
Pictures were taken using a JVC TK-C1380 digital camera (JVC Deutschland GmbH, 
Friedberg, Deutschland). Microcapsule sizes were assessed by measuring the 
diameters of representative microcapsules by applying the calibrated JVC Digital 
Screen Measurement Comet software. 
Scanning electron microscopy (SEM) 
The morphology and structure of the freeze-dried microcapsules was analyzed 
with a Field Emission Scanning Electron Microscope Joel JSM-6500F (Joel Inc., 
Peabody, MA, USA). Therefore, microcapsules were first cut with a Mikrotom-
Kryostat-HM500 microtome (MICROM Laborgeräte GmbH, Waldorf, Germany). 
Briefly, microcapsule samples were frozen on the sample holder pin of the microtome, 
cut, lyophilized and examined by SEM.  
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Samples were fixed with a double-sided adhesive carbon tape (Bal-Tec AG, 
Balzers, Liechtenstein) to a custom made brass stub. The fixed samples were 
sputtered with carbon (Bal-Tec AG, Balzers, Liechtenstein) under vacuum for 
approximately 2 minutes inside a MED020 sputtering device (Bal-Tec AG, Balzers, 
Liechtenstein). Subsequently, the sputtered samples were analyzed.  
Confocal laser scanning microscopy (CLSM) 
Aliquots of 10 to 20 µL of the FITC labeled VLP microcapsule formulations were 
pipetted on a glass object holder plate and were covered with a glass cover slide. The 
samples were assessed using a Zeiss LSM 510 Meta fluorescence confocal laser 
scanning microscope (Zeiss Microscope Systems, Jena, Germany) equipped with a 
C-Apochromat 40x / 1.2 W Korr objective. For excitation of the fluorophore the 488 nm 
line of an Ar laser was used. The CLSM pictures were analyzed with the Zeiss LSM 
Image Browser software (Zeiss Microscope Systems, Jena, Germany). 
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3. AF4 AS NEW ANALYTICAL TOOL FOR THE 
INVESTIGATION OF THE PHYSICAL STABILITY 
OF VLP  
3.1 Introduction 
For the development of virus-like particle (VLP) based pharmaceutical products 
the application of reliable analytical tools is of great importance. For quality control 
purposes the methods need to be sufficiently sensitive to detect and quantify even 
small varieties between different API bulk materials, and varying formulations upon 
manufacture and storage. For the assessment of physical properties of viruses and 
virus-like particles three main techniques are established: (1) Transmission electron 
microscopy (TEM) [Vogt et al., 1999; Casini et al., 2004; Hansen et al., 2005],  
(2) Dynamic light scattering (DLS) often referred to as photon correlation 
spectroscopy (PCS) or quasi-elastic light scattering (QELS) [Santos et al., 1996; 
Brandau et al., 2003; Shi et al., 2005] and (3) Size exclusion chromatography  
(SE-HPLC) [Zlotnick et al., 2000; Rueda et al., 2000; Schmidt et al., 2000]. The 
utilization of TEM may be ascribed to the high resolution enabling accurate particle 
analysis. Inherent drawbacks of this technique are random sampling – instead of an 
overall sample analysis – and time consuming preparation and measurement 
procedures. DLS is described as a powerful, fast, non-destructive method for the 
determination of the average hydrodynamic radii, and size distributions of particles in 
their natural liquid environment. Thereby, increasing average sizes and polydispersity 
indices indicate aggregation of the particles [Griffin et al., 1993]. However, the size 
resolution is rather low and the obtained size distribution is rather inaccurate; the 
particles must differ in radius by about twofold to be resolved. Furthermore, the 
accurate quantification of different particle fractions is not feasible [Stock et al., 1985; 
Jiskoot et al., 2005]. SE-HPLC represents the gold standard for the analysis of the 
physical stability of proteins and is also used for the characterization of large 
biomolecules like virus-like particles. The drawbacks of SE-HPLC are its limited 
resolution capacity of especially high molecular weight molecules and the fact that 
only the analysis of soluble aggregates is possible [Litzen et al., 1993]. Consequently, 
for formulation development studies there is a strong need for a more sensitive 
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analytical tool that allows separation, characterization and quantification of different 
VLP fractions.  
Field-flow fractionation (FFF) was introduced in 1966 as a new versatile 
technique for the separation and characterization of high-molecular-weight molecules 
and particles [Giddings, 1966]. Since then various FFF techniques like sedimentation 
FFF, thermal FFF, electrical FFF, flow FFF and asymmetrical flow FFF (AF4) have 
been developed as reviewed recently by Fraunhofer et al. [Fraunhofer et al., 2004] 
and Reschiglian et al. [Reschiglian et al., 2005]. Among these, AF4 is described as 
the most versatile and widely used. The theory and basic mechanisms of AF4 are 
discussed in detail elsewhere [Wahlund et al., 1987; Schimpf, 2000; Fraunhofer et al., 
2004; Kowalkowski et al., 2006] and are thus only summarized in brief. In Figure 3.1.1 
the principle of separation is illustrated.  
 
 
Figure 3.1.1: Separation principle of AF4. 
A sample is injected into the hollow channel, which is at the downside 
(“accumulation wall”) limited by an ultrafiltration membrane with a certain MWCO 
(open for solvent, but not for species to be analyzed). After a focusing step, samples 
are eluted by a parabolic channel flow. At the same time, a cross-flow perpendicular 
to the carrier flow is applied which “pushes” the dispersed particles in the direction of 
the accumulation wall, where the cross-flow exits the channel via the membrane. 
Thereby, analytes are partitioned into regions with different flow velocities in 
dependence of their diffusion properties. In essence, the larger a particle, the smaller 
its diffusion coefficient acting in opposite direction than the convection from the  
cross-flow. Thus, the larger a particle, the stronger it is influenced by the cross-flow 
and the longer it is retained in the channel. As a consequence, smaller particles elute 
faster than larger ones. Due to the open architecture of the separation channel 
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particles in the size range from several nanometers up to a few microns are 
accessible for separation by field-flow fractionation [Giddings, 1993].  
During the last decades AF4 has gained more and more attention and was 
successfully applied for example for the analysis of the size and size distribution of 
monoclonal antibodies [Litzen et al., 1993], liposomes [Moon et al., 1993], lipid / DNA 
complexes [Lee et al., 2001], nanoparticles [Jores et al., 2004; Zillies, 2007], and 
viruses [Thielking et al., 1998]. Additionally, by coupling this technique with a 
multiangle laser light-scattering detector (MALLS) it became possible to obtain the 
molecular weight distributions of the fractionated species [Thielking et al., 1998; 
Wyatt, 1998; Fraunhofer et al., 2004]. 
In this context, it was the objective of the present work to develop an AF4 method 
as alternative tool for the analysis of VLP formulations and to investigate whether AF4 
can provide a better insight into VLP compositions than DLS and SE-HPLC.  
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3.2 Results and Discussion 
The VLP NicQb was used for the development of the AF4 method on an Eclipse2 
AF4 system (Wyatt Technology Europe GmbH, Dernbach, Germany) equipped with 
the “standard channel (25 cm)” (see chapter 2). The separation efficiency of an AF4 
method can be affected by manifold parameters like channel height, membrane 
material and molecular weight cut-off, eluent composition, focusing time, channel flow 
and cross-flow profile, and applied drug amount [Schimpf, 2000]. In preliminary 
experiments the following parameters were determined as fixed: 
 
a)  Spacer – 350 µm 
b) Eluent – 20 mM sodium phosphate buffer (pH 7.0) with 150 mM sodium 
chloride 
c)  Ultrafiltration membrane molecular weight cut-off – 10 kDa 
d) Channel flow – 1.5 mL / min 
e)  VLP amount – 20 µg 
3.2.1 Selection of Membrane Material 
First, the impact of the membrane material on the separation of VLP was 
analyzed.  The proper selection of the membrane material is important because 
during intensive focusing and during separation at high initial cross-flow rates the 
analyte is accumulated at the membrane, and thus adsorption phenomena can occur 
[Schimpf, 2000]. In this context regenerated cellulose, cellulose triacetate and 
polyethersulfone membranes were assessed. The cross-flow was kept at 2.0 mL / min 
for 30 minutes and was subsequently reduced to 0 mL / min within 10 minutes. The 
fractograms, depicted in Figure 3.2.1, revealed that regenerated cellulose was the 
most suitable membrane material. The fractionation of apparently diverse VLP 
fractions was feasible and the recovery of NicQb, determined from the UV signal, was 
96 %. Thus, it was assumed that almost no material was adsorbed onto the 
membrane. This might be related to the repulsion of the negatively charged NicQb 
(compare chapter 4) by the negatively charged cellulose residues. However, cellulose 
acetate, which is even more negatively charged, seemed not to be useful, as the 
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resolution of the distinctive peaks was worse and the recovery was clearly reduced 
(79 %) in comparison to regenerated cellulose. By using polyethersulfone two distinct 
VLP peaks with high resolution were obtained but a significant amount of NicQb was 
adsorbed to the membrane, the recovery was approximately 30 %. Hence, 
regenerated cellulose was determined as optimal membrane material. 
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Figure 3.2.1 Effect of membrane material on the separation of VLP: regenerated cellulose (1), 
polyethersulfone (2), and cellulose triacetate (3); all 10 kDa cut-off. 
3.2.2 Determination of Cross-Flow Profile  
The initially applied cross-flow of 2 mL / min at a channel flow of 1.5 ml / min 
exhibited good separation properties for NicQb. However, in the next step the effect of 
various cross-flows in the range of 0.5 up to 3.0 mL / min on the separation of NicQb, 
the peak symmetry and width was investigated. The resulting fractograms are 
displayed in Figure 3.2.2. It was demonstrated that increasing cross-flows led on the 
one hand to improved separation of apparently different VLP fractions but on the other 
hand to prolonged separation time and broadening of the specific peaks. The recovery 
of NicQb was higher than 95 % for all samples indicating that adsorption of NicQb to 
the membrane was not an issue. Finally, a cross-flow of 2.0 mL / min was chosen 
taking into account separation capacity and the symmetry of the particular peaks.  
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Figure 3.2.2 Effect of the varying cross-flow profiles on the separation of VLP: 0.5 mL / min (1), 
1.0 mL / min (2), 1.5  mL / min (3), 2.0  mL / min (4), 2.5  mL / min (5), and 3.0 mL / min (6) 
The main VLP peak was detected at about 23 minutes elution time. In order to 
further optimize the separation and to improve the elution of the “larger” VLP fractions 
the cross-flow profile was adjusted as described in the following. The cross-flow was 
reduced right after the elution of the main peak (26 min) from  
2.0 mL / min to 0.15 mL / min within 15 minutes and kept at this low flow for further 5 
minutes to enable the consecutive elution of larger VLP species. Subsequently, in a 
final step the cross-flow was completely deactivated to enable the elution of high 
molecular weight aggregates. The final cross-flow profile is illustrated in Figure 3.2.3. 
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Figure 3.2.3 AF4 cross-flow profile method A. 
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In Figure 3.2.4 the resulting fractogram with the UV signal and the calculated 
molar masses of the specific VLP species is displayed. It could be shown that the 
applied AF4 separation protocol was capable to resolve VLP compositions in VLP 
fragments, monomers, dimers, and oligomers / aggregates. Furthermore, by coupling 
the AF4 to UV and MALLS detectors, quantification and determination of the MW of 
the specific fractions was possible. For VLP monomers a MW about 3.5 MDa was 
determined. As the recombinantly produced VLPs have a lower amount of host cell 
RNA (about 25 %) [Bachmann et al., 2006] as compared to the native bacteriophage 
Qb (50 % RNA content) the data obtained fit well with the data from literature 
appointing the MW of the native phage to 4.2 MDa [Hohn et al., 1970].  Furthermore, 
the MW of the VLP dimers and trimers could be assigned to 6.3 MDa and 9.8 MDa, 
respectively (Table 3.2.1). Due to the high sensitivity of MALLS on high molecular 
weight analytes, molar masses for higher-order oligomers and high molecular weight 
aggregates could be calculated up to values > 108 Da. The presence of VLP 
monomers, dimers and trimers was confirmed by TEM analysis (Figure 3.2.5).   
Table 3.2.1  Molecular weights of specific NicQb fractions calculated from respective UV and 
MALLS signals (n = 3). 
 VLP monomer VLP dimer VLP trimer 
Molecular weight  
[MDa] 3.27 ± 0.02 6.27 ± 0.18 9.80 ± 0.82 
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Figure 3.2.4 UV signal and molecular weights of specific NicQb fractions calculated from respective 
UV and MALLS data. 
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Figure 3.2.5 TEM picture of NicQb. 
3.2.3 Repeatability 
The intended use of AF4 as a reliable tool for the quality control of VLP 
formulations demands high repeatability of the method. It was therefore of interest to 
study the repeatability of the determination of the relative amount of the different VLP 
species, expressed as the percentage of the total peak areas. A NicQb bulk  
(20 µg / injection) was, according to the instructions of the ICH guideline Q2 (R1), 
subjected to six independent measurements by AF4. The results, presented in  
Table 3.2.2., prove the repeatability of the applied AF4 method. Even for the VLP 
fractions present at low amounts (fragments and oligomers / aggregates) a relative 
standard deviation of less than 7 % was determined.   
Table 3.2.2 Repeatability of the AF4 analysis of NicQb (20 µg / injection). 
Fragments Monomer Dimer Oligomers / Aggregates Injection 
Relative peak areas [%] 
1 0.76 89.20 6.27 3.77 
2 0.82 89.25 6.05 3.88 
3 0.80 89.86 5.58 3.76 
4 0.82 90.00 5.66 3.52 
5 0.73 89.64 5.86 3.77 
6 0.80 89.49 6.47 3.24 
Average 0.79 ± 0.03 89.57 ± 0.32 5.98 ± 0.35 3.66 ± 0.23 
SDrel [%] 4.40 0.36 5.80 6.40 
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3.2.4 Comparison of AF4 to DLS and SE-HPLC 
 
After successful development of an AF4 method for VLP it was essential to 
compare its efficiency to the commonly used DLS and SE-HPLC techniques. For a 
better illustration of the differences of these three techniques consciously a 
formulation which was due to its excipient composition unsuitable for the stabilization 
of NicQb during freeze-drying and storage was selected. In the following DLS,  
SE-HPLC and AF4 data obtained for the NicQb formulation A17 (compare chapter 4, 
page 103 to 105) prior to freeze-drying (A) and for dried samples stored for 6 weeks at 
25 and 40 °C, respectively (B and C) are presented.  
The DLS results are shown in Figure 3.2.6. For the unstressed NicQb sample A 
the mean size of the VLP was determined at 30 nm with a very narrow size 
distribution as indicated by the polydispersity index of 0.10 and the width of the peak. 
The stressed NicQb samples revealed for increasing storage temperatures increasing 
mean sizes of the VLP and increasing PIs and peak widths. PI values of particulate 
systems higher than 0.1 denote the presence of several species [Griffin et al., 1993], 
which was related in this case to the formation of VLP oligomers and aggregates. As 
expected, DLS was not capable to resolve the different VLP fractions. 
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Figure 3.2.6 DLS size distribution by volume of NicQb sample A (black line), B (dark grey line), and 
C (light grey line).  
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The chromatograms obtained from the SE-HPLC analysis are depicted in  
Figure 3.2.7. It was obvious that the “stressed” samples B and C contained higher 
amounts of VLP oligomers and aggregates in comparison to the liquid formulation as 
for these samples a “shoulder” of the main peak appeared at a lower retention time.   
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Figure 3.2.7 Characterization of NicQb samples A (black line), B (dark grey line), and C (light grey 
line) by means of SE-HPLC.  
For a better understanding of the chromatogram SE-HPLC was coupled to a 
MALLS detector which enabled the determination of the molar mass distributions of 
the specific peaks (Figure 3.2.8). 
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Figure 3.2.8 Interpretation of SE-HPLC analysis of NicQb by coupling SE-HPLC to MALLS.  
 
AF4 as a New Analytical Tool for the Investigation of the Physical Stability of VLP 
___________________________________________________________________________ 
43 
 
The calculated molar masses indicated that the main peak not only consists of 
VLP monomer (~3.5 MDa) but additionally of VLP dimers (~7 MDa) and trimers  
(~10 MDa). The shoulder on the left side of the main peak comprises VLP oligomers 
and aggregates in a range of 107 up to 108 Da. The poor resolution of the different 
VLP fractions by SE-HPLC arises from the large size of the VLP which are already as 
monomers in the upper separation range of the used TSKgel G5000PWXL column 
(TSKgel PW Brochure*).  
By contrast AF4 was capable of resolving the different VLP fractions into VLP 
fragments, monomer, dimers, trimers and larger oligomers and aggregates  
(Figure 3.2.9). The amounts of the specific VLP fractions could be easily determined. 
The relative amounts of the VLP species, expressed as percentage of the total peak 
areas are given in Table 3.2.3 and are compared to the results obtained by SE-HPLC. 
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Figure 3.2.9 Characterization of NicQb samples A (black line), B (dark grey line), and C (light grey 
line) by AF4 coupled to MALLS.  
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Table 3.2.3 Characterization of NicQb samples A, B and C via AF4 and SE-HPLC. As VLP 
monomers, dimers and trimers were not resolved by SE-HPLC they were summarized in the table.  
Fragments Monomer Dimer Trimer Oligomers / Aggregates  Sample 
Relative peak areas [%] 
A 1.37 ± 0.11 86.93 ± 0.16 5.98 ± 0.12 1.93 ± 0.03 3.79 ± 0.13 
B 2.92 ± 0.13 60.84 ± 0.27 16.25 ± 0.13 7.9 ± 0.04 12.09 ± 0.31AF4 
C 6.11 ± 0.10 44.17 ± 0.80 16.16 ± 0.51 8.97 ± 0.42 24.60 ± 1.82
A 1.31 ± 0.08 98.54 ± 0.06 0.15 ± 0.02 
B 2.87 ± 0.03 95.49 ± 0.19 1.65 ± 0.22 SE-HPLC 
C 6.27 ± 0.14 88.09 ± 0.41 5.64 ± 0.27 
 
Concerning the amount of VLP fragments both methods revealed the same 
values whereas the determined amounts of VLP oligomers (larger than VLP trimers) 
and aggregates varied significantly. SE-HPLC analysis revealed far lower amounts of 
VLP oligomers and aggregates which might be explained by: (1) Deprivation of 
insoluble high molecular weight aggregates from analysis due to the exclusion limit of 
the SE-HPLC column, (2) Inaccurate integration of the oligomer / aggregate peak due 
to the poor resolution, (3) Abrasion of VLP oligomers and aggregates due to the 
harsher conditions (high shear forces) connected with SE-HPLC in comparison to AF4 
(no stationary phase), and / or (4) Generation of VLP aggregates during the focusing 
step of AF4 analysis. The deprivation of high molecular weight aggregates from SE-
HPLC analysis could be excluded because no clear decrease of the total peak area 
could be observed. VLP aggregation induced during AF4 analysis seemed to be 
improbable due to the high reproducibility of the results obtained but further 
investigations in this context are necessary. Hence, it was assumed that either the 
shearing degradation by the stationary phase of VLP aggregates and / or the 
inaccurate integration of the VLP aggregate peak might have led to these different 
results.  
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It was found that AF4 exceeds by far the capabilities of DLS and SE-HPLC with 
regard to the analysis of the physical stability of VLP. AF4 can be used for the 
separation of VLP compositions and quantification of the single fractions, where DLS 
renders only trends. However, in terms of a fast progress in formulation development 
the utilization of DLS as a fast and easily applicable method seemed to be reasonable 
to delimitate initially large numbers of formulations to the most promising ones.  
SE-HPLC exhibited only a poor capability of analyzing the physical stability of VLP, 
but it was found that it is a reliable tool for the investigation of the chemical stability of 
VLP because of the proper determination of VLP fragments. However, it has to be 
mentioned that the currently used SE-HPLC method might be improved by using e.g. 
other column types, but a further optimization of the SE-HPLC method was beyond 
the scope of the present work. In summary it could be stated that AF4 is a very 
powerful tool for the accurate characterization of VLP formulations and overcomes the 
limitations of DLS and SE-HPLC.  
3.2.5 Improvement of AF4 Method by Using New Channel Technology 
In 2006 Wyatt Technology Europe GmbH introduced a new small AF4 separation 
channel (18 cm). It was described that, in comparison to the standard channel  
(25 cm), the application of the small channel improves resolution, enables shorter 
equilibration and analysis times, and reduces eluent volumes. At the same time 
increasing peak heights are obtainable which in turn might lead to lower detection 
limits, and thus, enable the reduction of the injected amount. Hence, it was 
investigated whether the before described AF4 method for VLP, developed for the  
standard AF4 channel (25 cm), could be optimized by using the new, shorter AF4 
separation channel (18cm). For this purpose comparative AF4 measurements were 
performed. Qb VLP were analyzed either with the standard channel according to 
method A (Figure 3.2.3) or with the new channel by applying method B  
(Figure 3.2.10). VLP amounts in the range of 5 – 20 µg and 2.5 – 10 µg were applied 
for the standard and the shorter AF4 channel, respectively.  
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Figure 3.2.10 AF4 cross-flow profile method B. 
The resulting AF4 fractograms are displayed in Figure 3.2.11. The figure 
illustrates the advantage of the small channel in comparison to the standard channel: 
at the same injected amounts sharper, higher peaks were obtained. Thus, the 
determination of the MW of the VLP monomer and dimer was feasible even at 2.5 µg 
injected VLP amount when using the small channel whereas for correct determination 
of the MW of the VLP dimer the injected amount needed to be higher than 10 µg 
when the standard channel was used.  
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Figure 3.2.11 AF4 analysis of different amounts of NicQb by using Wyatt’s new channel (18 cm) 
 – 2.5 µg (1), 5 µg (2) and 10 µg (3) – in comparison to Wyatt’s standard channel (25 cm) – 5 µg (4),  
10 µg (5) and 20 µg (6). 
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Concerning the amounts of the different VLP species (Table 3.2.4) both methods 
revealed comparable values over the whole amount range tested. However, the 
lowest amount applied for the small channel (2.5 µg) was further reduced to one half 
of the lowest amount applied for the standard channel.  
Table 3.2.4 AF4 analysis of NicQb by using Wyatt’s standard channel (25 cm) in comparison to 
Wyatt’s new channel (18 cm).   
Fragments Monomer Dimer Oligomers / Aggregates 
Channel 
VLP amount 
[µg] Relative peak areas [%] 
20 0.80 ± 0.05 88.11 ± 0.03 6.56 ± 0.19 4.53 ± 0.18 
10 0.92 ± 0.03 87.67 ± 0.08 6.29 ± 0.19 5.12 ± 0.14 25 cm 
5 0.84 ± 0.04 86.58 ± 1.01 6.84 ± 0.17 5.74 ± 0.80 
10 1.03 ± 0.15 87.42 ± 0.30 6.60 ± 0.51 4.95 ± 0.06 
5 1.02 ± 0.06 87.47 ± 0.30 6.47 ± 0.06 5.05 ± 0.18 18 cm 
2.5 0.93 ± 0.06 87.65 ± 0.34 6.41 ± 0.01 5.01 ± 0.27 
 
Furthermore, as indicated in Table 3.2.5 the analysis time and the eluent volume 
could be remarkably reduced by using Wyatt’s small channel.  
Table 3.2.5 Comparison between method A (standard channel) and B (small channel). 
 Standard Channel 25 cm 
Small Channel 
18 cm 
Time [min] 56 31 
Eluent volume [mL] 159 70 
Injection amount [µg] 10 - 20 2.5 - 10 
 
Thus, it could be stated that the new channel technology was a clear 
improvement for VLP characterization as compared to the standard channel. It 
enables a clearly increased sample throughput and the accurate characterization of 
VLP compositions at remarkably low VLP concentrations.  
 
 
AF4 as a New Analytical Tool for the Investigation of the Physical Stability of VLP 
___________________________________________________________________________ 
 
48 
 
3.3 Summary 
The successful development of AF4 methods for the assessment of VLP 
compositions was presented. It was found that AF4 exceeds the separation capacity 
of DLS and SE-HPLC. AF4 enabled the proper separation of a VLP composition into 
VLP fragments, monomers, dimers, oligomers and aggregates. Furthermore, by 
coupling AF4 to UV and MALLS detectors accurate quantification of the specific 
fractions and the determination of the molecular weight distributions were feasible. 
Thus, AF4 seemed to be a valuable tool for the characterization of VLP compositions.   
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4 DEVELOPMENT OF A STABLE, FREEZE-DRIED 
FORMULATION FOR A VIRUS-LIKE PARTICLE 
BASED VACCINE AGAINST NICOTINE 
ADDICTION 
4.1 Introduction 
Tobacco misuse is the single leading preventable cause of death worldwide. The 
World Health Organization (WHO) estimates that there are 1.3 billion smokers 
worldwide and nearly 5 million tobacco-related deaths each year. Despite widespread 
knowledge of tobacco’s dangerous health effects, smoking continues to pose a 
serious public health threat, as the number of smokers is increasing steadily#. 
According to the 2004 Surgeon General’s Report* nearly 70 % of smokers want to 
stop smoking but less than 5 % who make a quitting attempt are successful.  By 2006 
smoking cessation products on the market included two types of medications:  
(1) Nicotine replacement therapy in the form of nicotine gums, inhalers, nasal sprays 
or transdermal patches, and (2) Treatment with the antidepressant bupropion, acting 
by attenuating withdrawal symptoms. However, clinical trials have shown that the 
long-term abstinence rates were only 6-10 % above placebo when using these 
medications§. Thus, there still is a high need for new therapies. In 2006 ChantixTM 
(Pfizer Inc.) with varenicline as a new chemical compound, acting by modulating 
receptor activity in the brain, was approved by the FDA. Even though varenicline 
exceeds commonly achieved abstinence rates, only 23 % of the smokers remained 
abstinent after 1 year   [Maurer et al., 2007]. However, the sales of Chantix, 883 
million dollars in 2007§, clearly demonstrated the high economic value of new drugs 
for smoking cessation. 
 
 
 ____________________________________________________________________ 
# http://www.wpro.who.int/media_centre/fact_sheets/fs_20060530.htm 
*  http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2004/index.htm 
& http://www.nice.org.uk/Docref.asp?d=30634 
§  http://seekingalpha.com/article/61585-pfizer-s-chantix-poised-for-blockbuster-sales?source=feed 
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Vaccination against nicotine is an innovative approach followed by Nabi 
Pharmaceuticals (NicVAX), Celtic Pharma (TA-NIC), and Cytos Biotechnology AG 
(NicQb).  Clinical trials with Pseudomonas aeruginosa exoprotein A (NicVAX), 
recombinant cholera toxin B (TA-NIC), and Qb VLP nicotine conjugates (NicQb) have 
been shown to induce strong nicotine-specific antibody responses leading to the 
prevention of relapses by sequestering nicotine in the blood from immunized smokers 
[Cerny, 2005; Maurer et al., 2006; Boyd, 2006; Maurer et al., 2007]. However, besides 
the proof of efficacy and safety of these vaccines the development of stable 
formulations is essential for their commercialization and might turn the scale in the 
nip-and-tuck race towards market entry. The aim of the present work was to develop 
stable formulations for the VLP based vaccine candidate NicQb from Cytos 
Biotechnology AG. 
Many biopharmaceuticals, such as vaccines, proteins and peptides, are often not 
sufficiently stable in aqueous solutions to allow distribution and storage, particularly at 
room temperature. They are susceptible to chemical (hydrolysis of glycosilic and 
peptide bonds and linking sequences, oxidation, deamidation, disulfide exchange, 
racemisation, and beta elimination) and / or physical degradation (denaturation, 
aggregation, precipitation, and adsorption) in liquid formulations [Manning et al., 1989; 
Cleland et al., 1993; Brandau et al., 2003; Wang, 2005]. During shipping products can 
be subjected to further stresses that can lead to denaturation, e.g. agitation, exposure 
to high and / or low temperatures, and freezing [Arakawa et al., 2001]. Additionally, 
even if optimal formulation and shipping systems might be designed, damage during 
long-term storage may not be prevented sufficiently [Manning et al., 1989; Carpenter 
et al., 1997].  
In order to achieve more robust formulations dried forms were often produced 
because in the dried state particularly chemical reactions are intended to be 
substantially retarded [Franks, 1998; Lai et al., 1999]. Common drying techniques are 
freeze-drying [Carpenter et al., 1997; Wang, 2000], vacuum-drying [Mattern et al., 
1999; Sharma et al., 2004], spray-drying [Lee, 2002; Harris et al., 2004; Ameri et al., 
2006] and spray-freeze-drying [Maa et al., 1999]. Among these freeze-drying is the 
most widely used technique for the preparation of biopharmaceuticals for parenteral 
administration. Currently 46 % of the marketed biopharmaceutical  products are 
lyophilizates [Costantino et al., 2004]. It is a well established process to improve the 
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stability of particularly labile drugs such as proteins [Wang, 2000] and complex 
vehicles like virus vaccines [Scott et al., 1976; Adebayo et al., 1998; Sarkar et al., 
2003; Zhai et al., 2004; Abdul-Fattah et al., 2007], viral vectors [Talsma et al., 1997; 
Evans et al., 2004; Cruz et al., 2006], liposomes [Engel et al., 1994; Zingel et al., 
1996; Hinrichs et al., 2005] and lipid-DNA complexes [Allison et al., 2000; Molina et 
al., 2004].  
A typical freeze-drying process consists of three main stages, i.e. freezing, 
primary drying and secondary drying. First the solution is frozen to a temperature 
below the critical temperature of the formulation and held for several hours at this 
temperature to allow complete solidification. The critical temperature of a formulation 
is the collapse temperature Tc, above which the intestinal water in the frozen matrix 
becomes significantly mobile, which in turn might lead to the loss of the macroscopic 
structure during freeze-drying. Tc has been considered to be about 2 °C higher than 
the Tg’ of an amorphous system or to be equivalent to the eutectic temperature of a 
crystalline system. During primary drying ice is transferred from the product to the 
condenser by sublimation and crystallization onto the cold coils in the condenser. It 
starts when the chamber pressure is reduced to improve the rate of ice sublimation 
and the shelf temperature is raised to supply the heat removed by ice sublimation. 
The driving force is provided by the partial pressure difference of water at the 
subliming ice surface and at the condenser. Upon secondary drying the unfrozen, 
adsorbed water is removed from the product by desorption and subsequent 
condensation in order to reduce the residual moisture content to a level optimal for 
stability. Secondary drying is typically carried out at higher temperature so that 
desorption of water may occur at a practical rate [Pikal, 1994; Franks, 1998; Wang, 
2000; Nail et al., 2002; Tang et al., 2004; Costantino et al., 2004].  
However, during freeze-drying the drug is exposed to two distinct stresses which 
can cause significant damage to the drug, i.e. freezing and drying.  
During freezing drug stability can be influenced by (1) Cold denaturation 
[Privalov, 1990] (2) Exposure to ice-water interfaces [Chang et al., 1996], (3) Salt and 
drug concentration effects [Pikal, 2004], (4) pH shifts due to selective crystallization of 
specific buffer species [Anchordoquy et al., 1996a; Sarciaux et al., 1999], (5) 
Mechanical damage by growing ice crystals [Zhai et al., 2004], and (6) Crystallization 
of protective excipients [Carpenter et al., 1989; Izutsu et al., 1993].  
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Upon drying the removal of stabilizing hydration shells can influence the stability 
of the drug [Prestrelski et al., 1993], In an aqueous solution proteins are fully 
hydrated. The removal of the hydration shell may disrupt the native state of a protein 
and cause denaturation and probably the loss of activity [Arakawa et al., 1991; 
Prestrelski et al., 1995].  
Therefore, to ensure the stability of the drug during freeze-drying stabilizing 
excipients have to be employed [Wang, 2000; Rexroad et al., 2002; Carpenter et al., 
2002; Tang et al., 2004].  
Surfactants, like polysorbates, are added to prevent aggregation of the drug in 
the liquid formulation, during freezing and reconstitution. Surfactants drop the surface 
tension of formulations and might consequently reduce the driving force of protein 
adsorption and / or aggregation at ice-water interfaces formed during freezing [Chang 
et al., 1996; Jones et al., 2001; Shi et al., 2005].  
Cryoprotectants like sugars (e.g. trehalose and sucrose), polymers (e.g. 
polyethylene glycol and human serum albumin), and amino acids are used to stabilize 
the active pharmaceutical ingredient in solution and upon freezing. They hinder 
protein molecules from unfolding by the preferential exclusion mechanism, which 
favours the native protein conformation exhibiting the minimum surface area  
[Arakawa et al., 1982; Arakawa et al., 1991; Carpenter et al., 1999].  
Lyoprotectants, especially the disaccharides sucrose and trehalose, are utilized 
to stabilize the drug during drying [Wang, 2000].  The two main mechanisms proposed 
are the “vitrification“ and the “water-replacement” hypotheses.  “Vitrification” ascribes 
to the formation of an amorphous glass during lyophilization leading to increased drug 
stability by slowing down conformational changes of biomolecules [Franks, 1994; Fox, 
1995; Hancock et al., 1997; Crowe et al., 1998; Chang et al., 2005]. The “water 
replacement hypothesis” involves the formation of hydrogen bonds between the 
protein and excipients. The excipients serve as water substitutes and hinder protein 
unfolding and intra- or interprotein hydrogen bonding during dehydration [Carpenter  
et al., 1990; Arakawa et al., 1991; Crowe et al., 1993a; Crowe et al., 1993b; Allison  
et al., 1999].    
Bulking agents are applied to achieve more elegant and stable cakes. In this role 
mannitol is often used because it crystallizes to a substantial degree during 
lyophilization and forms a mechanically strong cake. However, it is well-known that 
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crystalline excipients when used alone are not necessarily able to provide sufficient 
stability. Thus, in order to achieve elegant and stable products mixtures of mannitol 
with sucrose or trehalose are used [Johnson et al., 2002; Izutsu et al., 2002; Liao et 
al., 2005].  
Upon long-term storage the stability of a labile biopharmaceutical can further be 
affected by several factors like storage temperature, glass transition temperature 
[Hancock et al., 1995], residual moisture content [Shalaev et al., 1996; Breen et al., 
2001; Klibanov et al.i, 2004] and crystallization of amorphous excipients [Costantino et 
al., 1998; Lai et al., 1999].  
In this chapter the development of stable NicQb lyophilizates meeting the 
requirements for large scale clinical study and commercial use is described. The 
influence of different pH values and various excipients like surfactants, polyols, sugars 
and salts on the stability of NicQb in liquid formulations, during  
freeze-thawing, freeze-drying, and finally upon storage of the dried product was 
investigated. Besides standard analytical tools like DLS, light obscuration, SE-HPLC, 
RP-HPLC and LDS-PAGE, the developed AF4 method described in chapter 3 is used 
for the analysis of VLP stability.  
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4.2 Results and Discussion  
4.2.1 pH Stability Study - NicQb 
The stability of vaccines in solutions is strongly influenced by solution conditions 
like pH, ionic strength, osmolality and the presence of excipients. Among these 
parameters formulation pH is described as one of the most critical variables 
concerning the chemical and physical stability of vaccines [Brandau et al., 2003]. As 
the drug has first to be formulated in a liquid prior to freeze-drying and has to be 
handled for several hours in the liquid state (especially in the context of large scale 
manufacture) the influence of the pH has to be properly investigated. Furthermore, the 
formulation pH can also affect the stability of dried products during long-term storage 
[Townsend et al., 1990; Costantino et al., 1994; Song et al., 2001].  
 
Therefore, the stability of NicQb was investigated in dependence of the pH of a 
liquid formulation. NicQb solutions in a pH range of 4.6 up to 8.2 were manufactured 
by adjusting the pH of the bulk material either with 0.1 N NaOH or 0.1 N H3PO4 and 
subsequent dilution of the solutions to 1 mg / mL NicQb. The samples were stored at 
room temperature up to 14 days. After storage samples were analyzed via DLS,  
SE-HPLC and RP-HPLC at least in duplicate. 
Chemical stability of NicQb  
RP-HPLC analysis revealed that the content of free nicotine derivatives 
increased with increasing pH values (Figure 4.2.1). Up to a pH of 6.6 the amount of 
free nicotine derivatives was below 5 % even after storage for 14 days at ambient 
temperature. Between pH 6.6 and 8.2 the amount of cleaved nicotine increased 
markedly with increasing pH values upon storage. After 2 weeks, almost 50 % of total 
nicotine was cleaved at a pH of 8.2.  
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Figure 4.2.1 Amount of free nicotine derivatives as determined by RP-HPLC after manufacture and 
after 2, 7 and 14 days. 
The data obtained from SE-HPLC analysis (Figure 4.2.2) revealed that with 
increasing pH values the amount of fragmentation products of NicQb increased clearly 
upon storage within 7 days at room temperature. Up to a pH of 7.0 the amount of 
fragmentation products increased only up to 2 % in comparison to the starting material 
whereas at higher pH values the amount of fragmentation products rose up to 15 % at 
a pH of 8.2.  
Thus, addressing the stability of the esterbond between the VLP-linker and 
nicotine and the integrity of the VLP it could be stated that a pH value below 6.6 is 
desirable.  
 
 
Figure 4.2.2 Amount of fragmentation products of NicQb as determined by SE-HPLC after 
manufacture and after 7 days. 
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Physical stability of NicQb  
Concerning the physical stability of NicQb DLS measurements revealed that with 
increasing pH values the aggregation level of NicQb decreased (Figure 4.2.3). The 
polydispersity index (PI) decreased and the intensity of the main NicQb peak 
increased, indicating a decreasing polydisperse size distribution. Below a pH of 6.2 
the intensity of the main NicQb peak was less than 95 %. At a pH of 4.6 not only a 
remarkable increase of the PI and decrease of the intensity of the main peak could be 
observed, but even a second peak at a size of several 100 nm appeared, proving the 
presence of VLP aggregates (Figure 4.2.4).  
 
Figure 4.2.3 Proportion of main NicQb peak and PI as determined by DLS after 14 days storage at 
RT by applying the intensity conversion model. 
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Figure 4.2.4 Size distribution as determined by DLS for NicQb sample at a pH of 4.6 stored for 14 
days at RT. 
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Aggregation of dispersed particles can be influenced by the electrostatic 
properties of a formulation, like pH and salt concentration. If the zeta potential of 
charged particles such as protein complexes are near zero, particle aggregation can 
occur whereas at significant positive and negative zeta potential values particles might 
be stabilized by repulsive electrostatic forces [Jiskoot et al., 2005]. In order to find out 
whether the increasing amount of aggregated species of NicQb with decreasing pH 
values could be related to low absolute zeta potential values of the particles, NicQb 
solutions in a pH range of 3.4 to 7.2 were analyzed with the Malvern Zetasizer 
Nano ZS. The results are depicted in Figure 4.2.5. 
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Figure 4.2.5 Zeta potential of NicQb in dependence of the pH. 
It was found that the zeta potential of NicQb was 0 mV at a pH of 4.7, which 
marks the isoelectric point, and that in the pH range of 3 to 6 the absolute zeta 
potential values were below 20 mV which, as described above, can lead to particle 
aggregation.  
Hence, the DLS and zeta potential measurements revealed that with respect to 
aggregation of NicQb the pH of the formulation should be higher than 6.2.  
Summary 
In summary two divergent results were observed. Concerning the chemical 
stability of NicQb pH values below 6.6 were favourable whereas with respect to the 
physical stability the pH of the solution should be higher than 6.2. Therefore, a 
compromise between the hydrolysis of the esterbond between VLP-linker and nicotine 
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and the degradation of the VLP on the one hand, and aggregation of the VLP at low 
pH values on the other hand had to be made. A pH range from 6.2 up to 6.6 appeared 
to be optimal to assure both chemical and physical stability of NicQb in a liquid 
formulation.  
4.2.2 Freeze-Thaw (FT) Studies - NicQb 
A freeze-drying process consists of two major steps: freezing of the drug solution, 
and drying of the frozen solid under vacuum. Each step generates different kinds of 
stresses, and depending on the specific properties of a drug its stability can be 
influenced by either one and / or both steps [Wang, 2000; Rexroad et al., 2002]. 
Therefore, the impact of each single step on the stability of NicQb and the effect of 
stabilizing excipients had to be scrutinized. Freeze-thawing is routinely used as a tool 
to determine the effects of various stresses connected to freezing on the stability of a 
drug [Jiang et al., 1998; Anchordoquy et al., 2001].  
A wide variety of excipients have been employed to prevent freezing-induced 
denaturation, including surfactants, disaccharides and polymers. For example, 
polysorbates were described as potent cryoprotectants for viruses [Evans et al., 
2004], virus-like particles [Shi et al., 2005] and proteins [Chang et al., 1996; Kreilgaard 
et al., 1998; Sarciaux et al., 1999; Jones et al., 2001]. The efficiency of trehalose as 
efficient cryo- and lyoprotectant was shown for several virus vaccines [Gupta et al., 
1996; Worrall et al., 2001; Sarkar et al., 2003].  
Thus, in order to study the effect of the freezing step on the stability of NicQb and 
the particular influence of the clinically approved excipients polysorbate 20 and 
trehalose on its stability during freeze-thawing was investigated. Additionally, the 
effect of sodium chloride, which is often used to adjust the tonicity of liquid 
formulations [Costantino et al., 2004] and is described to be able in some cases to 
stabilize biopharmaceuticals [Liu et al., 1991; Schwendeman et al., 1995],  was 
analyzed.  
1 mL of NicQb solutions with a drug concentration of 0.2 mg / mL, with 30, 60, 90 
or 150 mM sodium chloride, 10 % trehalose, with or without addition of 0.005 % 
polysorbate 20 were filled into 1.5 mL Eppendorf Tubes (Eppendorf AG, Hamburg, 
Germany). Additionally, samples without trehalose, 0.005 % polysorbate 20 and 
30 mM NaCl were prepared. With respect to the findings from the pH stability study 
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the samples were buffered with 20 mM sodium phosphate salts at a pH of 6.4. The 
samples were frozen by placing the tubes in a refrigerator at -80 °C.  After a minimum 
of 3 hours the samples were thawed at ambient temperature. Freeze-thaw cycles 
were repeated 5 times. As aggregation of protein therapeutics induced by 
denaturation at ice-water interfaces is described as the major degradation pathway 
during freezing [Chang et al., 1996; Jones et al., 2001], the focus of this experiment 
was laid on the physical stability of NicQb. Thus, the samples were analyzed before 
and after freeze-thaw cycling via DLS and light obscuration at least in duplicate. 
Effect of trehalose and polysorbate 20 on the stability of NicQb  
In order to investigate the single effect of polysorbate 20 and trehalose on the 
stability of NicQb formulations with or without either one or both excipients was 
assessed after freeze-thawing.  The results obtained by DLS and light obscuration are 
displayed in Figure 4.2.6 and Figure 4.2.7. It was found that trehalose had no clear 
stabilizing effect on NicQb during freeze-thawing whereas polysorbate 20 had a 
significant protective effect. For the formulations with polysorbate 20 neither a clear 
increase of the number of particles > 1 µm nor a clear increase of the polydispersity 
index and decrease of the main NicQb peak was detected. The protective effect of 
polysorbate 20 can be explained by either binding to hydrophobic regions of the drug 
thereby preventing interaction with hydrophobic surfaces [Bam et al., 1995] or by 
competing with the therapeutic for adsorption at liquid-surface interfaces  
[Shi et al., 2005].  
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Figure 4.2.6 Polydispersity indices and proportions of main NicQb peak in dependence of trehalose 
(0 vs. 10 %) and polysorbate (0 vs. 0.005 %) addition before freeze-thawing and after 5 freeze-thaw 
cycles.  
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Figure 4.2.7 Number of particles > 1 µm in dependence of trehalose (0 vs. 10 %) and polysorbate 
(0 vs. 0.005 %) addition before freeze-thawing and after 5 freeze-thaw cycles. 
Effect of sodium chloride and polysorbate 20 on the stability of NicQb  
DLS data revealed that with increasing concentrations of sodium chloride in 
NicQb formulations without polysorbate 20 the proportion of the main NicQb peak 
decreased, indicating an increase of the aggregation level. Furthermore, the PI of 
these formulations was higher than 0.4, referring to a polymodal size distribution 
(Figure 4.2.8). Such a destabilizing effect of sodium chloride at higher salt 
concentrations on proteins and other biopharmaceuticals like for example hepatitis A 
virus has been reported in several cases [Volkin et al., 1996; Chi et al., 2003].   
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A proposed mechanism is the shielding of repulsive forces between similarly charged 
groups by sodium chloride leading to an increase in drug aggregation [Brange et al., 
1997].  
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Figure 4.2.8 Polydispersity indices and proportions of main NicQb peak in dependence of sodium 
chloride concentration (30, 60, 90 and 150 mM), formulated without (A / B) or with (C / D) polysorbate 20 
(0.005 %) before freeze-thawing and after 5 freeze-thaw cycles; samples contained 10 % trehalose. 
In contrast, in the presence of polysorbate 20 aggregation of NicQb could be 
prevented, even at high sodium chloride concentrations. However, the best results 
rendered the NicQb formulation with the lowest amount of sodium chloride (30 mM), 
0.005 % polysorbate 20 and 10 % trehalose with 99.9 % proportion of the main NicQb 
peak and a PI of 0.20 (Figure 4.2.8).   
The findings of the DLS measurements were confirmed by data obtained by light 
obscuration. As illustrated in Figure 4.2.9 aggregation of NicQb upon freeze-thawing, 
indicated by increasing numbers of particles ≥ 1 µm, could be prevented by 
polysorbate 20 together with trehalose. However, the clear trend observed by DLS 
that increasing amounts of sodium chloride could be correlated to increasing 
aggregation levels was not supported by light obscuration measurements as the 
number of particles > 1 µm did not increase steadily.   
 
 
Freeze-Drying of a VLP Based Vaccine 
___________________________________________________________________________ 
 
66 
 
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
30 60 90 150
NaCl conc. [mM]
pa
rt
ic
le
s 
> 
1 
µm
before after
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
30 60 90 150
NaCl conc. [mM]
pa
rt
ic
le
s 
> 
1 
µm
before after
A B
pa
rt
ic
le
s 
> 
1 
µm
pa
rt
ic
le
s 
> 
1 
µm
 
Figure 4.2.9 Number of particles > 1 µm in dependence of sodium chloride concentration (30, 60, 90 
and 150 mM), formulated without (A) or with (B) polysorbate 20 (0.005 %) before freeze-thawing and 
after 5 freeze-thaw cycles; samples contained 10 % trehalose. 
Summary  
It can be stated that the addition of polysorbate 20 was very beneficial to prevent 
aggregation of NicQb during freeze-thawing and that the addition of high 
concentrations of sodium chloride should be avoided. Even though it was found that 
trehalose had no protective effect during freeze-thawing it might serve as 
lyoprotectant during the drying step. 
4.2.3 Freeze-Drying (FD) Studies - NicQb 
The effect of the freezing step on the stability of NicQb was investigated during 
freeze-thaw experiments. Now, the stability of NicQb throughout the whole FD 
process depending on formulation composition and process parameters had to be 
investigated. The focus was laid on the development of formulations which meet the 
following criteria: (1) The drug should be stable during manufacture and storage, 
ideally even at ambient temperature; (2) It should be composed of FDA approved 
excipients; (3) It should have an acceptable and reproducible appearance; and (4) 
Ideally the lyophilizate should be reconstitutable with water to a parenteral applicable 
isotonic solution. Concerning the final freeze-drying process the aim was to establish 
a rapid, economical and robust process with respect to drug stability and appearance 
of the resulting lyophilizate. Furthermore, the process parameters like cooling rate, 
temperature, and vacuum should be easily transferable to standard large-scale 
lyophilizers enabling the manufacture of larger batches in the future.  
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Selection of formulations 
The lead concentration of NicQb was 1.0 mg / mL and the fill volume was 
determined to 0.6 mL / vial. Furthermore, trehalose was selected as lyoprotectant and 
hereby in a concentration of 10%. 
Trehalose and sucrose are often used as lyoprotectants. The proposed 
stabilizing mechanisms were described in previous sections. Trehalose has been 
selected as lyoprotectant because of the following reasons:  
(1) A freeze-concentrated trehalose solution has a Tg’ about 3 °C higher than 
sucrose (trehalose -29.5 °C vs. sucrose -32°C [Levine et al., 1988]) enabling 
drying at higher temperatures resulting in shorter freeze-drying times [Tang  
et al., 2004];  
(2) Dried amorphous trehalose has a higher glass transition temperature as 
compared to sucrose [Slade et al., 1995], and thus, a higher temperature of 
“zero” mobility [Yu, 2001] which can lead to an improved long-term stability 
[Green et al., 1989; Molina et al., 2004], especially at ambient temperature; 
(3) Trehalose is less hygroscopic [De Giulio et al., 2005]; 
(4) Trehalose has a very low chemical reactivity [Roser, 1991; O'Brien, 1996]; 
(5) The glycosilic bond of trehalose is in comparison to sucrose far more stable 
[Moelwyn-Hughes, 1929; Higashiyama, 2002] which might lead to an 
improved long-term stability as the resulting decomposition product glucose 
has the propensity to degrade proteins via the Maillard reaction [Hageman, 
1992].  
A trehalose concentration of 10 % has been selected. This high concentration 
was chosen because high amounts of amorphous stabilizers protect complex 
particulate systems like viruses, lipid / DNA complexes and nanoparticles [Allison et 
al., 2000; Zhai et al., 2004; Zillies, 2007] better than lower amounts. However, at 
trehalose concentrations higher than 10 % the primary drying time could increase 
significantly [Hatley et al., 1996; Nail et al., 2002]. Furthermore, at a trehalose 
concentration of 10 % the resulting solution could already be isoosmotic [Cleland et 
al., 2001], and thus, the lyophilizate could easily be reconstituted with water to the 
initial volume to a parenterally applicable solution.  
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The advantage of the addition of polysorbate 20 as cryoprotectant was described 
in the previous paragraph. In this study the adequate concentration of polysorbate 
should be selected.  
Another important factor is the selection of the pH and the buffer species. The pH 
stability study revealed that NicQb is stable only in a narrow pH range. Above a pH of 
6.6 it is prone to chemical degradation and below a pH of 6.2 NicQb tends to 
aggregate. In contrast to the formulations investigated in the freeze-thaw stability 
study the pH was reduced from 6.4 to 6.2 with the intention to further increase the 
chemical stability of the drug (see pH stability study). This seemed to be reasonable 
as it was found from the freeze-thaw studies that the aggregation of the drug could be 
prevented by polysorbate 20.  
Concerning the buffer type sodium phosphate, potassium phosphate and 
histidine / histidine HCl (all 20 mM) were tested. Even though sodium phosphate is 
one of the most commonly used buffer species for lyophilizates [Schwegman et al., 
2005], there is still a lively discussion about a possible pH shift to more acidic pH 
values, caused by a more readily crystallization of Na2HPO4 than NaH2PO4 during the 
freezing step, which can lead to denaturation of proteins [Nema et al., 1993; Chang et 
al., 1996; Anchordoquy et al., 1996b].  Hence, as for potassium phosphate buffered 
systems a pH shift is not that distinct [Sarciaux et al., 1999] and histidine buffered 
formulations show no pH shift [Osterberg et al., 1999] these two buffer species were 
tested as alternatives to sodium phosphate. 
Additionally, the effect of varying concentrations of sodium chloride (0 mM up to 
150 mM) on the stability of NicQb upon the whole freeze-drying process was 
investigated. AF4 was introduced to monitor the effect of sodium chloride on the 
physical stability of NicQb more closely. 
Finally, in view of clinical dose finding studies, the most promising formulation 
candidate should be assessed towards its capability to stabilize NicQb in the 
concentration range of 0.2 to 2.0 mg / mL. 
Consequently, the NicQb formulations described in Table 4.2.1 were prepared 
and used for freeze-drying studies.  
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Table 4.2.1:  Compositions of NicQb formulations. 
Code NicQb [mg] 
Trehalose 
dihydrate 
[% (w/v)] 
Polysorbate20 
[% (w/v)] 
Sodium 
chloride 
[mM] 
Sodium 
phosphate 
[mM] 
Potassium 
phosphate 
[mM] 
Histidine 
[mM] pH 
A01 0.60 10 - - 20 - - 6.2 
A02 0.60 10 0.0025 - 20 - - 6.2 
A03 0.60 10 0.005 - 20 - - 6.2 
A04 0.60 10 0.0075 - 20 - - 6.2 
A05 0.60 10 0.010 - 20 - - 6.2 
A06 0.60 10 0.005 - - 20 - 6.2 
A07 0.60 10 0.005 30 - 20 - 6.2 
A08 0.60 10 0.005 60 - 20 - 6.2 
A09 0.60 10 0.005 90 - 20 - 6.2 
A10 0.60 10 0.005 150 - 20 - 6.2 
A11 0.60 10 0.005 - - - 20 6.2 
A12 0.12 10 0.005 - 20 - - 6.2 
A13 0.36 10 0.005 - 20 - - 6.2 
A14 1.2 10 0.005 - 20 - - 6.2 
Cycle development rationale  
The aim was to develop a freeze-drying cycle possible for the lyophilization of all 
the formulations described in Table 4.2.1. As agreed with Cytos Biotechnology AG, 
the cycle was developed for a 0.6 mL fill in 2R class 1 glass vials. Therefore, 
freeze-drying cycle A (Table 4.2.2) was designed.  
The formulations were cooled to - 50 °C at a cooling rate of 1 °C / min. This 
moderate cooling rate was applied because as described by Tang et al. [Tang et al., 
2004] this seems to be a good compromise between reasonable supercooling 
resulting in moderate ice surface areas and uniform ice structure, and short times 
during which the drug is exposed to the freeze-concentrated solution. Higher 
supercooling achievable by freezing methods like liquid nitrogen freezing, loading 
vials onto precooled shelves, or ramped cooling on the shelves leads to the formation 
of small ice crystals and larger ice / liquid interfaces [Jiang et al., 1998]. This might be 
beneficial if the formation of larger ice crystals is crucial for the drug stability, e.g. 
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disrupture of especially complex, large particles like viruses [Zhai et al., 2004]. 
However, the large ice / water interface can lead to surface-induced denaturation 
[Chang et al., 1996]. Furthermore, applying such enhanced freezing methods can lead 
to heterogeneity between vials and is not practical because the cooling rate in 
common freeze-driers is limited to less than 2 °C / min [Costantino et al., 2004]. Slow 
freezing leads to smaller ice / liquid interfaces which reduces surface-induced 
degradation, but prolongs the time the drug exists in the freeze-concentrated liquid 
state which in turn can affect its stability [Heller et al., 1999; Bhatnagar et al., 2007].   
Table 4.2.2 Freeze-drying protocol A. 
Step Time  [min] 
Temperature  
[°C] 
Pressure  
[mbar] 
Loading 00:00:00 20 1013 
00:01:10 -50 1013 
Freezing 
00:03:00 -50 1013 
00:00:01 -50 0.045 
00:00:15 -35 0.045 
20:00:00 -35 0.045 
00:02:30 -20 0.045 
Primary drying 
10:00:00 -20 0.045 
00:01:20 20 0.045 
Secondary drying 
10:00:00 20 0.045 
 
The target freezing temperature was set to -50 °C in order to cool the 
formulations below their glass transition temperature, the temperature above which a 
product might loose its macroscopic structure due to mobilization of the intestinal 
water in the frozen matrix [Wang, 2000]. In order to determine the Tg’ of the 
formulations DSC measurements were performed. The results obtained are 
summarized in Table 4.2.3. The lowest Tg’ was -39 °C for formulation A10. The 
decrease of Tg’ with increasing sodium chloride concentrations is related to the 
increase of the quantity of unfrozen water in the freeze-concentrate. The unfrozen 
water in turn acts as plasticizer and decreases Tg’ [Her et al., 1995]. In order to 
provide a safety margin and to allow complete solidification of all formulations the 
target freezing temperature was determined to -50 °C and kept for 3 hours prior to 
primary drying.  
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Table 4.2.3:  Glass transition temperatures of maximally freeze-concentrated solutions. 
Code Tg’ [°C] Code Tg’ [°C] 
A01 -34.3 A08 -35.2 
A02 -34.0 A09 -36.7 
A03 -34.4 A10 -39.0 
A04 -34.4 A11 -31.5 
A05 -34.8 A12 -33.2 
A06 -32.8 A13 -33.1 
A07 -34.1 A14 -33.6 
 
In a next step the chamber pressure and the shelf temperature to be applied 
during primary drying had to be defined. Current dogma requires that formulations are 
freeze-dried below Tg’ to avoid macroscopical collapse [Pikal, 1990; Wang, 2000; 
Tang et al., 2004; Costantino et al., 2004]. Even though freeze-drying below Tg’ 
demands a very low target product temperature and in consequence longer processes 
it was decided to follow this recommendation as the major goal was to establish a 
robust and safe freeze-drying cycle. Therefore, the target product temperature was 
determined to -40 °C (vapour pressure of ice = 0.128 mbar) in the initial phase of the 
freeze-drying process. The chamber pressure impacts both heat and mass transfer. 
According to Nail et al. it should be between one-fourth and one-half of the vapour 
pressure of ice at the target product temperature to allow a high sublimation rate, but 
high enough to enable sufficient and homogeneous heat transfer [Nail et al., 2002]. 
Therefore, the chamber pressure was set to 0.045 mbar which seemed to be a good 
compromise between a high sublimation rate and heat transfer provided by the 
conductivity of the vapour phase. The chamber pressure was controlled by a Pirani 
gauge. In order to provide the heat removed by sublimation the shelf temperature is 
normally set a few degrees above the target product temperature. As an excessive 
heat input may lead to an increase of the product temperature above its Tg’ which 
might lead to product collapse [Adams et al., 1996] the shelf temperature was first set 
to -35 °C and was raised to -20 °C after 20 hours to accelerate primary drying. The 
endpoint of primary drying is reached when all the frozen water is removed and the 
rate of water sublimation is significantly reduced. Then, the product temperature 
shows a clear increase, followed by a plateau [Nail et al., 2002]. To monitor the 
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product temperature during freeze-drying thermocouples were placed in the centre of 
the vials. Figure 4.2.10 shows an exemplarily process documentation. It illustrates that 
during primary drying steps the product reaches or exceeds the shelf temperature 
indicating that primary drying was completed within the determined time frames.  
Furthermore, no macroscopical collapse of any of the tested formulations was 
observed.  
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Figure 4.2.10 Example - process documentation.  
Secondary drying is typically carried out at accelerated temperature to enable 
fast desorption of the remaining water [Franks, 1998]. However, the shelf temperature 
should be increased slowly, because early in secondary drying the amorphous 
product has high residual moisture content, and thus, low glass transition 
temperature, which make collapse possible [Tang et al., 2004]. Consequently, the 
temperature was increased from -20 °C to 20 °C at a heating rate of 0.5 °C / min. 
Then, the product was dried for further 10 hours at 20 °C and 0.05 mbar to reduce the 
residual moisture content.  
After freeze-drying all formulations showed excellent appearance, exemplarily 
shown for formulation A03 in Figure 4.2.11, and were amorphous as indicated by XRD 
measurements (Figure 4.2.12). The lyophilizates could be easily reconstituted with 
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water within 5 seconds. All formulations were clear after reconstitution and contained 
no visible particles.   
 
 
Figure 4.2.11 Appearance NicQb formulation A03 after freeze-drying. 
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Figure 4.2.12  XRD of freeze-dried NicQb formulation A03. 
Furthermore, it could be shown that by applying the developed process low 
residual moisture < 1.3 % (Table 4.2.4) could be achieved for all formulations tested. 
Low residual moisture contents are desirable, especially in view of long-term stability, 
because water can affect the drug stability in two ways, as reactant or as a plasticizer 
of the amorphous formulation [Shalaev et al., 1996].  
 
 
 
Freeze-Drying of a VLP Based Vaccine 
___________________________________________________________________________ 
 
74 
 
Table 4.2.4:  Residual moisture content after freeze-drying. 
Code RM [%] Code RM [%] 
A01 1.3 A08 0.7 
A02 0.9  A09 0.9 
A03 1.1 A10 1.2 
A04 1.1 A11 0.4 
A05 1.2 A12 0.5 
A06 0.3  A13 0.6 
A07 0.6 A14 0.5 
 
High glass transition temperature is considered to be one of the most important 
parameters for long-term stability of a labile drug. It has been suggested that the glass 
transition temperature should be 50 °C above the intended storage temperature to 
minimize molecular mobility to the point of zero mobility and achieve sufficient stability 
[Hancock et al., 1995; Breen et al., 2001]. It is described that the Tg of a formulation 
can be reduced by 10 °C by each percent of moisture content [Franks, 1994; Rossi  
et al., 1997] which might lead at high residual water contents to product collapse and 
degradation of the drug [Franks, 1998; Wang, 2000; Molina et al., 2004]. The glass 
transition temperatures determined for the formulations without sodium chloride were 
above 80 °C (Table 4.2.5), which is in good correlation with literature [Crowe et al., 
1996; Hancock et al., 1997; Chen et al., 2000]. Exemplarily, the thermogram obtained 
for formulation A03, is shown in Figure 4.2.13. Hence, it was assumed that concerning 
the mobility of the dried formulations all formulations should be capable of stabilizing 
NicQb.  Unfortunately, the formulations A07 – A10, formulations with increasing 
sodium chloride concentrations, could not be analyzed by DSC due to the limitation of 
lyophilized samples.  
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Table 4.2.5:  Tg of NicQb formulations after freeze-drying (n=2). 
Code Tg [°C] Code Tg [°C] 
A01 85.0 A08 ND 
A02 82.6 A09 ND 
A03 84.1 A10 ND 
A04 82.9 A11 94.0 
A05 81.1 A12 101.4 
A06 89.4  A13 102.7 
A07 ND A14 100.6 
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Figure 4.2.13 DSC heating scan of freeze-dried NicQb formulation A03. 
In summary it could be stated that the developed freeze-drying process led to 
amorphous products with excellent appearance, low residual moisture levels and high 
glass transition temperatures. It could be concluded that this freeze-drying cycle is 
suitable for all the formulations tested. However, by employing more aggressive 
conditions it should be possible to achieve higher drying efficiency, but a further 
process optimization was not in the focus of this work because the current cycle 
already met the requirements of being robust, short and transferable to any pilot and 
production freeze-dryer.  
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In the following sections the effects of the different formulations (Table 4.2.1) on 
the stability of NicQb upon freeze-drying are described. Therefore, the samples were 
analyzed before and after freeze-drying by SE-HPLC, AF4 and DLS at least in 
duplicate. In the following paragraphs SE-HPLC and AF4 results are presented. DLS 
data are not shown as for all samples comparable results were obtained and it was 
shown that AF4 exceeds by far the capability of DLS with regard to the analysis of the 
physical stability of VLP (compare chapter 3). 
Effect of varying polysorbate 20 concentrations on the stability of NicQb  
In order to determine the minimum concentration of polysorbate 20 necessary to 
prevent NicQb aggregation during freeze-drying five NicQb formulations (1 mg / mL) 
with increasing polysorbate 20 concentrations from 0 up to 0.01 % were prepared. 
The formulations also contained 10 % trehalose dihydrate (w / v) as lyoprotectant and 
were buffered with 20 mM sodium phosphate (formulations A01 – A05, Table 4.2.1).  
AF4 measurements revealed that aggregation of NicQb upon freeze-drying could 
be clearly influenced by polysorbate 20. Formulation A01, without polysorbate, 
showed a clear increase of the aggregation level from initially 3.9 % aggregates (the 
term aggregates includes all VLP species larger than VLP dimers) to 7.9 % after 
freeze-drying indicating that trehalose alone was not sufficient to avoid aggregation of 
NicQb upon freeze-drying. By contrast, if polysorbate was added in a concentration of 
0.0025 % aggregation could be prevented. A further increase of the polysorbate 20 
concentration showed no further positive effect on the stability of NicQb (Figure 
4.2.14 A).  
The data obtained from SE-HPLC analysis showed that with the exception of 
formulation A01, none of the formulations led to an increase (more than 1.0 %) of 
NicQb fragments (Figure 4.2.14 B). Thus, it seemed that polysorbate 20 not only 
prevented NicQb aggregation but also inhibited VLP degradation during lyophilization.  
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Figure 4.2.14 Stability of NicQb (1 mg / mL) in dependence of varying polysorbate concentrations. 
Aggregation level determined by AF4 (A). Amount of NicQb degradation products determined by 
SE-HPLC (B). 
Consequently, it could be stated that the addition of polysorbate 20 was very 
beneficial to stabilize NicQb upon freeze-drying, especially with respect to the 
inhibition of NicQb aggregation. A concentration of 0.005 % seemed to be 
recommendable in order to provide a safety margin to the lowest effective 
concentration (0.0025 %).  
Effect of different buffer systems on the stability of NicQb  
In order to investigate the effect of different buffer types on the stability of NicQb 
upon freeze-drying formulations including sodium phosphate, potassium phosphate 
and histidine buffer (all 20 mM) were assessed (formulations A03, A06 and A11, 
Table 4.2.1). The pH was adjusted to 6.2. The NicQb concentration was 1 mg / mL. 
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Additionally, the formulations contained trehalose dihydrate 10 % (w / v) and 0.005 % 
polysorbate 20.  
AF4 measurements revealed that in none of the formulations the aggregation 
level of NicQb was increased upon freeze-drying. The amount of aggregated species 
of NicQb in the histidine buffered formulations was already initially slightly higher than 
in the phosphate buffered formulations (Figure 4.2.15 A). The reason for this result is 
not clear because the different buffered NicQb solutions were all prepared from the 
same API batch.  
The data obtained from SE-HPLC analysis showed that none of the formulations 
led to a significant increase of the fragmentation products. In comparison to the liquid 
formulation prior to freeze-drying the fragmentation level was increased for at most 
1.0 %, again the histidine buffered solution showed the highest initial level of NicQb 
fragments (Figure 4.2.15 B).  
In conclusion it could be stated that none of the tested buffer compositions had a 
negative effect on the stability of NicQb during freeze-drying, and thus, all buffer 
species tested were conceivable. As described above a pH drop in the sodium 
phosphate buffered formulation might occur due to a more readily crystallization of 
one buffer component during the freezing step [Pikal, 1994; Shalaev et al., 2002]. 
From the results obtained during the pH stability study it was assumed that a pH drop 
could lead to an increase of the aggregation level. However, as no significant 
alteration of NicQb purity was observed it was supposed that either crystallization of 
the buffer was prevented by the amorphous trehalose matrix, a mechanism already 
proposed by Chang et al. [Chang et al., 1992], and / or the low buffer concentration 
[Pikal, 1999], and thus, no pH change occurred, or aggregation of NicQb was inhibited 
by polysorbate 20 and trehalose and fragmentation did not happen in the short time 
the formulation was present in the liquid state. Due to the slightly higher levels of 
aggregated and fragmented VLP species in the histidine buffered liquid formulation 
prior to freeze-drying, as compared to the phosphate buffered formulations, histidine 
was not considered in further studies.   
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Figure 4.2.15 Stability of NicQb (1 mg / mL) in dependence of different buffer species. Aggregation 
level determined by AF4 (A). Amount of NicQb degradation products determined by SE-HPLC (B). 
Effect of varying sodium chloride concentrations on the stability of NicQb  
Even though the results obtained from the freeze-thaw experiments already 
indicated that sodium chloride leads to aggregation of NicQb during freezing, it was 
the intention of the current experiment to investigate the effect of sodium chloride in 
the concentration range of 0 up to 150 mM (formulations A06 – A10) on the stability of 
NicQb upon the whole freeze-drying process. This was interesting because at this 
time point an AF4 method, as a more sensitive tool for the analysis of VLP aggregates 
in comparison to DLS, was available. All formulations tested contained 1 mg / mL 
NicQb, 10 % trehalose dihydrate and 0.005 % polysorbate 20.  
AF4 measurements revealed that in the presence of polysorbate 20 and 
trehalose up to a sodium chloride concentration of 60 mM no aggregation of NicQb 
occurred, whereas at sodium chloride concentrations higher than 90 mM the 
aggregation level of the NicQb formulations increased with increasing sodium chloride 
 
Freeze-Drying of a VLP Based Vaccine 
___________________________________________________________________________ 
 
80 
 
concentrations. For formulation A10 (150 mM sodium chloride) the level of aggregates 
increased from initially 6.5 % prior to freeze-drying up to 10.3 % after freeze-drying 
(Figure 4.2.16 A).  
Addressing the integrity of NicQb SE-HPLC analysis showed that sodium 
chloride in the concentrations tested had no negative effect as no increase of the 
fragmentation level could be observed (Figure 4.2.16 B).  
It was concluded that sodium chloride has a negative effect on NicQb when 
added in concentrations higher than 90 mM, even in the presence of polysorbate 20. 
However, as no protective effect of sodium chloride was observed at lower 
concentrations and the addition of the salt is not necessary to adjust the tonicity of the 
formulations it was assumed that the addition of sodium chloride to lyophilized NicQb 
formulations should be prevented. 
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Figure 4.2.16 Stability of NicQb (1 mg / mL) in dependence of varying sodium chloride concentrations. 
Aggregation level determined by AF4 (A). Amount of NicQb degradation products determined by 
SE-HPLC (B). 
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Effect of varying trehalose / NicQb weight ratios on the stability of NicQb  
From previous experiments it was found that an optimal formulation for NicQb at 
a concentration of 1 mg / mL should be composed of trehalose dihydrate (10 %) and 
polysorbate 20 (0.005 %), buffered with either sodium phosphate or potassium 
phosphate. Finally, with regard to clinical dose finding studies, formulations with 
different NicQb concentrations had to be prepared. Ideally, in respect of double blind 
trials, the lyophilizates with different NicQb amounts should have the same 
appearance and should be reconstitutable to isotonic, parenterally applicable 
solutions of the same final volume. Thus, four formulations with NicQb concentrations 
in the range of 0.2 to 2.0 mg / mL, 10 % trehalose dihydrate, 0.005 % polysorbate 20 
and 20 mM sodium phosphate with a fill of 0.6 mL were prepared (formulations A12, 
A13, A03 and A14, Table 4.2.1). In this context the effect of different trehalose to 
NicQb ratios could be investigated. The resulting trehalose to NicQb weight ratios are 
displayed in Table 4.2.6. 
Table 4.2.6 Trehalose / NicQb weight ratios of specific NicQb formulations. 
Code NicQb conc. [mg / mL] 
Trehalose conc. 
 [mg / mL] 
Weight ratio  
Trehalose / NicQb 
A14 2.0 90 45 
A03 1.0 90 90 
A13 0.6 90 150 
A12 0.2 90 450 
 
Based on the findings of Zillies [Zillies, 2007], Allison et al. [Allison et al., 2000], 
Zhai et al. [Zhai et al., 2004] and Cleland et al. [Cleland et al., 2001] who showed that 
increasing ratios of disaccharide to gelatine nanoparticle, lipid / DNA complex, herpes 
simplex virus 2 and monoclonal antibody ratios, respectively led to increasing drug 
stability upon freeze-drying it was not expected that in our case the increase of the 
trehalose to NicQb weight ratio has a negative influence on the drug stability. 
Furthermore, it was not supposed that the slight decrease of the excipient to drug ratio 
of the “lead” formulation A03 from 90 : 1 to 45 : 1 in the formulation A14 might have a 
great influence on drug stability.  
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AF4 and SE-HPLC measurements revealed that in all formulations tested NicQb 
remained stable upon freeze-drying; neither increase of the aggregation level nor an 
increase of fragments was observed (Figure 4.2.17).   
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Figure 4.2.17 Stability of NicQb in dependence of varying drug concentrations. Aggregation level 
determined by AF4 (A). Amount of NicQb degradation products determined by SE-HPLC (B). 
Consequently, it could be stated that in the range of 45 : 1 up to 450 : 1 
trehalose /  NicQb (w / w) in a solution also containing 0.005 % polysorbate 20, NicQb 
could be stabilized by trehalose upon freeze-drying. The preparation of lyophilizates 
with similar appearance, which could be easily reconstituted with 0.6 mL water to 
isotonic solutions, and NicQb concentrations of 0.2 mg / mL up to 2.0 mg / mL was 
feasible.  
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Conclusion 
A robust freeze-drying cycle was developed that was successfully used to  
freeze-dry all formulations tested herein. Lyophilizates with elegant appearance and 
low residual moisture levels were achieved. Furthermore, from a technical point of 
view the freeze-drying cycle can easily be transferred to large-scale production 
freeze-dryers. It was found that a formulation composed of 10 % (w/v) trehalose 
dihydrate, 0.005 % (w/v) polysorbate 20 and either sodium phosphate or potassium 
phosphate as buffer agent was very beneficial to preserve the stability of NicQb in a 
concentration of 0.2 to 2.0 mg / mL during freeze-drying. Additionally, the lyophilizates 
could easily be reconstituted with water to parenterally applicable isotonic solutions.  
4.2.4 Storage Stability Studies - NicQb Lyophilizates 
In order to define a formulation capable of stabilizing NicQb upon storage four 
formulations (A03, A06, A14, and A15, Table 4.2.7) were assessed in a storage 
stability study for 15 weeks, at 2-8 °C, 25 °C / 60 % RH and 40°C / 75 % RH, 
respectively. Selected formulations, A03 and A15, were tested up to 25 weeks.  
Table 4.2.7 Compositions of NicQb formulations assessed for long-term stability. 
Code NicQb [mg] 
Trehalose 
dihydrate 
[% (w/v)] 
Mannitol 
[% (w/v)] 
Polysorbate20 
[% (w/v)] 
Sodium 
phosphate 
[mM] 
Potassium 
phosphate 
[mM] 
pH 
A03 0.6 10 - 0.005 20 - 6.2 
A06 0.6 10 - 0.005 - 20 6.2 
A15 0.6 10 - 0.005 20 - 5.8 
A16 0.6 1.1 4.4 0.005 20 - 6.2 
 
A03 and A06 were the lead formulations designated from the freeze-drying 
experiments with either sodium phosphate or potassium phosphate as buffering 
agents. A15, a formulation similar to A03 except for a solution pH of 5.8, was included 
because of the higher chemical stability of the drug at lower pHs (refer to pH stability 
study). The aim was to investigate whether degradation of the VLP and the cleavage 
of nicotine upon storage are reduced at this pH. Based on the findings of the  
freeze-thaw and freeze-drying studies it was now in the focus to determine whether 
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the theoretically more pronounced aggregation of NicQb at the lower pH value might 
be prevented by polysorbate 20. These three formulations were freeze-dried 
according to protocol A (chapter 2). Additionally, formulation A16 composed of 
mannitol as bulking agent and trehalose as lyoprotectant in a weight ratio of 4:1 was 
included. The underlying rationale was that a combination of a crystalline bulking 
agent (mannitol) and a non-crystallizing disaccharide could offer on the one hand a 
robust crystalline matrix enabling shorter drying times (primary drying could be 
conducted at higher temperatures due to the eutectic point of mannitol at -1.5°C [Kim 
et al., 1998]), and on the other hand protects the drug by the amorphous disaccharide 
part [Johnson et al., 2002; Izutsu et al., 2002; Liao et al., 2005; Chatterjee et al., 
2005]. Formulation A16 was freeze-dried according to protocol B (Table 4.2.8).  
Table 4.2.8 Freeze-drying protocol B. 
Step Time  [min] 
Temperature  
[°C] 
Pressure  
[mbar] 
Loading 00:00:00 20 1013 
00:01:10 -50 1013 
Freezing 
00:03:00 -50 1013 
00:00:01 -50 0.045 
04:00:00 -15 0.045 Primary drying 
20:00:00 -15 0.045 
00:00:01 -15 0.007 
06:00:00 40 0.007 Secondary drying 
10:00:00 40 0.007 
 
Primary drying was carried out at -15 °C according to Tang et al.  
[Tang et al., 2004] who proposed that combined formulations with both amorphous 
stabilizer and crystalline bulking agent can be dried more than 20 °C higher than the 
Tg’ of the specific formulation without resulting in macrocollapse. The Tg’ of 
formulation A016 was determined to -43.5 °C. Secondary drying was performed at  
40 °C in order to prevent the possible formation of an unstable mannitol hydrate at 
lower drying temperature [Yu et al., 1999]. An annealing step typically applied to 
enable complete crystallization of mannitol  [Izutsu et al., 1993; Searles et al., 2001; 
Ma et al., 2001; Lu et al., 2004] was not included because as proposed by Johnson et 
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al. mannitol crystallizes completely in formulations containing higher weight ratios of 
mannitol to disaccharide than 2 to 1 [Johnson et al., 2002].  
The samples were analyzed at multiple time points, at least in duplicate, 
according to Table 4.2.9. 
Table 4.2.9 Stability study plan. 
Test interval (weeks) 
CRITERIA 
0 6 15 25 (option) 
Characteristics Test method 
Li
qu
id
   
LY
O
 
2-
8 
°C
   
 
25
 °
C
   
 
40
 °
C
 
2-
8 
°C
   
 
25
 °
C
   
 
40
 °
C
 
2-
8 
°C
   
 
25
 °
C
   
 
40
 °
C
 
Appearance lyophilisate / 
reconstituted solution Visual inspection • / • • / • / • • / • / • • / • / • 
Reconstitution Time Time − / • • / • / • • / • / • • / • / • 
pH of reconstituted solution pH meter − / • • / • / • • / • / • • / • / • 
Residual moisture (RM) KF titration − / • • / • / • • / • / • • / • / • 
Tg  (solid) DSC − / • • / • / • • / • / • • / • / • 
Morphology  XRD − / • − / − / − − / − / • − / − / − 
Free nicotine RP-HPLC • / • • / • / • • / • / • • / • / • 
NicQb integrity SE-HPLC 
• / • 
• / • / • • / • / • • / • / • 
NicQb degradation LDS-PAGE 
• / • 
• / • / • • / • / • • / • / • 
RNA integrity SE-HPLC 
• / • 
• / • / • • / • / • • / • / • 
NicQb aggregation AF4 
• / • 
• / • / • • / • / • • / • / • 
NicQb aggregation DLS 
• / • 
• / • / • • / • / • • / • / • 
Particulate matter Light obscuration 
• / • 
• / • / • • / • / • − / − / − 
 
Complete data sets for all methods, formulations and storage conditions are 
presented in tables in the annex of this chapter. In the following paragraphs a 
selection of the most significant results is presented. 
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Characterization of the physical state of the lyophilizates 
After freeze-drying all formulations showed excellent appearance. The trehalose 
based formulations A03, A06 and A15 resulted in stable cakes with only rare cracks 
and a marginal shrinkage. Upon storage, even at accelerated temperature none of 
these formulations showed significant alteration. The reason for the good 
macroscopical stability of the formulations A03, A06 and A15 is the high glass 
transition temperature of the mainly trehalose based matrix. Formulation A16 
exhibited no  shrinkage neither during freeze-drying nor upon storage which can be 
assigned to its mostly crystalline structure. Pictures of representative lyophilizates 
stored for 3 months at 40 °C are shown in Figure 4.2.18. 
 
Figure 4.2.18 Appearance of NicQb lyophilizates after 15 weeks storage at 40 °C. 
Residual moisture of all formulations was initially determined to be below 0.5 % 
(Figure 4.2.19). The mannitol / trehalose based formulation A16 exhibited the lowest 
initial water content of 0.15 %  which could be related to the higher secondary drying 
temperature applied for this formulation (FD protocol B). Upon storage for 15 and 25 
weeks at 2-8 °C and 25 °C / 60 % RH, respectively,  only a negligible increase of the 
water content (increase of RM content < 0.3 %) was observed. Upon storage at  
40 °C / 75 % RH significantly higher amounts of water were absorbed from the 
stoppers by all formulations, but even here the increase of the residual moisture level 
was below 1.0 % (Figure 4.2.19). According to Shalaev and Zografi low residual 
moisture content is important to minimize chemical degradation upon storage and to 
prevent plasticizing of the amorphous matrix [Shalaev et al., 1996].  
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Figure 4.2.19 Residual moisture content of freeze-dried NicQb formulations right after the drying 
process and after 6, 15 and 25 weeks storage at 40 °C / 75 % RH.  
The plasticizing effect of water was clearly observed by the Tgs of the 
amorphous trehalose based formulations A03, A06 and A15. Right after freeze-drying 
the glass transition temperatures were between 96 and 99 °C which is in good 
accordance to literature [Crowe et al., 1996; Hancock et al., 1997]. After storage at  
2-8 °C and 25 °C / 60 % RH no clear changes of the Tgs could be detected. Upon 
storage at 40 °C / 75 % RH a decrease of the Tgs of 5-10 °C of the initial value was 
noted (Figure 4.2.20) which could be related to the increase of the water content. The 
decrease of the Tgs by increasing water contents is confirmed by literature; as 
described by Franks depression of Tg can amount to 10 degrees for each percent of 
moisture uptake by the lyophilizate [Franks et al., 1991].  
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Figure 4.2.20  Glass transition temperatures of freeze-dried NicQb trehalose based formulations after 
the drying process and after 6, 15 and 25 weeks storage at 40 °C / 75 % RH. 
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As highlighted in the previous section high glass transition temperature of a 
formulation is considered to be one of the most important parameters for long-term 
stability of a labile drug. Following the recommendations of Hancock et al. the glass 
transition temperature should be 50 °C above the intended storage temperature to 
minimize molecular mobility to the point of zero mobility and achieve sufficient stability 
[Hancock et al., 1995]. The intended storage temperature was ambient temperature, 
so that the desired glass transition temperature was designated to  
70 °C.  The formulations A03, A06 and A15 met these requirements over the whole 
time span tested.  
Additionally to the DSC runs XRD measurements revealed that the formulations 
A03, A06 and A15 were amorphous after freeze-drying and that the glassy state was 
maintained upon storage for 15 weeks, even at 40 °C, exemplarily shown for 
formulation A03 (Figure 4.2.21).  
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Figure 4.2.21 Physical state of NicQb formulation A03 determined by XRD after manufacture and after 
15 weeks storage at 40 °C. 
Concerning the physical state of the mannitol / trehalose based formulation A16 
the XRD measurements revealed that after freeze-drying the lyophilizates were 
partially crystalline / partially amorphous and that the amorphous mannitol crystallized 
in an uncontrolled manner upon storage at 40 °C (Figure 4.2.22). The physical state 
was additionally analyzed by DSC. Amorphous mannitol is known to crystallize upon 
heating [Izutsu et al., 1994; Kim et al., 1998]. First DSC heating scans of the 
formulation stored for 15 weeks showed that mannitol crystallized completely upon 
storage at 40 °C because no exothermal event, indicating crystallization of amorphous 
mannitol could be observed. By contrast, the samples stored at 2-8 °C and 25 °C 
remained partially amorphous (Figure 4.2.23). Here, exothermal events comparable to 
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the starting material, indicating crystallization of mannitol, were observed. The melting 
point of mannitol, determined from the second heating scan was always around  
156 °C; it was not affected by storage time or condition. According to Burger et al. this 
melting temperature corresponds to the δ-modification of mannitol [Burger et al., 
2000]. This finding was confirmed by the XRD measurements (Figure 4.2.22), 
because specific peaks for the α- and β-modifications of mannitol at 17.3 °2-Theta 
and 14.7 °2-Theta, respectively, did not appear in the diffractogram [Hawe et al., 
2006]. Furthermore, XRD measurements showed that mannitol hydrate was not built 
during freeze-drying as the specific peak of 17.9 °2-Theta did not appear in the 
diffractogram. These results indicate that mannitol, in contrast to the proposal of 
Johnson et al. [Johnson et al., 2002], did not completely crystallize during  
freeze-drying. An uncontrolled crystallization of mannitol upon storage is undesirable 
because it is proposed to affect the stability of labile drugs, as e.g, described for 
gelatin nanoparticles [Zillies, 2007] and monoclonal antibodies [Costantino et al., 
1998].    
 
Figure 4.2.22 Physical state of NicQb formulation A16 determined by XRD after manufacture and after 
15 weeks storage at 40 °C / 75 % RH. 
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Figure 4.2.23 First DSC heating scans of NicQb formulation A16 after manufacture and after 15 
weeks storage at 40 °C / 75 % RH. 
Characterization of the reconstituted lyophilized formulations 
The lyophilizates were reconstituted right after lyophilization and after storage 
with 0.6 mL highly purified water. All samples could easily be dissolved within 5 
seconds. After reconstitution the appearance of all formulations was comparable and 
was not altered by storage temperature and time. The solutions were colourless and 
free of visible particles. Furthermore, the pH of the formulations remained stable upon 
the whole stability study. Additionally, the osmolality of reconstituted lyophilizates of all 
formulations was determined after manufacture. It was found that all formulations 
were isoosmotic (Table 4.2.10).  
Table 4.2.10 Osmolality of reconstituted NicQb lyophilizates 
Code Osmolality  [mosm/kg] 
A03 318 
A06 318 
A15 314 
A16 320 
Stability of NicQb  
The physical stability of NicQb was analyzed by AF4, DLS and light obscuration. 
In the following the results obtained for these three analytical methods are exemplarily 
shown for the samples before and after freeze-drying and after storage at 
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40 °C / 75 % RH. Complete data sets for all storage conditions are presented in 
Tables 4.5.1, 4.5.6 and 4.5.7 of the annex.  
Concerning the aggregation of NicQb AF4 measurements (Figure 4.2.26) as well 
as DLS (Figure 4.2.25) and light blockage analysis (Figure 4.2.24) indicated that all 
formulations were capable of stabilizing the drug substance during freeze-drying. 
None of the performed analytical methods revealed any significant changes from the 
liquid formulations prior to freeze-drying to the lyophilized formulations. The 
preservation of the physical stability of NicQb during freeze-drying might be related to 
the prevention of VLP aggregation at interfaces by polysorbate 20 [Shi et al., 2005], 
and to the protection of the drug in the amorphous trehalose matrix by vitrification and 
water replacement [Hancock et al., 1997; Allison et al., 1999; Chang et al., 2005]. DLS 
measurements revealed no significant changes of the proportions of the main NicQb 
peak and the polydispersity indices (Figure 4.2.25 and Table 4.5.7 in the annex); 
furthermore, the determined average size of the VLP remained constant for all 
formulations and storage conditions (37 ± 1 nm). Additionally, light blockage 
measurements denoted no significant changes of NicQb stability upon storage for any 
of the assessed formulations, even at accelerated temperature (Figure 4.2.24 and 
Table 4.5.6 in the annex).  
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Figure 4.2.24 Number of particles > 1 µm, determined by light blockage, in NicQb formulations A03, 
A06, A15 and A16 prior to freeze-drying, right after freeze-drying and after storage for 6 and 15 weeks at 
40 °C / 75 % RH. 
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Figure 4.2.25 Proportions of main NicQb peak (A) and polydispersity indices of NicQb (B), determined 
by DLS, in NicQb formulations A03, A06, A15 and A16 prior to freeze-drying, right after freeze-drying and 
after storage for 6, 15 and 25 weeks at 40 °C / 75 % RH. 
AF4 analysis, the most sensitive method for the determination of VLP 
aggregation (see chapter 3), indicated a slight increase (increase of aggregation level 
< 3 %) of NicQb aggregates in all formulations upon storage. This increase of the 
aggregation level was observed for all storage temperatures (Figure 4.2.26 and Table 
4.5.1 in the annex). It was found that the theoretically more pronounced aggregation 
of the VLP at the lower pH value in formulation A15 was prevented by polysorbate 20. 
Hence, it seemed that NicQb could be stabilized in the amorphous trehalose matrix of 
formulations A03, A06 and A15 as well as in the partially crystalline (mannitol) / 
partially amorphous (trehalose) matrix of formulation A16. The crystallization of 
mannitol upon storage (see previous paragraph) did not affect the physical stability of 
NicQb, at least in the presence of amorphous trehalose.  
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Figure 4.2.26 Amount of NicQb oligomers and aggregates, determined by AF4, in NicQb formulations 
A03, A06, A15 and A16 prior to freeze-drying, right after freeze-drying and after storage for 6, 15 and 25 
weeks at 2-8 °C (A), 25 °C / 65 % RH (B) and 40 °C / 75 % RH (C). 
The chemical stability of NicQb was investigated using SE-HPLC, RP-HPLC and 
LDS-PAGE. Chemical instability of NicQb results in the disassembly of the VLP into 
monomers or multimers of the Qb coat protein, degradation of the RNA incorporated 
in the VLP and / or the dissociation of the hapten nicotine and the Qb VLP. 
Furthermore, the single coat proteins could be hydrolyzed to smaller peptide chains. 
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SE-HPLC measurements revealed that the integrity of NicQb was preserved in all 
formulations during freeze-drying and subsequent storage at all temperatures tested. 
Only a slight increase of the amount of degradation products such as single Qb coat 
proteins or multimers of the Qb coat proteins and RNA form the inner core could be 
observed (Figure 4.2.27 and Table 4.5.2 in the annex). Thus, it appeared that all 
formulations were capable of stabilizing the VLP against disassembly even at 
accelerated storage temperature.  
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Figure 4.2.27 Amount of fragmentation products of NicQb, determined by SE-HPLC, in NicQb 
formulations A03, A06, A15 and A16 prior to freeze-drying, right after freeze-drying after storage for 6, 15 
and 25 weeks at 2-8 °C (A), 25 °C / 65 % RH (B) and 40 °C / 75 % RH (C). 
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In order to assess the integrity of the incorporated RNA SE-HPLC analysis was 
carried out. This was important because as described by Vaughan et al. RNA might 
be prone to hydrolysis even in dried formulations [Vaughan et al., 2006]. The RNA 
was first extracted from the VLP and subsequently analyzed. Hydrolysis of the RNA 
would result in smaller RNA fragments that would lead to a shift of the RNA signal to 
higher retention times and / or the appearance of further RNA peaks. The SE-HPLC 
results revealed that the RNA remained stable in all formulations upon the whole time 
span tested, independent of the storage temperature. Neither shifts in the retention 
time of the three specific RNA peaks at 8.7, 10.4 and 10.9 min could be observed, nor 
could additional RNA peaks be detected. Exemplarily, the chromatograms obtained 
for formulation A03 after manufacture and after storage for 25 weeks at 40 °C / 75 % 
RH are depicted in Figure 4.2.28.  
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Figure 4.2.28 SE-HPLC analysis of RNA integrity of NicQb formulation A03 after freeze-drying and 
after storage for 25 weeks 40 °C / 75 % RH. 
With respect to the stability of the esterbond linking nicotine to the VLP surface, 
RP-HPLC analysis revealed that it remained stable during freeze-drying in all 
formulations tested. Upon storage at 2-8 °C and 25 °C only a marginal increase  
(< 0.5 %) of the content of free nicotine derivatives was detected for all formulations 
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(Table 4.5.3 of the annex) which was obviously more pronounced after storage at  
40 °C (Figure 4.2.29). The increasing hydrolysis of the esterbond could either be 
related to the increasing water content and / or decreased stability of the esterbond at 
higher temperatures, illustrated exemplarily in Figure 4.2.30 for formulation A03 after 
25 weeks storage time. However, even for these samples the amount of free nicotine 
derivatives was below 1.5 % of total coupled nicotine after 25 weeks.  
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Figure 4.2.29 Amount of free nicotine derivatives, determined by RP-HPLC, in NicQb formulations 
A03, A06, A15 and A16 after storage for 6, 15 and 25 weeks at 40 °C / 75 % RH. Data for the liquid 
formulations and the lyophilized starting material are not shown, because the free nicotine content was 
below the limit of quantification (≤ 0.2 %). 
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Figure 4.2.30 Amount of free nicotine derivatives, determined by RP-HPLC and moisture content, 
determined by KF titration, in NicQb formulations A03 stored at 40 °C / 75 % RH for 25 weeks.  
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LDS-PAGE was performed to analyze the stability of the Qb coat proteins. 
Degradation products of the Qb coat protein monomer appear as bands of an 
apparent molecular weight smaller than the molecular weight of the Qb coat protein 
monomer (14.1 kDa). All silver stained gels obtained for the formulations before 
freeze-drying, after freeze-drying and after storage, independent of storage 
conditions, showed two bands corresponding to an approximate molecular weight of 
5-6 kDa and 11-13 kDa. After storage at 2-8 °C and 25 °C up to 15 weeks (A06 and 
A16) or 25 weeks (A03 and A15) an increase of these bands was not observed for 
any of the four formulations. After storage at 40 °C the intensity of these bands 
increased for all formulations, but quantification (comparison to standard dilutions) 
revealed that it was still less than 0.1 % of the intensity of the band corresponding to 
the Qb coat protein monomer. Exemplarily, an LDS-PAGE gel obtained for formulation 
A03 after storage for 25 weeks at 40 °C / 75 % RH is displayed in Figure 4.2.31. 
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Figure 4.2.31 LDS-PAGE analysis of NicQb formulation A03 after 25 weeks storage at  
40 °C / 75 % RH.   
As the formulations A03 and A15, which differ only in the pH, showed almost 
similar results for the amounts of degradation products and free nicotine derivatives it 
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could be stated that for the dried formulation the pH effect is not that distinctive as for 
liquid formulations (compare pH stability study).  The study revealed that lowering the 
pH in formulation A15 (pH 5.8) as compared to the lead formulation A03 (pH 6.2) led 
to no further improvement of the chemical stability of NicQb.  
Conclusion 
It was found that all formulations tested were capable of stabilizing NicQb during 
freeze-drying. Physical as well as chemical stability of NicQb was maintained 
throughout the performed freeze-drying processes. Stable lyophilizates with excellent 
appearance and moisture contents below 0.5 % were produced.  
Upon storage over 15 weeks (formulations A06 and A16) and 25 weeks 
(formulations A03 and A15), respectively, at 2-8 °C, 25 °C / 60 % RH and  
40 °C / 75 % RH for all formulations no significant changes concerning the physical 
stability of NicQb could be observed. Concerning the chemical stability of NicQb it was 
found that all formulations were capable of preserving the integrity of the VLP, the 
incorporated RNA and the Qb coat proteins upon the whole time span, independent of 
the storage temperature. In view of the stability of the bond between nicotine and the 
Qb VLP only a marginal increase of the amount of nicotine derivatives, cleaved from 
the VLP surface, could be detected for the samples stored at 40 °C which could be 
traced back to the slight increase of the residual moisture content. However, the 
proportion of cleaved nicotine was for all formulations still below 1.5 %.  
With respect to the morphology of the lyophilizates it was found that the trehalose 
based formulations remained amorphous upon storage at all temperatures whereas 
the mannitol / trehalose based formulation led to an uncontrolled crystallization of 
mannitol upon storage at 40 °C. Even though the stability of NicQb was not affected 
by this uncontrolled crystallization of mannitol such uncontrolled changes are 
undesirable. Therefore, the freeze-drying process applied for this formulation should 
be optimized so that mannitol crystallizes completely in a controlled manner during the 
process. 
Finally, it was concluded that all formulations were suitable candidates for the 
stabilization of NicQb during freeze-drying and upon storage, even at ambient 
temperature.  
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4.2.5 Bioactivity Testing of NicQb Lyophilizates 
The stability study revealed that the formulations A03, A06 and A15 were 
capable of stabilizing NicQb upon storage. Nevertheless, the retention of biological 
activity had to be verified. As the three formulations were comparable concerning the 
physical and chemical stability of NicQb, only formulation A03 was assessed for 
bioactivity. The bulk material (used as internal standard, stored at -80 °C), and 
lyophilized samples (frozen at -20 °C after manufacture) were compared to samples 
stored at 2-8 °C, 25 °C and 40 °C for 41 weeks. The respective antibody titers (dose 
of 100 µg) are shown in Figure 4.2.32. 
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Figure 4.2.32  Bioassay analysis of NicQb formulation A03 upon immunisation of mice with 100 µg of 
formulated product stored at different temperatures for 41 weeks. P-values obtained by comparison with 
the bulk material (defined as internal standard STD) and formulated product stored at  
-20 °C (T0) using an unpaired two-tailed t-test with a confidence interval of 95 % are shown on top of 
each bar. Differences identified as significant are marked by asterisk (*). 
Upon immunization with 100 µg NicQb none of the samples stored for 41 weeks, 
independent of storage temperature, showed loss of activity in comparison to the 
material right after manufacture (Figure 4.2.32). An unpaired two-tailed t-test 
(confidence interval 95 %) performed for the results of each preparation in comparison 
to the bulk material also showed no significant differences, except for A03 stored at 
2-8 °C, with a p-value only slightly below 0.05. In this case an even higher antibody 
titer was determined for the lyophilisate as compared to the standard.  
Finally, it could be concluded that even long-term storage of NicQb formulation 
A03 at accelerated temperatures did not result in lower antibody titers in comparison 
to the bulk material and the formulation right after freeze-drying.  
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4.2.6 Optimization of Freeze-Drying Process for Mannitol / Trehalose 
Based Formulation and Study of the Effect of a Pure Crystalline 
Formulation on the Stability of NicQb 
Data obtained during the stability study for formulation A16 with mannitol as 
bulking agent and trehalose as lyoprotectant revealed that this composition was 
capable of stabilizing NicQb during freeze-drying and storage at 2-8 °C and 25 °C 
over 15 weeks. However, upon storage at 40 °C uncontrolled crystallization of the 
partially amorphous mannitol was observed. Thus, the aim of this experiment was to 
optimize the freeze-drying process to ensure controlled, complete mannitol 
crystallization during the freeze-drying process. This can be achieved by applying an 
annealing step, a thermal treatment step in which samples are maintained at a 
specific subfreezing temperature for a period of time [Izutsu et al., 1993; Lueckel et 
al., 1998a; Searles et al., 2001; Lu et al., 2004].  Hence, formulation A16 was  
freeze-dried according to two freeze-drying protocols: without (FD protocol B,  
chapter 2) and with (FD protocol C, chapter 2) a 2 hour annealing step at -15 °C. 
Additionally, for a better understanding of the effect of an amorphous matrix in 
comparison to a crystalline or partially crystalline matrix on the stability of NicQb a 
further formulation (A17), composed of 1 mg / mL NicQb, 5 % mannitol, 0.005 % 
polysorbate 20 and 20 mM sodium phosphate (pH 6.2) was freeze-dried according to 
freeze-drying protocol C (chapter 2).  The stability of the drug and the physical state of 
all formulations were investigated right after manufacture and after storage for 6 
weeks at 2-8 °C, 25 °C and 40 °C. 
Characterization of the physical state of the lyophilizates 
After freeze-drying all formulations showed excellent appearance which was not 
altered upon storage. The residual moisture content of all formulations was initially 
below 0.5 % and increased only slightly upon storage. Even after storage for 6 weeks 
at 40 °C the water content was still below 0.8 % (Figure 4.2.33). 
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Figure 4.2.33 Residual moisture, determined by KF titration, in NicQb formulations A16 prepared by 
applying FD protocol B (marked with an asterisk) and by applying FD protocol C (without asterisk) and 
A17 (freeze-dried by using FD protocol C) right after freeze-drying and after storage for 6 weeks. 
All dried formulations showed a typical XRD peak pattern for crystalline mannitol. 
For formulation A17 peaks of all mannitol modifications (α-, β- and δ-mannitol) were 
detected, whereas both A16 formulations, independent of implementation of an 
annealing step, showed solely the typical peaks for δ-mannitol [Kim et al., 1998; Hawe 
et al., 2006] (Figure 4.2.34). The formation of δ-modification, which is described to be 
less stable than the α- and β- modifications [Yu, 2003], might be provoked by the 
cosolute trehalose [Kim et al., 1998].   
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Figure 4.2.34 XRD diffractograms of NicQb formulations A16 prepared by applying FD protocol B 
(marked with an asterisk) and by applying FD protocol C (without asterisk) and A17 (freeze-dried by 
using FD protocol C) right after freeze-drying. 
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The DSC measurements revealed that mannitol in formulation A16 was only 
partially crystalline when freeze-dried without annealing whereas it was completely 
crystalline when an annealing step was applied. The first DSC heating scan of the 
non-annealed material showed an exothermal event which could be referred to the 
crystallization of amorphous mannitol [Kim et al., 1998]. This crystallization peak of 
mannitol was not detected for the lyophilizates of the formulations A16 and A17 which 
were produced according to freeze-drying protocol C including an annealing step 
(Figure 4.2.35).  
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Figure 4.2.35 First heating DSC scan of NicQb formulations A16 prepared by applying FD protocol B 
(marked with an asterisk) and by applying FD protocol C (without asterisk) and A17 (freeze-dried by 
using FD protocol C) right after freeze-drying. 
XRD measurements performed after 6 weeks storage showed no changes in the 
peak pattern, independent of storage temperature, for any of the formulations tested 
(data not shown). By contrast, DSC measurement revealed that, according to the 
findings from the former stability study, the partially amorphous mannitol in formulation 
A16 produced with FD protocol B crystallized completely upon storage at 40 °C. 
However, formulations A16 and A17 produced with FD protocol C exhibited no 
changes in the thermal behavior. Thus, it was concluded that applying an annealing 
step was necessary to achieve complete mannitol crystallization during freeze-drying 
and to prevent uncontrolled crystallization of mannitol upon storage.  
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Stability of NicQb 
Concerning the physical stability of NicQb it was found that independent from 
applying an annealing step formulation A16 was capable of stabilizing the drug during 
freeze-drying and upon storage for 6 weeks at 2-8 °C, 25 °C and 40 °C. AF4 results 
revealed only a slight increase of the aggregation level during freeze-drying and upon 
storage (Figure 4.2.36). The preservation of the physical stability of NicQb by 
formulation A16 might be achieved by the prevention of direct interactions of the drug 
within the amorphous disaccharide portion as proposed for example by Chatterjee et 
al. and Johnson et al. [Johnson et al., 2002; Chatterjee et al., 2005]. By contrast, for 
formulation A17 an increase of the amount of aggregates was observed which was 
even more pronounced after storage at 25 °C and 40 °C, respectively  
(Figure 4.2.36). This observation can be explained by the findings of Izutsu et al. and 
Lueckel et al. who described that potentially protective interactions of mannitol with a 
labile drug are lost by crystallization of mannitol upon freeze-drying. Furthermore, it is 
described that crystallization of mannitol can also change the degree of freeze-
concentration which in turn can lead to drug aggregation upon processing and storage 
[Izutsu et al., 1994; Lueckel et al., 1998b].  
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Figure 4.2.36  Amount of NicQb oligomers and aggregates, determined by AF4, in NicQb formulations 
A16 prepared by applying FD protocol B (marked with an asterisk) and by applying FD protocol C 
(without asterisk) and A17 (freeze dried by using FD protocol C) right after freeze-drying and after 
storage for 6 weeks. 
With respect to the chemical stability of NicQb SE-HPLC and RP-HPLC 
measurements indicated that the stability of NicQb was preserved during  
freeze-drying and upon storage by formulation A16, independent of the applied FD 
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protocol, whereas for formulation an increase of NicQb fragments and of the amount 
of free nicotine derivatives was detected after storage at 40 °C (Figure 4.2.37 and 
Figure 4.2.38).  Interestingly, the increase of the free nicotine derivatives in 
formulation A17 seemed not to be solely dependent on the residual water content as 
all formulations revealed comparable amount of residual moisture. It appeared that 
the instability of the bond between nicotine and the Qb VLP is closely related to the 
aggregation NicQb. One explanation might be an autocatalytic hydrolysis of the 
esterbond between nicotine and the succinyl linker enabled by the accumulation of 
NicQb, and thus, possible direct chemical interactions.  
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Figure 4.2.37 Amount of NicQb fragments, determined by SE-HPLC, in NicQb formulations A16 
prepared by applying FD protocol B (marked with an asterisk) and by applying FD protocol C (without 
asterisk) and A17 (freeze-dried by using FD protocol C) right after freeze-drying and after storage for 6 
weeks. 
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Figure 4.2.38 Amount of free nicotine derivatives, determined by RP-HPLC, in NicQb formulations 
A16 prepared by applying FD protocol B (marked with an asterisk) and by applying FD protocol C 
(without asterisk) and A17 (freeze-dried by using FD protocol C) right after freeze-drying and after 
storage for 6 weeks. 
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The integrity of the RNA incorporated in the VLP, determined by Bioanalyzer, 
remained stable for all formulations and storage condition, all samples showed the 
same RNA pattern. Furthermore, LDS-PAGE analysis revealed that the integrity of the 
Qb coat proteins was not affected by any of the formulations independent of the 
storage conditions, similar Qb coat protein band profiles were obtained for all 
samples.   
Conclusion 
It can be stated that a completely crystalline matrix was not capable of stabilizing 
NicQb during freeze-drying and upon storage. This observation is in accordance to 
the findings of Izutsu et al. and Chang et al. who  proposed that the implementation of 
an amorphous lyoprotectant is indispensable for the protection of a labile drug [Izutsu 
et al., 1994; Chang et al., 1996]. On the other hand the combination of crystalline 
mannitol as bulking agent, leading to physically remarkably stable lyophilizates with 
excellent appearance, and amorphous trehalose, which stabilizes the drug, seemed to 
be a further promising formulation for NicQb. The performance of an annealing step 
led to complete crystallization of mannitol during the freeze-drying process, and thus 
the initially observed, unwanted uncontrolled crystallization of mannitol upon storage 
could be resolved.   
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4.3 Summary  
During the present work the development of stable NicQb lyophilizates meeting 
the requirements for large scale clinical study and commercial use was demonstrated. 
Due to the well structured study setup from pH, freeze-thaw,  
freeze-drying and finally long-term stability studies a very fast progress towards a 
commercializable product was feasible.  
A grid of parameters critical for stabilizing the VLP based vaccine NicQb during 
freeze-drying and storage at 2-8 °C and ambient temperature was determined. It was 
found that an amorphous disaccharide matrix was suitable for the stabilization of 
NicQb. The addition of polysorbate 20 was very beneficial for preventing aggregation 
of the VLP.  Furthermore, it was shown that combined formulations of a crystalline 
bulking agent together with an amorphous disaccharide can also be applied for the 
manufacture of stable freeze-dried NicQb formulations. The freeze-dried formulations 
showed all excellent appearance, were composed of approved excipients, and could 
easily be reconstituted to parenterally applicable isotonic liquids.  
Finally, full retention of biological activity of VLP lyophilizates, even after 
long-term storage, was demonstrated. 
Furthermore, robust, short freeze-drying processes which can easily be 
transferred to large-scale production freeze-dryers were developed.  
.  
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4.5 Annex 
Table 4.5.1 Amount of NicQb oligomers and aggregates, determined by AF4, in NicQb formulations 
prior to freeze-drying, freeze-dried NicQb formulations right after freeze-drying and after storage for 6, 15 
and 25 weeks, respectively, at 2-8 °C, 25 °C / 60 % RH and 40 °C / 75 % RH. 
Oligomers and aggregates [%] 
Start 6 weeks 15 weeks 25 weeks Formulation 
Liquid LYO 2-8°C 25°C 40°C 2-8°C 25°C 40°C 2-8°C 25°C 40°C 
A03 5.03 ± 0.19 
5.13 
± 0.25 
6.10 
± 0.00 
6.35 
±0.07 
6.55 
± 0.35 
7.05 
± 0.07 
6.15 
± 0.21 
6.60 
± 0.00 
8.00 
± 1.27 
7.80 
± 0.42 
7.10 
± 0.14 
A06 6.13 ± 0.78 
5.77 
± 0.12 
6.50 
± 0.28 
6.20 
±0.57 
6.37 
± 0.67 
7.20 
± 0.42 
7.00 
± 0.14 
6.60 
± 0.00 n/a n/a n/a 
A15 5.43 ± 0.13 
5.27 
± 0.21 
6.95 
± 0.21 
6.80 
± 0.28 
6.95 
± 0.35 
6.90 
± 0.14 
7.10 
± 0.14 
7.90 
± 0.42 
8.35 
± 0.35 
7.35 
± 0.07 
7.75 
± 0.21 
A16 5.13 ± 0.24 
5.50 
± 0.00 
6.45 
± 0.35 
5.90 
± 0.57 
6.35 
± 0.49 
6.95 
± 0.21 
7.15 
± 0.07 
6.20 
± 0.14 n/a n/a n/a 
 
 
Table 4.5.2 Amount of degradation products of NicQb, determined by SE-HPLC, in NicQb 
formulations prior to freeze-drying, freeze-dried NicQb formulations right after freeze-drying and after 
storage for 6, 15 and 25 weeks, respectively, at 2-8 °C, 25 °C / 60 % RH and 40 °C / 75 % RH. 
Degradation products [%] 
Start 6 weeks 15 weeks 25 weeks Formulation 
Liquid LYO 2-8°C 25°C 40°C 2-8°C 25°C 40°C 2-8°C 25°C 40°C 
A03 1.54 ± 0.23 
2.34 
± 0.07 
2.35 
± 0.02 
2.34 
±0.02 
2.55 
± 0.01 
2.40 
± 0.04 
2.33 
± 0.01 
2.59 
± 0.01 
2.75 
± 0.28 
2.37 
± 0.10 
2.60 
± 0.03 
A06 1.57 ± 0.03 
1.98 
± 0.04 
2.07 
± 0.03 
2.02 
±0.01 
2.02 
± 0.02 
2.13 
± 0.02 
2.07 
± 0.01 
2.32 
± 0.06 n/a n/a n/a 
A15 1.54 ± 0.23 
2.47 
± 0.01 
2.51 
± 0.01 
2.47 
± 0.01 
2.75 
± 0.00 
2.55 
± 0.01 
2.51 
± 0.01 
2.79 
± 0.01 
2.36 
± 0.01 
2.37 
± 0.01 
2.74 
± 0.01 
A16 1.54 ± 0.23 
2.69 
± 0.21 
2.58 
± 0.25 
2.42 
± 0.16 
2.83 
± 0.13 
3.01 
± 0.47 
2.37 
± 0.12 
3.04 
± 0.07 n/a n/a n/a 
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Table 4.5.3 Amount of free nicotine derivatives, determined by RP-HPLC, of NicQb formulations 
prior to freeze-drying, freeze-dried NicQb formulations right after freeze-drying and after storage for 6, 15 
and 25 weeks, respectively, at 2-8 °C, 25 °C / 60 % RH and 40 °C / 75 % RH. 
Free nicotine [% of total nicotine] 
Start 6 weeks 15 weeks 25 weeks Formulation 
Liquid LYO 2-8°C 25°C 40°C 2-8°C 25°C 40°C 2-8°C 25°C 40°C 
A03 <0.20* <0.20* 0.35 ± 0.00 
0.38 
±0.00 
0.77 
± 0.02 
0.30 
± 0.00 
0.41 
± 0.00 
1.05 
± 0.06 
0.45 
± 0.02 
0.61 
± 0.02 
1.32 
± 0.02 
A06 <0.20* <0.20* 0.31 ± 0.02 
0.38 
±0.00 
0.75 
± 0.06 
0.31 
± 0.02 
0.43 
± 0.00 
1.03 
± 0.00 n/a n/a n/a 
A15 <0.20* <0.20* 0.31 ± 0.02 
0.38 
± 0.00 
0.69 
± 0.06 
0.29 
± 0.02 
0.38 
± 0.00 
0.95 
± 0.08 
0.45 
± 0.02 
0.57 
± 0.00 
1.25 
± 0.12 
A16 <0.20* <0.20* 0.34 ± 0.02 
0.43 
± 0.04 
0.72 
± 0.02 
0.33 
± 0.00 
0.53 
± 0.06 
1.35 
± 0.06 n/a n/a n/a 
* Amount of nicotine not detectable due to detection limit 
 
Table 4.5.4 Residual moisture content of freeze-dried NicQb formulations right after freeze-drying, 
and after storage for 6, 15 and 25 weeks, respectively, at 2-8 °C, 25 °C / 60 % RH and 40 °C / 75 % RH. 
Residual moisture [%] 
Start 6 weeks 15 weeks 25 weeks Formulation 
LYO 2-8°C 25°C 40°C 2-8°C 25°C 40°C 2-8°C 25°C 40°C 
A03 0.49 ± 0.00 
0.60 
± 0.06 
0.63 
±0.07 
0.89 
± 0.04 
0.56 
± 0.08 
0.74 
± 0.08 
1.20 
± 0.03 
0.66 
± 0.01 
0.79 
± 0.04 
1.55 
± 0.00 
A06 0.49 ± 0.13 
0.54 
± 0.04 
0.61 
±0.04 
0.82 
± 0.04 
0.44 
± 0.05 
0.65 
± 0.18 
1.12 
± 0.01 n/a n/a n/a 
A15 0.51 ± 0.01 
0.56 
± 0.11 
0.60 
± 0.01 
0.81 
± 0.01 
0.52 
± 0.04 
0.58 
± 0.01 
1.20 
± 0.04 
0.52 
± 0.03 
0.66 
± 0.01 
1.39 
± 0.07 
A16 0.15 ± 0.06 
0.11 
± 0.06 
0.20 
± 0.01 
0.52 
± 0.01 
0.12 
± 0.04 
0.29 
± 0.05 
0.94 
± 0.06 n/a n/a n/a 
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Table 4.5.5 Tg (point of inflection) of freeze-dried trehalose based NicQb formulations right after 
freeze-drying, and after storage for 6, 15 and 25 weeks, respectively, at 2-8 °C, 25 °C / 60 % RH and  
40 °C / 75 % RH. 
Glass transition temperature Tg [°C] 
Start 6 weeks 15 weeks 25 weeks Formulation 
LYO 2-8°C 25°C 40°C 2-8°C 25°C 40°C 2-8°C 25°C 40°C 
A03 98.9 ± 0.61 
96.75 
± 5.44 
96.27 
± 2.15 
94.95 
± 4.88 
98.2 
± 2.12 
96.60 
± 1.84 
89.27 
± 1.42 
100.25 
± 0.21 
97.50 
± 1.84 
93.15 
± 1.34 
A06 97.13 ± 1.94 
97.85 
± 9.83 
95.90 
± 0.14 
91.05 
± 0.35 
100.65 
± 0.07 
97.85 
± 3.46 
90.65 
± 0.21 
100.55 
± 1.91 
92.65 
± 2.76 
89.25 
± 0.64 
A15 96.35 ± 6.01 
101.25 
± 3.18 
94.83 
± 7.22 
96.50 
± 2.40 
97.10 
± 0.28 
96.85 
± 0.07 
90.05 
± 2.47 n/a n/a n/a 
 
 
Table 4.5.6 Number of particles ≥ 1 and ≥ 10 µm, respectively, determined by light obscuration, in 
NicQb formulations prior to freeze-drying, freshly reconstituted solutions of freeze-dried NicQb 
formulations right after freeze-drying, and after storage for 6, 15 and 25 weeks, respectively, at  
2-8 °C, 25 °C / 60 % RH and 40 °C / 75 % RH. 
Number of particles ≥ 1 µm and ≥ 10 µm / mL 
Start 6 weeks 15 weeks Formulation 
Liquid LYO 2-8°C 25°C 40°C 2-8°C 25°C 40°C 
1418 
± 856 
1105 
± 229 
818 
± 190 
1190 
± 102 
560 
± 354 
843 
± 751 
623 
± 610 
788 
± 666 
A03 
30 ± 27 95 ± 53  33 ± 22 58 ± 43 35 ± 31 208 ± 223 33 ± 39 23 ± 15 
1425 
± 1102 
1140 
± 785 
678 
± 179 
1225 
± 516 
578 
± 158 
720 
± 712 
958 
± 979 
1423 
± 987 
A06 
42.5 ± 34 100 ± 70 13 ± 5 18 ± 10 33 ± 15 53 ± 32 33 ± 13 18 ± 13 
1980 
±1337 
1263 
±722 
1463 
± 816 
795 
± 500 
1173 
± 578 
1848 
± 1556 
748 
± 551 
1308 
± 724 
A15 
45 ± 27 50 ± 57 15 ± 6 40 ± 14 30 ± 25 245 ± 178 23 ± 33 48 ± 44 
1758 
± 952 
788 
± 382 
438 
± 107 
838 
± 146 
570 
± 260 
1150 
± 721 
1690 
± 1377 
1118 
± 295 
A16 
25 ± 17 70 ± 35 10 ± 14 38 ± 31 13 ± 5 218 ± 101 13 ± 10 23 ± 10 
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Table 4.5.7 Proportion of main NicQb peak and polydispersity index of NicQb formulations prior 
to freeze-drying, freshly reconstituted solutions of freeze-dried NicQb formulations right after 
freeze-drying, and after storage for 6, 15 and 25 weeks, respectively, at 2-8 °C, 25 °C / 60 % RH and  
40 °C / 75 % RH. 
Proportion of main NicQb peak [%]  and PI 
Start 6 weeks 15 weeks 25 weeks Formulation 
Liquid LYO 2-8°C 25°C 40°C 2-8°C 25°C 40°C 2-8°C 25°C 40°C 
98.11 
± 1.74 
99.14 
± 0.82 
99.05 
± 0.84 
98.85 
± 0.70 
99.38 
± 0.44 
98.63 
± 0.85 
98.85 
± 1.02 
99.30 
± 0.44 
98.58 
± 0.78 
98.88 
± 0.37 
98.75 
± 0.81 
A03 
0.15 
± 0.00 
0.16 
± 0.00 
0.16 
± 0.00 
0.16 
± 0.01 
0.15 
± 0.00 
0.15 
± 0.00 
0.15 
± 0.01 
0.16 
± 0.01 
0.16 
± 0.01 
0.16 
± 0.01 
0.17 
± 0.01 
99.44 
± 0.38 
99.61 
± 0.30 
99.39 
± 0.31 
99.38 
± 0.32 
99.36 
± 0.48 
99.10 
± 1.07 
98.78 
± 0.43 
99.10 
± 1.07 n/a n/a n/a 
A06 
0.15 
± 0.00 
0.15 
± 0.00 
0.15 
± 0.00 
0.17 
± 0.00 
0.14 
± 0.00 
0.15 
± 0.00 
0.15 
± 0.01 
0.15 
± 0.01 n/a n/a n/a 
97.88 
± 1.05 
98.23 
± 1.29 
98.67 
± 0.83 
99.11 
± 0.25 
99.54 
± 0.27 
99.45 
± 0.31 
98.68 
± 1.99 
99.45 
± 0.50 
99.55 
± 0.17 
99.40 
± 0.24 
99.25 
± 0.52 
A15 
0.16 
± 0.00 
0.16 
± 0.00 
0.16 
± 0.00 
0.16 
± 0.01 
0.16 
± 0.01 
0.16 
± 0.01 
0.17 
± 0.01 
0.16 
± 0.00 
0.17 
± 0.01 
0.16 
± 0.01 
0.19 
± 0.03 
99.27 
± 0.62 
98.97 
± 1.06 
99.20 
± 0.70 
99.78 
± 0.08 
99.23 
± 0.74 
99.50 
± 0.34 
99.30 
± 0.43 
99.55 
± 0.26 n/a n/a n/a 
A16 
0.15 
± 0.00 
0.15 
± 0.00 
0.15 
± 0.00 
0.15 
± 0.01 
0.14 
± 0.01 
0.15 
± 0.01 
0.15 
± 0.01 
0.15 
± 0.00 n/a n/a n/a 
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5. DEVELOPMENT OF SUSTAINED RELEASE 
SYSTEMS FOR VIRUS-LIKE PARTICLE BASED 
VACCINES 
5.1 Introduction 
Vaccines aiming on the prevention or therapy of diseases typically require 
multiple applications to achieve the desired immune response [Bloom, 1989; Cleland, 
1999; Kaufmann, 2004]. This frequent dosing is inconvenient with respect to patient’s 
compliance and treatment costs. Hence, the development of single injection vaccine 
formulations is highly desirable. In 1979 Preis et al. introduced an implant formulation 
based on the non-degradable copolymer ethylene-vinyl acetate (EVAc), with BSA as 
model antigen, which was capable of releasing the antigen continuously over several 
months, and thus, leading to comparably high antibody titers as a multiple application 
of a liquid BSA formulation [Preis et al., 1979]. Based on these promising experiments 
great efforts have been taken during the last decades to develop single injection 
vaccines. A major milestone in this context was, without any doubt, the World Health 
Programme for Vaccine Development, initiated in the late 1980, with neonatal tetanus 
as its first target. This initiative clearly accelerated research in the area of controlled 
delivery devices for antigens, from peptides and proteins to viruses. For example 
Dewar et al. showed that the immune response of rabbits to HSA microspheres 
encapsulating Nodamura virus was significantly higher and longer lasting than for the 
fluid antigen [Dewar et al., 1984]. Similar observations were made by Greenway et al. 
in a mice model who employed PLGA microcapsules for the immunization against 
venezuelan equine encephalomyelitis virus [Greenway et al., 1995]. Sturesson et al. 
encapsulated inactivated rotavirus in PGLA microspheres and demonstrated high 
antibody levels in mice [Sturesson et al. 2000]. The existing literature on formulation 
strategies for vaccines is copious, as exemplarily displayed in Table 5.1.1., and even 
more research work has been done in the field of controlled release formulations for 
therapeutic peptides and proteins. 
However, up to now only a few controlled release devices, all based on poly 
(lactide) (PLA) and poly (lactide-co-glycolide) (PLGA) are on the market (Lupron® 
Depot, Zoladex®, Eligard®, Profact® Depot, Enantone® Depot, Sandostatin® LAR 
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Depot, Trenantone®, Decapeptyl® Depot and Suprefact® Depot), and all of them 
include peptides rather than proteins and vaccines.  
Table 5.1.1 Examples of single-dose vaccine systems. 
Delivery system Vaccine / immunogen Material  Reference 
Bovine serum 
albumin EVAC [Preis et al., 1979] 
Bovine serum 
albumin Cholesterol and lecithin [Khan et al., 1991] 
Recombinant 
dichelobacter 
nodosus pili 
Cholesterol and lecithin [Walduck et al., 1998] 
Avidin and 
clostridial toxoid Silicone 
[Lofthouse et al., 2002;  
Kemp et al., 2002] 
Malaria vaccine 
(SPf66) PLGA [Dorta et al., 2002] 
Implant 
Plasmid DNA Agarose [Toussaint et al., 2007] 
In situ forming 
implant Plasmid DNA PLGA [Eliaz et al., 2002] 
Minipellet 
Tetanus toxoid 
and diphteria 
toxoid 
Collagen [Higaki et al., 2001] 
Tetanus toxoid PLA and PLGA 
[Esparza et al., 1992; Alonso  
et al., 1994; Chang et al., 1996; 
Johansen et al., 1998; Sanchez 
et al., 1999; Katare et al., 2006] 
Tetanus toxoid Gelatin / poloxamer core and PLGA shell [Tobio et al., 1999a] 
Tetanus toxoid PLGA and ABA-triblock copolymers [Jung et al., 2002] 
Tetanus toxoid PLGA and chitosan [Jaganathan et al., 2005] 
Tetanus toxoid Mineral oil core and PLGA shell [Sanchez et al., 1996] 
Diphtheria toxoid 
and tetanus toxoid PLA and PLGA 
[Johansen et al., 1999;  
Peyre et al., 2003] 
Microparticles 
Haemophilus 
influenza b 
conjugate, 
diphtheria toxoid, 
tetanus toxoid and 
pertussis toxoid 
PLA and PLGA [Boehm et al., 2002] 
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Delivery system Vaccine / immunogen Material Reference 
Diphteria toxoid PLA [Singh et al., 1991] 
Recombinant HIV 
envelope protein 
(MN gp120) 
PLGA 
[Cleland et al., 1994; Moore et al., 
1995; Cleland et al., 1996b; 
Cleland et al., 1997;  
Cleland et al., 1998] 
Hepatitis B virus 
surface antigen 
Hydroxypropyl cellulose 
core and PLGA shell [Lee et al., 1997] 
Hepatitis B virus 
surface antigen PLGA 
[Singh et al., 1997; Shi et al., 
2002; Feng et al., 2006] 
Hepatitis B virus 
surface antigen PELA [Li et al., 2002] 
Malaria antigen PLA and PLGA  [Thomasin et al., 1996] 
Malaria antigen  PLA and PCL with phospholipids and lipid A [Amselem et al., 1992] 
Staphylococcal 
enterotoxin B PLGA [Eldridge et al., 1991] 
Pneumotropic 
bacterial antigen PLA and PLGA [Kofler et al., 1996] 
PEI / DNA 
complexes Chitosan [Domb, 2006; Zhou et al., 2007] 
Nodamura virus RSA [Dewar et al., 1984] 
Venezuelan 
equine 
encephalitis virus 
PLGA [Greenway et al., 1995] 
Bovine serum 
albumin 
Squalen core and PLGA 
or PCL shell [Youan et al., 2001] 
Monovalent 
influenza vaccine PLA and PLGA 
[Coombes et al., 1998;  
Hilbert et al., 1999] 
Trivalent influenza 
vaccine PLGA and PIBCA [Chattaraj et al., 1999] 
Inactivated duck 
parvovirus PLA and PLGA [Palinko-Biro et al., 2001] 
Rotavirus vaccine Poly (acryl starch) and PLGA [Sturesson et al., 2000] 
Microparticles 
Avidin and 
clostridial toxoid Lipospheres [Domb, 2006] 
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Poly (α-hydroxy esters) PLA and PLGA found most widespread use due to their 
excellent safety and biocompatibility [Gombotz et al., 1995; van de Weert et al., 2000; 
Johansen et al., 2000b; Schwendeman, 2002]. Furthermore, applying these polymers 
tailor-made release kinetics, like continuous or pulsed release, can be achieved by 
varying parameters like molecular weight of the monomers, PLA to PLGA ratio, size 
and shape of the final formulation (microparticles, implants), addition of further 
excipients like pore building substances, e.g. PEG, and different preparation methods 
[Johansen et al., 2000a; Kang et al., 2001; Sandor et al., 2001; Wang et al., 2002]. 
This is an important issue as up to now it is still unclear which release profile induces 
the most potent immune response [Lofthouse, 2002; O'Hagan et al., 2003]. Even 
though most of the scientists claim that a pulsed release, which mimics the common 
vaccination schedule, is preferable [Medlicott et al., 1999; Lima et al., 1999; Gander  
et al., 2001] other studies demonstrated that a continuous release profile also induced 
high antibody titers [Preis et al., 1979; Cleland et al., 1996a; Toussaint et al., 2007].  
Despite these benefits several inherent shortcomings of PLA / PLGA and the 
resulting detrimental effects on the stability especially of complex drugs like proteins 
and vaccines during processing, storage and release might explain the limited 
success of these polymeric delivery systems [Fu et al., 2000; van de Weert et al., 
2000; Schwendeman, 2002; Perez et al., 2002; Sinha et al., 2003; Bilati et al., 2005].  
The broad spectrum of techniques for the preparation of implants and 
microparticles and linked drug stability issues are summarized in Table 5.1.2. With the 
exception of the manufacture of implants by simple compression all other fabrication 
methods implicate stress factors that may alter drug stability. The major drawback 
seems to be the use of organic solvents for the dissolution of the polymers leading, in 
dependence of the applied preparation method, to the formation of water / organic 
solvent or solid drug / organic solvent interfaces. Antigens, which are typically 
composed of proteins (substances with an amphiphilic character) tend to adsorb at 
such interfaces which consequently can result in protein unfolding followed by  
non-covalent aggregation [Schwendeman et al., 1997; Sanchez et al., 1999; Sah, 
1999a; Sah, 1999b; van de Weert et al., 2000].  
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Table 5.1.2 Common techniques for the preparation of implants and microparticles and linked 
problems. 
Formulation Preparation Challenges on drug stability References 
Direct compression 
of PLGA and solid 
drug 
 -  
[Ramchandani et al., 1997; 
Takahashi et al., 2004;  
Onishi et al., 2005] 
Solvent casting Exposure to organic solvent 
[Garcia et al., 2002;  
Dorta et al., 2002;  
Santovena et al., 2006] 
Molding Exposure to high temperature [Park et al., 1995] 
Implants 
Extrusion Exposure to high temperature and pressure [Witt et al., 2000] 
In situ forming 
implants 
Implant formation 
at the injection site  Exposure to organic solvent 
[Eliaz et al., 2000;  
Ravivarapu et al., 2000;  
Matschke et al., 2002;  
Packhaeuser et al., 2004] 
Solvent 
evaporation and 
extraction 
Exposure to organic solvent 
/ water interfaces and shear 
/ cavitation / forces and 
temperature stress during 
emulsification in 
dependence of the applied 
emulsification process 
[Alonso et al., 1994; Greenway 
et al., 1995; Schwendeman  
et al., 1996; Schwendeman  
et al., 1997; Sanchez et al., 
1999; Sah, 1999b; van de 
Weert et al., 2000; Yeo et al., 
2001; Shi et al., 2002; Jiang  
et al., 2004; Freitas et al., 
2005; Feng et al., 2006] 
Phase separation 
Exposure to organic solvent 
/ water interfaces and shear 
/ cavitation forces 
[Esparza et al., 1992; 
Thomasin et al., 1998; 
Johansen et al., 1999;  
Peyre et al., 2003] 
Spray drying 
Exposure to organic solvent 
/ water interfaces and shear 
forces 
[Khan et al., 1992; Johansen 
et al., 1998; Johansen et al., 
1999; Jain, 2000; 
Peyre et al., 2003] 
Microcapsules 
Supercritical fluid 
precipitation Exposure to organic solvent 
[Jain et al., 1998; Jain, 2000; 
Tamber et al., 2005] 
 
In addition to the stress factors identified during processing several detrimental 
conditions for antigens evolve in PLA / PLGA based systems during release [Chang  
et al., 1996; Schwendeman et al., 1997; Schwendeman, 2002; Sinha et al., 2003; 
Jiang et al., 2005]. Poly (α-hydroxy esters) matrices undergo bulk erosion, meaning 
that polymer degradation is slower than the water uptake of the device. Consequently, 
the matrix is completely wetted before cleavage of the polymer chains begins 
[Gombotz et al., 1995; Goepferich, 1996; von Burkersroda et al., 2002]. Hence, upon 
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incubation the matrix degrades (homogeneously) throughout the device and the acidic 
degradation products are trapped within the matrix, accumulate, and lead to an 
altered microenvironment: 
(1) pH drop [Zhu et al., 2000; Fu et al., 2000] 
(2) Increase of osmotic pressure [Brunner et al., 1999] 
(3) Accumulation of reactive species [Lu et al., 1995; Lucke et al., 2002] 
These changes in the environment may cause protein unfolding, aggregation and 
chemical degradation, and thus, lead to a loss of efficacy. Additionally, water uptake 
of the polymer matrix during incubation leading to an increase in antigen mobility can 
result in conformational changes of epitopes and consequently to antigen aggregation 
[Schwendeman et al., 1995; Costantino et al., 1994]. Furthermore, interactions 
between PLA / PLGA or degradation products thereof with the antigen can cause 
inactivation of the antigen and incomplete release [Crotts et al., 1997; Johansen et al., 
1999; Palinko-Biro et al., 2001].  
Thus, to overcome these stability concerns several attempts have been taken. 
For example, basic additives such as magnesium hydroxide and calcium carbonate 
were introduced as buffer salts to counteract the pH drop within PLGA devices during 
hydrolytic polymer degradation [Johansen et al., 1998; Zhu et al., 2000; Zhu et al., 
2000]. Other approaches suggest the addition of pore forming substances, like e.g. 
PEG, or the use of PELA copolymers to ameliorate the potential pH decrease during 
matrix degradation. Thereby, the porosity of the matrix is increased which in turn 
accounts for the accelerated diffusion of acidic degradation products out and of buffer 
components into the device [Jiang et al., 2001; Perez et al., 2002; Zhou et al., 2003].  
Another attempt was the development of microcapsule formulations consisting of 
an inner oily core, in which the antigen is entrapped, surrounded by an outer PLGA 
shell. The oily core is deemed to protect the antigen against deleterious environmental 
conditions like moisture and acidic pH and to prevent permeation of PLGA 
degradation products until the polymer shell is degraded and releases the inner core 
[Sanchez et al., 1996].  
Besides investigations on stabilization strategies within PLGA-based devices 
several alternative matrix materials for the delivery of proteins have been investigated 
(Table 5.1.1). Among them  especially lipids, e. g. fatty acids, glycerides and waxes, 
gain more and more attention as matrix formers for parenteral controlled release 
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devices [Khan et al., 1991; Opdebeeck et al., 1993; Walduck et al., 1998; Mohl et al., 
2004; Maschke et al., 2004; Koennings et al., 2005]. Lipids as natural, physiological 
materials, exhibit an excellent biocompatibility [Reithmeier et al., 2001; Guse et al., 
2006]. A potential advantage compared to PLGA is the prevention of an acidic 
microenvironment, and thus, potentially preservation of drug integrity upon release.  
Furthermore, with lipids additional preparation methods such as melt dispersion 
or spray congealing are applicable for particulate devices which do not require the use 
of organic solvents [Reithmeier et al., 2001; Maschke et al., 2007].  Due to the 
excellent compressibility of lipids the preparation of implants can be realized by 
compression without the employment of heat, what can be beneficial with respect to 
both production costs and protein stability [Wang, 1989; Mohl et al., 2004]. However, 
first attempts taken by Kent et al. to develop cholesterol based controlled release 
devices for macromolecules failed due to the poor release rates which might be 
related to the low diffusivity of large molecules and the lack of an interconnected pore 
network [Kent, 1994]. Later on, Mohl et al. demonstrated that by adding PEG as pore 
forming substance to tristearin implants this drawback could be overcome and release 
rates up to 50 % for BSA and 90 % for interferon α-2a within 30 days were attainable 
[Mohl, 2003]. However, a drawback of such lipidic implants is their unclear 
biodegradability. In vivo experiments revealed lack of erosion for pure triglyceride 
based devices, so that large devices would need to be removed by surgical recision 
after completed release [Vogelhuber et al., 2003; Guse et al., 2006]. Nevertheless, 
there is some information available that drawbacks related to lipid biodegradation can 
be solved by admixing of amphiphilic lipids, such as phospholipids, to the implant 
formulation [Khan et al., 1991].  
Summing up, lipids are deemed to be promising matrix materials and the 
potential of lipid-based sustained release systems for the delivery of vaccines might 
be investigated as alternate to the standard PLGA. In the following chapter preliminary 
experiments towards the development of sustained release devices for VLP based 
vaccines are presented. The in vitro release behavior of two model VLP vaccines, 
AngQb and QbG10p33, from PLGA and lipid based implant formulations was studied 
and the in vivo efficacy of these provisional sustained release devices was tested in 
mice. Additionally, basic experiments towards the preparation of an enhanced 
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sustained release device, PLGA microcapsules with an oily inner core, were 
performed.  
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5.2 Results and Discussion 
5.2.1 Preparation of VLP Lyophilizates as Starting Material 
First, for the preparation of sustained release devices for VLP the designated 
VLP candidates had to be freeze-dried. Therefore, based on the findings of the 
formulation development studies for NicQb (compare chapter 4) it was investigated 
whether AngQb and QbG10p33 can be stabilized during freeze-drying by the same 
excipients like NicQb, i.e. polysorbate 20 and trehalose.  
Preformulation studies, performed by Cytos Biotechnology AG, revealed that the 
optimal pH for AngQb was 7.2 and that the addition of low amounts of sodium chloride 
was important to preserve its integrity. Thus, in a first attempt the AngQb formulation 
FA01 (Table 5.2.1) was freeze-dried according to freeze-drying protocol A (see 
chapter 2).  
Table 5.2.1:  Compositions of AngQb formulation FA01 (filling volume - 0.7 mL). 
Code VLP [mg] 
Trehalose  
[mg] 
Polysorbate20 
[% (w/v)] 
Sodium 
chloride 
[mM] 
Sodium 
phosphate 
[mM] 
pH 
FA01 1.40 47.25 0.005 50 20 7.2 
 
AF4 measurements revealed that the integrity of AngQb in formulation FA01 was 
preserved upon freeze-drying. Neither fragmentation nor aggregation of AngQb was 
observed (Figure 5.2.1).  
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Figure 5.2.1 Stability of AngQb, determined by AF4, in formulation FA01 prior to and after FD.  
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Interestingly, the experiment indicated that an excipient combination of trehalose 
as lyoprotectant and polysorbate 20 as cryoprotectant, as it was used for NicQb, was 
also capable to stabilize AngQb upon freeze-drying.  
However, for the preparation of sustained release devices with adequate drug 
payloads, there was the need to prepare highly concentrated VLP lyophilizates.  
Hence, in a second step the AngQb / trehalose ratio (w / w) was reduced from 1 : 33.8 
(formulation FA01) to 1 : 6 (formulation FA02, Table 5.2.2) leading to an AngQb 
concentration of 300 µg /  2.5 mg lyophilizate. Formulation FA02 was freeze-dried 
according to freeze-drying protocol A (chapter 2).  
Table 5.2.2 Compositions of AngQb formulation FA02 (filling volume - 0.6 mL). 
Code VLP [mg] 
Trehalose  
[mg] 
Polysorbate20 
[% (w/v)] 
Sodium 
chloride 
[mM] 
Sodium 
phosphate 
[mM] 
pH 
FA02 2.24 13.50 0.005 50 20 7.2 
 
After freeze-drying lyophilizates with excellent appearance and a residual 
moisture content of 1.2 % were obtained. AF4 measurements indicated that even at 
this low lyoprotectant / drug weight ratio the integrity of AngQb was maintained upon 
freeze-drying (Figure 5.2.2).  
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Figure 5.2.2 Stability of AngQb, determined by AF4, in formulation FA02 prior to and after FD.  
 
Consequently, the freeze-dried AngQb formulation FA02 was used as starting 
material for the preparation of sustained release systems. 
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For QbG10p33 no data were available concerning its stability with respect to 
varying pHs or the presence of sodium chloride. Thus, according to the experiences 
made with NicQb (see chapter 4) and AngQb (see above) formulation FQ01 (Table 
5.2.3), with and QbG10p33 concentration of 300 µg / 2.5 mg (QbG10p33 / trehalose 
weight ratio 1 : 7.5), was freeze-dried according to protocol A (chapter 2).  
Table 5.2.3 Compositions of QbG10p33 formulation FQ01 (filling volume - 0.6 mL). 
Code VLP [mg] 
Trehalose  
[mg] 
Polysorbate20 
[% (w/v)] 
Sodium 
phosphate 
[mM] 
pH 
FQ01 1.80 11.56 0.005 20 7.2 
 
After freeze-drying lyophilizates with excellent appearance and a residual 
moisture content of 1.7 % were obtained. AF4 measurements revealed that the 
integrity of QbG10p33 was maintained upon freeze-drying (Figure 5.2.3). The API 
bulk already contained relatively large amounts of QbG10p33 oligomers and 
aggregates but the proportion of this VLP fraction was not altered during  
freeze-drying.  
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Figure 5.2.3 Stability of QbG10p33, determined by AF4, in formulation FQ01 prior to and after FD.  
It can be stated that the excipient composition of trehalose as lyoprotectant and 
polysorbate 20 as cryoprotectant was, according to the results obtained for NicQb and 
AngQb, also capable of stabilizing QbG10p33. Hence, formulation FQ01 was used as 
starting material for the manufacture of sustained release devices.  
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5.2.2 Definition of Release Study Parameters 
Selection of container and release medium 
The release medium used for in vitro release studies with AngQb and QbG10p33 
sustained release formulations was phosphate buffered saline composed of 50 mM 
sodium chloride and 20 mM sodium phosphate buffer at a pH of 7.2. Furthermore, 
sodium azide was added at a concentration of 0.05 % as bacteriostatic agent. This 
composition was chosen based on the results obtained during preformulation studies, 
performed by Cytos Biotechnology AG, which indicated the highest stability of AngQb 
at this salt concentration and pH. Preliminary experiments performed with AngQb 
solutions (1 mg / mL) at 37 °C indicated that it tended to fragmentate even at this 
“optimum” pH (Figure 5.2.4).  Based on these results the release media was 
exchanged at least every third day.  
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Figure 5.2.4 Stability of AngQb (1 mg / mL) at 37 °C at pH 7.2, determined via SE-HPLC. 
 
The determination of the most appropriate container for release studies is 
another crucial parameter, because upon long-term release studies the amount of 
VLP in the release medium was expected to be extremely low (< 20 µg / mL). 
Adsorption of VLP to the container surface might result in lower drug concentrations 
detected in the release medium. Therefore, the adsorption behavior of AngQb to four 
different container types was investigated: (1) Standard Eppendorf reaction tubes, (2) 
LoBind Eppendorf reaction tubes (Eppendorf AG, Hamburg, Germany), (3) 2R class 1 
glass vials (Schott AG, Mainz, Germany), and (4) TopPac® vials (Schott AG, Mainz, 
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Germany). Adsorption of AngQb to the different containers was analyzed at two drug 
concentrations, 20 µg / mL and 100 µg / mL, respectively, upon incubation at 37 °C for 
7 days. As surfactants are often used to prevent adsorption to surfaces [Cleland et al., 
1997; Tobio et al., 1999b; Palinko-Biro et al., 2001; Jaganathan et al., 2005], the 
effect of polysorbate 20 (0.01 % w / w), on the adsorption behavior of AngQb to the 
above mentioned containers was additionally examined. The AngQb amount in the 
respective samples was determined via RP-HPLC (see chapter 2). The results 
obtained revealed a strong adsorption of AngQb to all container types in the absence 
of polysorbate 20, where glass vials and TopPac® vials exhibited the worst results 
with more than 50 % adsorption after 7 days at an AngQb concentration of 
20 µg / mL. By adding polysorbate 20 to the AngQb solutions adsorption to the 
container surfaces could be clearly reduced, exemplarily displayed in Figure 5.2.5 for 
the AngQb solution of 20 µg / mL. The results indicated that the most favorable 
container was the LoBind Eppendorf reaction tube. Here, less than 10 % of AngQb 
were adsorbed to the container after 3 days. Thus, LoBind Eppendorf reaction tubes 
were used as container for the release studies with AngQb and QbG10p33 sustained 
release devices and polysorbate 20 was added in a concentration of 0.01 % (w / w) to 
the release medium. 
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Figure 5.2.5 Adsorption behavior of AngQb (20 µg / mL) in the presence of 0.01 % polysorbate 20 to 
different container types upon 7 days storage. AngQb concentration determined via RP-HPLC. 
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Evaluation of quantification method 
For in vitro release studies an adequate analytical method for drug quantification 
is inevitable. Common methods for protein based drugs are the bicinchoninic acid 
(BCA) [Chattaraj et al., 1999; Higaki et al., 2001; Feng et al., 2006] and Bradford 
[Thomasin et al., 1996] assays, which are both applicable for protein concentrations 
down to 1 µg / mL. Besides these colorimeteric assays ELISA es a further commonly 
used quantification method which is applicable even for antigen concentrations in the 
ng range [Singh et al., 1991; Jung et al., 2002; Katare et al., 2006].  
However, as all of these methods have some specific drawbacks their 
applicability for the quantification of VLP was investigated.  
The Bradford assay is a dye binding assay in which a differential color change of 
Coomassie Brilliant Blue dye from 465 nm to 595 nm occurs due to stoichiometric 
protein binding. From the optical absorbance the protein concentration can be 
calculated by using a protein standard curve [Bradford, 1976]. This assay is very 
sensitive to surfactants especially at very low protein concentrations [Compton et al., 
1985]. Preliminary experiments with AngQb solutions indicated that even slight 
variations in the surfactant concentration had clear effects on the determined VLP 
amount. However, the addition of polysorbate 20 to the release medium was essential 
to prevent the adsorption of the VLP to the container. As potentially different amounts 
of polysorbate might adsorb to the container surfaces leading to varying amounts of 
polysorbate in the release medium it was assumed that this method was inappropriate 
for the quantification of VLP in the samples obtained during release studies.  
The BCA method involves the reduction of Cu2+ to Cu+ by peptidic bonds of 
proteins. The BCA chelates Cu+ ions with very high specificity to form a water soluble 
purple colored complex. This reaction can be measured by optical absorbance of the 
final Cu+ complex at 562 nm and is used for the determination of the protein 
concentration by applying a standard curve [Smith et al., 1985]. The method is  
non-sensitive to surfactants but susceptible to chelating substances, lipids and 
reducing substances [Smith et al., 1985; Kessler et al., 1986; Wiechelman et al., 
1988]. Preliminary experiments performed with AngQb solutions spiked with PEG (as 
potent release modifier) or lactic acid (as degradation product of PLGA) revealed that 
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both substances lead to deviant results. Hence, this protein quantification assay was 
useless as well.  
As the two commonly used colorimetric protein quantification methods were not 
well applicable a multi-step sandwich ELISA, as displayed in Figure 5.2.6, was 
developed for the quantification of VLP.  
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1) Coating with goat anti-rabbit IgG
2) Incubation with rabbit anti-Qb serum
3) Incubation with VLP standard or VLP sample
4) Incubation with mouse anti-Qb serum
5) Incubation with goat anti-mouse IgG coupled to 
horse-radish peroxidase
6) Addition of substrate (O-phenylendiamine-
dihydrochloride)
7) Measurement of absorbance at 450 nm
 
 
Figure 5.2.6 Organization of sandwich ELISA for the quantification of VLP. 
After optimization of the dilutions of the specific sera and antibody solutions linear 
standard curves (absorbance vs. concentration plot) for both VLP, AngQb and 
QbG10p33, exemplarily shown for AngQb in Figure 5.2.7, were established. 
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Figure 5.2.7 AngQb standard curve for the developed ELISA.  
Even though ELISA is a very specific quantification method for small antigens 
with single epitopes [Reid et al., 2000; Breuer, 2007], a problem can arise when 
working with large antigens, or especially large antigens that consist of multiple similar 
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subunits with potentially similar epitopes. For complex structures there is the risk of 
detecting not only the complete, intact antigens, but additionally fragmented species 
or single subunits. If e.g. a VLP is dissembled into 20 subunits that are all recognized 
by the ELISA, 20 fold too high results might be achieved. Therefore, it was 
investigated whether the developed ELISA detects purified, single Qb coat protein 
dimers (obtained by Cytos Biotechnology AG) as well. Unfortunately, this was the 
case so that even this highly sensitive quantification method could not be used. 
Finally, it could be stated that none of the commonly used methods was 
applicable for the quantification of VLP during release studies.  
Fortunately, a different approach could be applied. Cytos Biotechnology AG 
developed a RP-HPLC method for the quantification of Qb coat proteins (see  
chapter 2). The Qb VLP are assembled from 180 units of Qb coat protein monomer 
and are stabilized by tight non-covalent Qb coat protein dimer interactions and 
disulfide bonds linking each Qb coat protein dimer covalently to the rest of the coat 
[Golmohammadi et al., 1996].  For sample preparation the Qb VLP are first 
disassembled with dithiothreitol (DTT) and guanidine hydrochloride. Thereby, 
dithiothreitol, a reducing agent [Cleland, 1964], cleaves the disulfide bonds linking the 
coat proteins together, and guanidine hydrochloride, a chaotropic salt [Hatefi et al., 
1969], disrupts the non-covalent interactions and increases protein solubility. 
Subsequently, the Qb coat proteins are separated by RP-HPLC from potential 
impurities using an acetonitrile gradient under acidic conditions and are detected by 
UV absorption at 215 nm. Finally, the Qb coat protein content is determined by 
external calibration with a Qb standard. The concentration of the standards was 
determined by amino acid analysis. In Figure 5.2.8 a typical standard curve is shown, 
which reveals that this quantification method is applicable for Qb concentrations down 
to 0.1 µg / mL. Consequently, this RP-HPLC method was used for the quantification of 
VLP in samples obtained during release studies.  
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Figure 5.2.8 Qb coat protein standard curve obtained by RP-HPLC analysis.  
5.2.3 Implants 
The aim of these initial experiments was to study VLP release from implants, 
composed of PLGA or lipids as matrix materials, as simple models for sustained 
release devices. Implants were manufactured by simple compression of the matrix 
material and other excipients like pore forming substances and lyophilized VLP. This 
preparation method was chosen in order to prevent the exposure of the drug to stress 
factors like organic solvents and water / organic interfaces, shear stress or 
temperature, which are connected to preparation methods for microparticulate 
systems [Jain, 2000; Yeo et al., 2001; Sinha et al., 2003]. In addition such systems 
can be manufactured fast and easy without great operating expenses [Mohl, 2003; 
Onishi et al., 2005].  
AngQb, a therapeutic VLP for the treatment of hypertension, acting upon the 
induction of a specific anti-angiotensin antibody response [Ambuehl et al., 2007], and 
QbG10p33, a model VLP which was designed to induce T-cells additionally to an 
antibody response [Storni et al., 2004], were used for this purpose. The release 
behavior in dependence of the matrix material and the addition of further excipients 
like, e.g. pore forming agents, was investigated. Furthermore, the stability of the VLP 
upon processing and release was analyzed. Finally, the in vivo efficacy of VLP 
implants in comparison to multiple applications of a liquid formulation was studied.  
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AngQb implants  
Implants of 25 mg total weight each were produced according to the protocol 
introduced in chapter 2. In brief, five different formulations (Table 5.2.4, n = 3) were 
compressed (15 seconds, 2.0 kN) to small cylindric implants with a diameter of 3 mm, 
exemplarily shown for formulation IA01 and IA05 in Figure 5.2.9. The height of the 
PLGA based implants was about 2.6 mm whereas the tristearin based implants were 
about 3.3 mm high. The payload of AngQb was throughout all formulations 300 µg / 
implant. 
Table 5.2.4:  Compositions of AngQb implants (25 mg) used for in vitro release studies. 
Code AngQb lyophilizate 
Resomer® 
RG 502H 
Resomer®       
RG 502 
Dynasan 
118 PEG 6,000 Mg(OH)2
IA01 10 % 80 % - - 10 % - 
IA02 10 % - 80 % - 10 % - 
IA03 10 % 80 % - - 7 % 3 % 
IA04 10 % 80 % - - 6 % 4 % 
IA05 10 % - - 80 % 10 % - 
 
 
3 mm
3 mm
2.6 mm 3.3 mm
IA01 IA05
 
Figure 5.2.9  Compressed implants – formulation IA01 and IA05. 
Formulations IA01 and IA02 were chosen to study the effect of different PLGA 
materials on the release kinetics of VLP. Both polymers are composed of equivalent 
molar ratios of lactic acid to glycolic acid and have an average molecular weight of 
about 12 kDa and an inherent viscosity of 0.2 dL / g in chloroform. The difference 
between these two PLGAs is that Resomer® RG 502H exhibits free carboxylic acid 
end groups whereas in the case of Resomer® RG 502 these groups are end-capped. 
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As free carboxylic acid end groups autocatalytically accelerate the hydrolytic 
degradation of PLGA [Park, 1995] a faster release of the VLP was expected for 
Resomer® RG 502H. PEG 6,000 was added to these formulations as pore forming 
agent in order to enable an adequate release of the VLP by diffusion through a 
continuous porous network, formed within the matrix by fast dissolution of the 
hydrophilic PEG. Furthermore, by increasing the porosity of the matrix diffusion of 
acidic degradation products out of the device, and thus, prevention of a pH drop within 
the device, is described to potentially increase drug stability upon release [Bilati et al., 
2005; Jiang et al., 2005]. The PLGA based formulations IA03 and IA04 were selected 
based on the findings of Zhu et al. who showed that alteration of BSA upon release 
from PLGA implants and microspheres could be significantly reduced by the addition 
of poorly water-soluble basic salts like Mg(OH)2 which were coincorporated to 
neutralize the acidic microclimate pH [Zhu et al., 2000]. Formulation IA05, a lipid 
based formulation, was included as alternative to the standard PLGA. Such a 
tristearin / PEG based implant formulation was introduced by Mohl et al. who showed 
that it was capable of releasing BSA and interferon α-2a continuously up to 30 days 
[Mohl, 2003]. The potential advantage of lipids as matrix material in comparison to 
PLGA might be the prevention of an acidic environment, and thus, potentially 
preservation of drug integrity upon release. A drawback of lipids as matrix materials 
for sustained controlled release devices is their slow biodegradability.   
The release kinetics of the five AngQb implant formulations were investigated in 
an in vitro study over a time frame of 3 months. The cumulative release profiles of 
AngQb from the presented formulations are depicted in Figure 5.2.10. Importantly, it 
has to be mentioned that the RP-HPLC method applied can be used for the 
determination of the amount of VLP coat proteins in the release medium but not for 
stability testing as AngQb is disassembled before analysis (see page 136). PLGA 
implants swelled upon incubation and were almost completely degraded after 3 
months. By contrast, tristearin implants remained macroscopically unaltered 
throughout the release studies.  
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Figure 5.2.10 Cumulative in vitro release of AngQb from tristearin / PEG and PLGA / PEG implants 
over a time frame of 3 months.  
Following conclusions can be drawn from the presented data: 
(1) The PLGA / PEG based formulations IA01 and IA02 (10 % PEG) showed a high 
initial burst of about 55 % within the first day; A lower initial burst of ~ 50 % and 
~ 30 %, respectively, was observed for formulations IA03 (7 % PEG) and IA04 
(6 % PEG); The tristearin / PEG based formulation IA05 revealed an initial burst 
of ~ 25 %. 
(2) All formulations with exception of formulation IA04 showed a continuous release 
after the initial burst phase:  - IA01 another 25 % within day 2 – 26 
- IA02 another 15 % within day 2 – 8 
- IA03 another 30 % within day 2 – 50 
- IA05 another 45 % within day 2 – 70 
 which leveled off after the respective release periods. 
(3) For formulation IA04 a triphasic release behavior was observed. The initial burst 
was followed by a lag period up to day 27. Then, from day 27 to 84 another 
30 % were released.  
(4) All formulations revealed an incomplete release of AngQb. 
 
Formulations IA01 and IA02 showed, after a primary burst, no long-lasting or 
pulsed release of AngQb and might thus be no appropriate sustained release devices. 
Formulations IA03 and IA05 revealed a primary burst followed by a continuous AngQb 
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release up to 7 and 10 weeks, respectively. An adequate primary burst, which mimics 
the first vaccine dose, is desirable for sustained release devices for vaccines. 
Furthermore, a continuous antigen release was shown to be capable of inducing long-
lasting high antibody titers [Preis et al., 1979; Cleland et al., 1996a; Toussaint et al., 
2007], and thus, the respective formulations seemed to be promising sustained 
release devices for AngQb. However, the composition of formulation IA03 is still 
optimizable by reducing the high initial burst rate. Formulation IA04 might be a 
promising controlled release device due to its pulsed release profile. For example 
Thomasin et al. showed that a pulsed release of tetanus toxoid and malaria antigens 
from PLGA microspheres initiated high, long-lasting antibody titers in mice [Thomasin 
et al., 1996].  
 
Stability of AngQb during release from PLGA and lipid based implants 
From a quality and safety perspective the investigation of drug integrity upon 
release is an important issue. Appropriate analytical methods for the investigation of 
VLP degradation and aggregation are SE-HPLC and AF4 (compare chapter 3). 
However, both analytical methods have a limit of quantification of about 20 µg / mL. 
As the amount of AngQb released from the implant formulations investigated was 
after one ore two days below this limit, the integrity of AngQb could only be assessed 
by SE-HPLC and AF4 during the first days. Unfortunately, the analysis of the AngQb 
samples by AF4 was not feasible, probably due to interference of the excipients and / 
or degradation products of the matrix with the ultrafiltration membrane material. The 
SE-HPLC data for day 1 and 2 were compared to the starting material (Table 5.2.5). 
For all samples a slight increase of aggregated species and fragments was observed, 
but the proportion of the main AngQb peak was still > 90 %. As AngQb is rather 
unstable in solution (compare Figure 5.2.4 and Figure 5.2.14) it was not clear whether 
the observed degradation of AngQb was related to specific detrimental conditions 
upon release from the devices or was just a result of liquid storage. 
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Table 5.2.5 Stability of AngQb, determined via SE-HPLC, upon release from PLGA and lipid 
implants. 
Aggregates Main peak Fragments 
Formulation Time [d] 
Amount [%] 
AngQb   
lyophilizate FA02 - 0.1 98.7 1.1 
1 0.6 95.1 4.3 
IA01 
2 0.7 92.8 6.4 
1 0.6 94.4 5.1 
IA02 
2 0.9 92.0 7.1 
IA03 1 0.3 95.9 3.8 
IA04 1 0.1 96.7 3.2 
1 0.5 92.9 6.6 
IA05 
2 0.2 90.7 9.1 
 
Further discussion of release from PLGA implants 
The release of antigens from the bulk eroding, degradable polymer PLGA is 
generally controlled by a primary release from the surface and surface-near areas 
(initial burst) followed by a further release governed by three mechanisms: (1) 
liberation through a water-filled porous network, (2) degradation of the polymer, and / 
or (3) swelling of the system [Pitt, 1990; Cleland et al., 1994; Gombotz et al., 1995; 
Park, 1995; Johansen et al., 1999].   
The PLGA based AngQb implant formulations investigated in the present study 
exhibited different initial release rates. The primary burst relies on the initial 
penetration of water into the polymer matrix which initiates release of the drug 
entrapped very close to the surface of the matrix. Water dissolves the drug and 
enables its liberation through the developing interconnecting porous network. In 
general, the water uptake and consequently the initial release increases with 
increasing drug loadings, increasing amounts of hydrophilic porogens and increasing 
hydrophilicity of the matrix material [Perez et al., 2002; Yeo et al., 2004]. In our case 
the hydrophilicity of the matrix seemed to have no effect on the amount of initially 
liberated VLP. A similar burst of approximately 55 % was observed for formulation 
IA02, prepared with the end-capped PLGA Resomer® RG 502, and IA01, composed 
of the PLGA Resomer® RG 502H, with similar molar ratios of lactic to glycolic acids 
and the same molecular weight as Resomer® RG 502, but free carboxylic end-groups, 
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which increase the hydrophilicity of the polymer [Johansen et al., 1999]. As all 
formulations contain the same amount of VLP lyophilizate the different initial burst 
rates seemed to be solely depending on the PEG amount. With decreasing PEG 
amounts the initial burst decreased from 55 % for formulation IA01 and IA02  
(10 % PEG) over 50 % for formulation IA03 (7 % PEG) to 30 % for formulation IA04  
(6 % PEG).  
For formulations IA01, IA02 and IA03 a biphasic release profile was observed 
whereas formulation IA04 exhibited a triphasic release behavior. Formulations IA01 
and IA02 showed a short continuous release period of 26 and 8 days, respectively. 
The more prolonged release of AngQb from formulation IA01 (PLGA with free 
carboxylic end groups) in comparison to formulation IA02 (end capped PLGA) can be 
explained by the more pronounced water uptake and swelling of the more hydrophilic 
matrix, as illustrated in Figure 5.2.11, which facilitated the formation of larger pores, 
and thus, enabled increased liberation of the drug. After the short continuous release 
periods the release of AngQb leveled off due to the formation of acid and moisture 
induced AngQb aggregation and adsorption to the matrix (compare pages 145 – 148). 
For formulation IA03 a continuous release of AngQb was observed up to day 50. 
This continuous release of AngQb in comparison to formulation IA01 seemed to be 
related to the incorporation of Mg(OH)2 which was deemed to prevent AngQb 
aggregation upon incubation enabling prolonged release. These data are in good 
correlation to the findings of Zhou et al. who showed that BSA release from PLGA 
implants could be clearly increased by incorporation of poorly soluble basic additives. 
The postulated mechanism was that basic additives neutralize the acidic microclimate 
pH within the PLGA implant, consequently inhibit acid-induced BSA aggregation, and 
thus, facilitate a prolonged release of BSA [Zhu et al., 2000].  
The lag-phase obtained for formulation IA04 can be explained by its lower PEG 
(6 %) content in comparison to formulations IA01 (10 %) and IA03 (7 %). For 
formulation IA04 the water uptake was slowed down as illustrated by the swelling 
behavior of the implants (Figure 5.2.11), and thus, the formation of an interconnected 
pore network with sufficiently large pores was reduced until the matrix was degraded 
to such an extend so that the VLP could be released. However, after this lag phase a 
continuous, long-lasting AngQb release was observed which, following the theory of 
the hindrance of the release of aggregated species due to their size, led to the 
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assumption that in contrast to formulations IA01 and IA02 AngQb was protected to a 
certain level against acid-induced aggregation by coincorporated Mg(OH)2.  
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Figure 5.2.11 Swelling behavior of AngQb implants IA01, IA02, IA03 and IA04 upon 8 days 
incubation time. 
However, similar to formulations IA01 and IA02 the formulations IA03 and IA04 
revealed an incomplete release which might probably be affected by moisture induced 
aggregation, in later release periods acid induced aggregation (depletion of the 
Mg(OH)2 reservoir) and / or adsorption to the matrix.  
 
Discussion of release from tristearin implants 
The release profile from very slow degrading lipid matrices is generally controlled 
by release of the drug from the surface and surface-near areas, followed by leaching 
out of the drug through pores. As the matrix is impermeable for macromolecules the 
formation of an interconnected network is essential to facilitate the release of 
adequate amounts of the incorporated drug. This can be achieved by high drug 
loadings or the incorporation of hydrophilic substances, such as PEG. Thereby, first 
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the drug and the water soluble excipient located at the surface of the device and in 
surface-near areas are dissolved and released very fast. Then, water penetrates into 
the system and further dissolves the incorporated drug and the porogen leading to the 
creation a porous microstructure which in turn enables further leaching of the drug. At 
low drug loadings and / or too low amounts of porogen an interconnected network 
might not be achieved, so that not the entire drug has access to the water-filled pores, 
and thus, cannot be released [Kaewvichit et al., 1994; Vogelhuber et al., 2003; Mohl 
et al., 2004; Koennings et al., 2006; Herrmann et al., 2007b].  
The tristearin / PEG based AngQb implant formulation IA05 was produced 
following the findings of Mohl et al. who showed that interferon α-2a could be released 
almost completely (~ 90 %) upon a time span of 30 days from an almost similar 
implant formulation (10 % lyophilized interferon α-2a, 80 % tristearin, 10 % PEG 
6,000) [Mohl et al., 2004]. Comparing the release profiles from AngQb formulation 
IA05 to the interferon α-2a release data it is apparent that despite a comparable initial 
burst (~ 25 %) a lower amount of AngQb was released upon a clearly longer time 
span. A reason for this finding might be the remarkably higher molecular weight of 
AngQb (~ 4.1 MDa) in comparison to interferon α-2a (19 kDa). Even though smaller 
implants (3 mm vs. 5 mm diameter) were produced by applying lower compressions 
force (2.0 kN vs. 19.6 kN) and shorter compression time (15 s vs. 30 s), in order to 
facilitate the formation of larger pore diameters, liberation of the larger VLP was 
hindered. Other possible reasons for an incomplete release are adsorption of AngQb 
to the matrix and / or moisture induced aggregation of the drug induced by the slow 
hydration upon release (compare pages 146-147).  
 
Reasons for incomplete release 
In order to examine the adsorption behavior of AngQb to the specific matrix 
materials, placebo implants composed of 10 % placebo lyophilizate, 80 % Resomer® 
RG 502, Resomer® RG 502H or tristearin, respectively, and 10 % PEG 6,000 were 
produced according to the same protocol used for the preparation of the verum 
implants (see chapter 2). The placebo implants were placed in LoBind Eppendorf 
reaction tubes together with 1 mL AngQb solution (0.3 mg / mL – amount equal to 
payload of the verum implants, 20  mM sodium phosphate buffer, 0.01 % polysorbate 
20 and 0.05 % sodium azide, pH 7.2) and incubated for 7 days at 37 °C and an 
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agitation speed of 40 rpm. The AngQb concentration was monitored via RP-HPLC at 
least in duplicate. The results, depicted in Figure 5.2.12., revealed that almost 15 % of 
the material was adsorbed to all placebo implant formulations after 7 days incubation 
time. Thus, it was assumed that adsorption of AngQb to PLGA and tristearin is a 
potential cause for the incomplete release during in vitro studies.  
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Figure 5.2.12 Adsorption of AngQb (0.3 mg / mL) to placebo implants upon incubation for 7 days at 
37 °C. 
Now the effect of moisture induced aggregation of AngQb within the implants 
upon incubation was investigated. To simulate the slow hydration of dried AngQb 
within the implants upon release AngQb lyophilizates (FA02, Table 5.2.2) were stored 
unsealed for four weeks at 40 °C in a controlled humidity environment (75 % RH). 
Additionally, AngQb lyophilizates were stored in closed containers under the same 
conditions. After storage, the samples were reconstituted in 0.6 mL purified water. In 
contrast to the lyophilizates stored sealed the lyophilizates stored open could not be 
reconstituted completely, and large particles were macroscopically visible. Samples 
were filtered through a PVDF filter (0.22 µm pore size). All samples were analyzed by 
SE-HPLC at least in duplicate. In Figure 5.2.13 the proportions of the specific VLP 
fractions, in relation to the total amount of VLP in the untreated samples, are 
displayed. The results revealed that the most of the material aggregated upon open 
storage; the loss of about 90 % AngQb was ascribed to the formation of insoluble VLP 
aggregates which were removed by the filtration step.   
 
Development of Sustained Release Systems for VLP Based Vaccines 
___________________________________________________________________________ 
147 
 
0
10
20
30
40
50
60
70
80
90
100
FA02 starting material FA02 stored sealed FA02 stored open 
am
ou
nt
 [%
]
oligomers / aggregates
main peak
fragments
 
Figure 5.2.13 Stability of AngQb lyophilizates, determined by SE-HPLC, after storage for 4 weeks 
open or sealed at 40 °C and 75 % RH. The proportions of the different VLP fractions are expressed as 
relative amount to the total amount of the untreated sample.  
Moisture induced aggregation can be related to non-covalent aggregation 
induced by conformational changes of the drug due to an increased mobility 
[Schwendeman et al., 1995; Costantino et al., 1995; Perez et al., 2002] or covalent 
aggregation such as disulfide interchange [Liu et al., 1991]. As the leaching of huge 
aggregated VLP species from the specific implants might be more improbable than for 
the intact VLP, it was assumed that moisture induced aggregation was a further cause 
for the incomplete release of AngQb from the implant formulations investigated.  
With the aim to investigate whether acid induced aggregation was a further cause 
of incomplete AngQb release from PLGA implants, as for example proposed for BSA 
and tetanus toxoid [Johansen et al., 1998; Zhu et al., 2000], the stability of AngQb in 
dependence of the pH was investigated. Therefore, four AngQb solutions 
(0.3 mg / mL, 20 mM sodium phosphate buffer) with pHs of 4.0. 5.0. 6.0 and 7.2, 
respectively, were prepared by dilution of the API bulk with pH adjusted buffers. Right 
after manufacture, the AngQb solutions with a pH ≤ 6.0 were turbid indicating 
aggregation of AngQb. Consequently, the formulations were filtered through a PVDF 
filter (0.22 µg pore size) and subsequently incubated for 7 days at 37 °C and an 
agitation speed of 40 rpm. The stability of AngQb upon storage was investigated via 
AF4 and SE-HPLC at least in duplicate.  
Initial measurements showed that the whole AngQb material was aggregated in 
the solutions with a pH ≤ 5.0. The results obtained for the AngQb solutions with a pH 
of 6.0 and 7.2 are illustrated in Figure 5.2.14 and Figure 5.2.15. The results showed 
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that AngQb degraded upon incubation at both pHs and aggregated at a pH of 6.0. 
The loss of about 45 % AngQb observed for the liquid formulation with a pH of 6.0 
was ascribed to the formation of insoluble VLP aggregates which were removed by 
filtration. Thus, it was assumed that acid induced aggregation played a major role for 
the incomplete release of the drug from PLGA based implants. 
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Figure 5.2.14 Stability of AngQb at a pH of 7.2 (A) and 6.0 (B), determined by AF4, upon storage for 
7 days at 37 °C.   
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Figure 5.2.15 Stability of AngQb at a pH of 7.2 (A) and 6.0 (B), determined by SE-HPLC, upon 
storage for 7 days at 37 °C.   
Summary 
The in vitro release study revealed that the liberation of AngQb from PLGA or 
lipid based implants, as provisional sustained release devices, was feasible for 
several weeks. For PLGA based implants both, triphasic and biphasic release profiles, 
were achieved by variations of the matrix composition. The lipid based implant 
formulation exhibited a biphasic release profile. As literature describes the induction of 
high antibody titers for both release patterns for various antigens the development of 
single-dose formulations for VLP seemed to be feasible.  
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The integrity of AngQb released upon time could not be investigated due to low 
concentrations of the drug in the release media and the limitations of the accessible 
analytical methods. Additional experiments indicated that AngQb is rather unstable at 
pH < 7 that might develop upon degradation of the PLGA devices, and that the drug 
tends to moisture induced aggregation, a challenge that is connected to both matrix 
materials, and to adsorption to PLGA and tristearin. Thus, it was assumed that AngQb 
was an inappropriate VLP drug candidate for the investigated devices. As the stability 
issues of AngQb were all associated with an aqueous phase, “water-free” sustained 
release devices might overcome the challenges.  
QbG10p33 implants  
The experiments performed with AngQb implants (compare previous section) 
indicated that its stability was affected by environmental conditions like water uptake 
and / or acidic pHs evolving during incubation of PLGA and lipid implants. Therefore, it 
was investigated whether the second VLP drug candidate QbG10p33 is more stable 
than AngQb and might thus enable further in vitro and in vivo studies with implant 
formulations.  
 
Stability studies QbG10p33 
In order to study the effect of different pHs on the stability of QbG10p33 four  
solutions (0.3 mg QbG10p33 / mL, 20 mM sodium phosphate buffer) with pHs of 4.0. 
5.0. 6.0 and 7.2, respectively, were prepared by dilution of the API bulk with buffer 
solutions. In contrast to the observations made for AngQb (clouding of the solutions at 
pH ≤ 6.0, see page 147) all QbG10p33 solutions were clear after preparation, 
indicating a superior physical stability. The solutions were incubated for 7 days at  
37 °C and an agitation speed of 40 rpm. The stability of QbG10p33 upon storage was 
investigated via AF4 and SE-HPLC. The results obtained for the different QbG10p33 
solutions before and after storage are depicted in Figure 5.2.16 and Figure 5.2.17. 
The SE-HPLC measurements revealed no alteration of QbG10p33 integrity in any of 
the solutions tested (Figure 5.2.17). The results obtained by AF4 (Figure 5.2.16) 
showed slightly increased aggregation levels of QbG10p33 after storage at 
formulation pHs of 6.0, 5.0 and 4.0, respectively. At a pH of 7.2 no changes in VLP 
purity were observed. Thus, it was assumed that QbG10p33 was, in comparison to 
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AngQb (compare Figure 5.2.14 and Figure 5.2.15) more stable in the whole pH range 
examined.   
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Figure 5.2.16 Stability of QbG10p33 at a pH of 7.2, 6.0, 5.0 and 4.0, respectively, determined by AF4, 
before and after storage for 7 days at 37 °C.   
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Figure 5.2.17 Stability of QbG10p33 at a pH of 7.2, 6.0, 5.0 and 4.0, respectively, determined by  
SE-HPLC, before and after storage for 7 days at 37 °C.   
To investigate a possible moisture induced aggregation of QbG10p33, 
QbG10p33 lyophilizates (FQ01,Table 5.2.3) were stored unsealed and sealed for four 
weeks at 40 °C in a controlled humidity environment (75 % RH). After storage, the 
samples were reconstituted in 0.6 mL purified water. In contrast to the lyophilizates 
stored sealed the lyophilizates stored open could not be reconstituted completely, 
some particles were macroscopically visible. Therefore, these samples were filtered 
through a PVDF filter (0.22 µm pore size). All samples were analyzed by SE-HPLC 
and AF4, at least in duplicate, and the results obtained were compared to the starting 
material. In Figure 5.2.18 the proportions of the specific QbG10p33 fractions, in 
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relation to the total amount of QbG10p33 in the untreated samples, are displayed. For 
the QbG10p33 lyophilizates stored open a loss of about 20 % was observed. This loss 
was ascribed to the formation of insoluble aggregates which were removed by 
filtration. The amount of VLP oligomers and higher aggregates in the remaining 
material was determined to be 20 % (SE-HPLC analysis) and 50 % (AF4 analysis), 
respectively. The lower amount of detectable aggregated species in the SE-HPLC 
analysis might be related to either inaccurate integration of the oligomer / aggregate 
peak due to the poor resolution, abrasion of VLP aggregates due to the harsher 
conditions, i.e. high shear forces connected with SE-HPLC, and / or generation of VLP 
aggregates during the focusing step of the AF4 analysis. However, both analytics 
showed that QbG10p33 tends to moisture induced aggregation, but in comparison to 
the results obtained for AngQb (see Figure 5.2.13) the proportion of “intact” VLP was 
remarkably higher (50 % vs. 9 % main peak, determined by SE-HPLC).  
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Figure 5.2.18 Stability of QbG10p33 lyophilizates, determined by SE-HPLC (A) and AF4 (B), after 
storage for 4 weeks open or sealed at 40 °C and 75 % RH. The proportions of the different VLP fractions 
are expressed as relative amount to the total amount of the untreated sample.  
In summary it can be stated that QbG10p33 is far more stable than AngQb. 
Consequently, further in vitro release experiments with QbG10p33 implant 
formulations were conducted.  
 
In vitro release study 
QbG10p33 implants of 25 mg total weight each were produced according to the 
protocol introduced in chapter 2. In brief, four different formulations (Table 5.2.6,  
n = 3) were compressed (15 seconds, 2.0 kN) to small cylindric implants with a 
diameter of 3 mm. The payload of QbG10p33 was throughout all formulations 300 µg 
/ implant. 
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Table 5.2.6:  Compositions of QbG10p33 implants (25 mg) used for in vitro release studies. 
Code QbG10p33 lyophilizate 
Resomer® 
RG502H 
Dynasan 
118 PEG 6,000 Mg(OH)2 
IQ01 10 % 84 % - 6 % - 
IQ02 10 % 86 % - - 4 % 
IQ03 10 % 80 % - 6 % 4 % 
IQ04 10 % - 80 % 10 % - 
 
The formulations were selected on the basis of the in vitro release studies 
performed with AngQb implants (see previous section). Formulation IQ01 was 
adopted from formulation IA01 which exhibited a biphasic release profile. The content 
of the release modifier PEG was reduced from 10 % to 6 % to reduce the high primary 
burst observed for formulation IA01 (55 % within the first day). Formulation IQ02, 
similar to IQ01 but without PEG, was included to further investigate the effect of pore 
forming substances on the release behavior of VLP. IQ03 and IQ04 were similar to 
the AngQb implant formulations IA04 and IA05, respectively.  
The release kinetics of the four QbG10p33 implant formulations were 
investigated in an in vitro study over a time frame of 3 months. The cumulative release 
profiles of QbG10p33 from the presented formulations are depicted in Figure 5.2.19. 
The PLGA implants swelled upon incubation and were almost completely degraded 
after 3 months. By contrast, the tristearin implants remained macroscopically 
unaltered throughout the release studies.  
 
Following conclusions can be drawn from the presented data: 
(1) Formulations IQ01 and IQ02 revealed a triphasic release profile, with an initial 
burst of 30 % (IQ01) and 10 % (IQ02), followed by a lag phase lasting for 44 days 
(IQ 01) and 31 days (IQ02); After the lag phase another 30 % (IQ01) and 60 % 
(IQ02) QbG10p33, respectively, were released continuously up to day 90; 
(2) Formulations IQ03 and IQ04 showed a biphasic release behavior with an initial 
burst of about 10 % followed by a further continuous release of another 50 % 
within day 2 – 80 (IQ03) and 2 – 63 (IQ04), respectively; 
(3) All formulations revealed an incomplete release of QbG10p33. 
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Figure 5.2.19 In vitro release profiles (cumulative release) – QbG10p33 implants. 
The reasons for the different release behaviors of VLP from PLGA or lipid 
implants were already discussed in detail in previous sections. For QbG10p33 
formulations IQ03 and IQ04 almost similar release profiles where obtained as for the 
comparable AngQb formulations IA04 and IA05, respectively. As expected the initial 
burst of formulation IQ01 was reduced in comparison to formulation IA01 (30 % vs.  
55 %) due to the lower amount of release modifier PEG (6 % vs. 10 %). Furthermore, 
formulation IQ01 showed in contrast to formulation IA01, where the release leveled off 
after 26 days, a second continuous release period from day 44 to day 90 which might 
be promoted by the increased stability of QbG10p33. The more pronounced triphasic 
release profile observed for formulation IQ02 might be explained by the absence of an 
additional pore forming substance. Porogens typically favor swelling of the matrix and 
formation of an interconnected porous network with large pore diameters [Wang et al. 
2002]. Hence, the release of the VLP seemed to be delayed until advanced stages of 
matrix wetting, swelling and polymer degradation.  
The major cause for incomplete release of QbG10p33 seemed to be moisture 
induced aggregation (compare pages 150 - 151). To investigate whether adsorption 
was a further reason for incomplete release adsorption of QbG10p33 to placebo 
implants composed of 10 % placebo lyophilizate, 80 % Resomer RG 502H or 
tristearin, respectively, and 10 % PEG 6,000 was tested. Therefore, placebo implants 
were placed in LoBind Eppendorf reaction tubes together with 1 mL QbG10p33 
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solution (0.3 mg / mL – amount equal to payload of the verum implants, 20 mM 
sodium phosphate buffer, 0.01 % polysorbate 20 and 0.05 % sodium azide, pH 7.2) 
and incubated for 7 days at 37 °C and an agitation speed of 40 rpm. The QbG10p33 
concentration was monitored via RP-HPLC at least in duplicate. The results, 
illustrated in Figure 5.2.20, revealed that about 13 % and 7 % of the material was 
adsorbed to PLGA and lipid implants, respectively, after 7 days incubation time. 
Consequently, it was assumed that adsorption of QbG10p33 to the different matrix 
materials was a further cause for the incomplete release during in vitro studies.  
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Figure 5.2.20 Adsorption of  QbG10p33 (0.3 mg / mL) to placebo implants upon incubation for 7 days 
at 37 °C. 
 
Stability of QbG10p33 during release from PLGA and lipid based implants 
The stability of QbG10p33 during release from the different implant formulations 
was investigated via SE-HPLC. In contrast to the studies performed with AngQb 
implant formulations the concentration of QbG10p33 was high enough (> 20 µg / mL) 
to make the analysis of VLP integrity possible, even after several weeks of incubation. 
The results revealed that QbG10p33 released from the PLGA based formulations 
IQ01, IQ02 and IQ03 material was even after 1-2 months of incubation almost intact 
with 91 – 98 % of the main peak (Table 5.2.7). The analysis of QbG10p33 released 
from the lipid based implant formulation IQ04 was not possible due to the low amount 
liberated per time interval. However, it was assumed that QbG10p33 remained in the 
lipid matrix at least as stable as in the PLGA matrices [Schwendeman et al., 1997; 
Sanchez et al., 1999; Mohl, 2003].  
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Table 5.2.7 Stability of QbG10p33upon release from PLGA and lipid implants, determined via  
SE-HPLC. 
Aggregates Main peak Fragments 
Formulation Time [d] 
Amount [%] 
QbG10p33 
lyophilizate FQ01 - 1.3 98.0 0.7 
1 0.5 97.6 1.9 
5 1.2 96.6 2.2 IQ01 
51 3.1 96.5 0.4 
1 0.4 97.8 1.8 
2 0.5 99.4 0.3 
38 0.4 99.3 0.3 
IQ02 
55 8.1 91.2 0.7 
1 0.5 98.2 1.3 
2 0.2 99.5 0.3 IQ03 
38 1.1 98.2 0.7 
IQ04 1 0.6 98.6 0.8 
 
Summary 
The controlled release of QbG10p33 from implants with either PLGA or lipid as 
matrix material was feasible up to several weeks. For the lipid based implant 
formulation a biphasic release of QbG10p33 was achieved whereas in dependence of 
additives both biphasic and triphasic release profiles were obtained for PLGA based 
formulations. Furthermore, it was shown that QbG10p33 released from the different 
PLGA devices was almost intact during the first two months of incubation. An at least 
comparable stability of the drug was assumed for the lipid devices, as here less 
detrimental conditions evolve upon incubation than with PLGA devices.  
Hence, having different sustained release systems for QbG10p33 with different 
release kinetics on hand the efficacy of these provisional single dose formulations was 
investigated in vivo.  
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In vivo studies - QbG10p33 implants 
For bioactivity testing four QbG10p33 implant formulations (Table 5.2.8) were 
prepared according to the protocol described in chapter 2. The payload of all 
formulations was 300 µg QbG10p33 / implant. Formulations IQ02, IQ03 and IQ04 
were chosen because they revealed the most promising release profiles in vitro with a 
primary burst of about 10 % (~ 30 µg QbG10p33) followed by either continuous (IQ03 
and IQ04) or pulsed release (IQ02) of further 50 – 60 % of incorporated VLP (~150-
180 µg QbG10p33) within 3 months (compare Figure 5.2.19). Formulation IQ05 was 
similar to IQ03 with exception of the used PEG, here PEG 6,000 (IQ03) was 
exchanged by the FDA approved PEG 3,350 (like in Depo-ProveraTM). 
Table 5.2.8:  Compositions of QbG10p33 implants (25 mg) used for in vivo experiments. 
Code QbG10p33 lyophilizate 
Resomer® 
RG 502H 
Dynasan 
118 PEG 6,000 PEG 3,350 Mg(OH)2 
IQ02 10 % 86 % - - - 4 % 
IQ03 10 % 80 % - 6 % - 4 % 
IQ04 10 % - 80 % 10 % - - 
IQ05 10 % 80 % - - 6 % 4 % 
 
The in vivo experiments were carried out as described in chapter 2. In brief, the 
different implant formulations were administered to female C57BL / 6 mice (n = 4). 
Additionally, as a positive control, liquid QbG10p33 formulations (reconstituted 
lyophilizate FQ01) containing 50 µg VLP were applied either once (day 0) or three 
times (day 0, 7 and 14) to groups of 3 (single application) or 5 mice (threefold 
application), respectively. Furthermore, as negative control one placebo implant 
formulation, composed of 10 % placebo lyophilizate, 80 % Resomer® RG 502H,  
6 % PEG 6,000 and 4 % Mg(OH)2 was applied to a group of 4 mice. Sera from the 
different test groups were collected up to 12 weeks and analyzed by ELISA, to 
measure the specific anti-p33 IgG titers, and by FACS, to study the activation of  
p33-specific CD8+ T cells. In parallel in vitro release studies were performed with  
3 implants / formulation, respectively.  
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After three months the in vivo experiments were terminated and the mice were 
sacrificed. The implantation site was macroscopically examined and it was found that 
the PLGA implants were almost completely degraded whereas the appearance of the 
lipid implants was unaltered. No signs of inflammation or encapsulation were 
observed for none of the implant formulations tested.  
 
In vitro release profile  
The cumulative release profiles of QbG10p33 from the four implant formulations 
are illustrated in Figure 5.2.21. The PLGA implants swelled upon incubation and were 
almost completely degraded after 3 months. The tristearin implants remained 
macroscopically unaltered throughout the release studies.  
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Figure 5.2.21 In vitro release profiles (cumulative release) – QbG10p33 implants. 
The release profiles obtained for formulations IQ02, biphasic release, and IQ03, 
triphasic release, were despite slightly decreased total amounts, comparable to the 
previously performed in vitro study (compare Figure 5.2.19). The substitution of PEG 
6,000 in formulation IQ03 by PEG 3,500 in formulation IQ05 had no effect on the 
release behavior of QbG10p33. Similar release profiles were obtained for both 
formulations. Formulation IQ04 showed in contrast to the previously performed in vitro 
studies a changed release profile. After a similar initial burst of about 10 % VLP, no 
further QbG10p33 release was observed in this study whereas in the previous 
experiments a continuous release of further 50 % within 9 weeks was obtained. As 
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similar prepared QbG10p33 lyophilizates and the same excipients were used, and the 
same preparation protocol was applied the reason for this changed release behavior 
is unclear. Importantly, in former in vitro studies similar release profiles were obtained 
for comparable AngQb and QbG10p33 lipid implant formulations (see Figure 5.2.10 
and Figure 5.2.19). Furthermore, Mohl et al and Herrmann et al showed that 
reproducible release profiles of interferon α-2a from comparable lipid implant 
formulations (10 % lyophilized protein, 80 % tristearin, 10 % PEG 6,000) could be 
achieved when applying similar preparation protocols (e.g. compression force and 
duration) [Mohl et al., 2004; Herrmann et al., 2007a]. Thus, further investigations are 
necessary to determine the cause of the changed release profile.  
 
Antibody response 
The antibody titers obtained for the four implant formulations as well as for the 
positive and negative controls are illustrated in Figure 5.2.22.  
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Figure 5.2.22 Anti-p33 antibody response following a single or threefold s.c. administration of a liquid 
QbG10p33 formulation, or s.c. application of QbG10p33 implant formulations IQ02, IQ03, IQ04 and IQ05.   
Following conclusions can be drawn from the presented data: 
(1) All verum implant formulations as well as the single and threefold shots of liquid 
vaccine induced an anti-p33 specific antibody response within the first two weeks 
whereas no antibody response was observed for the placebo formulation;  
(2) A further increase of the antibody titers within day 14 to 21 was observed for the 
threefold shot of liquid vaccine and the implant formulations IQ02, IQ03 and IQ05;  
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(3) The antibody titers declined after 14 days for the single shot liquid vaccine and 
after 21 days for the implant formulations IQ03 and IQ05 and the threefold shot of 
liquid vaccine; 
(4) The antibody titers remained almost stable for formulation IQ02 from day 21 to 91 
and for formulation IQ04 from day 14 to 91. 
 
The results obtained for the single shot of the liquid formulation showed after a 
primary induction of an antibody response, within the first two weeks after application, 
declining antibody titers. A further increase of the antibody titers was achieved by the 
threefold weekly application of the liquid vaccine, but even for this group a decrement 
of the antibody titers was observed after three weeks. Hence, it was assumed that a 
multiple application of the liquid vaccine, at least for the chosen interval, leads to an 
increase of the antibody titers but does not lead to long-lasting high antibody titers. 
The PLGA implant formulations IQ03 and IQ05 induced similar to the threefold 
application of the liquid vaccine increasing antibody titers, within the first three weeks. 
The lower initial anti-p33 antibody titers in comparison to the threefold applied liquid 
formulation can be explained by the lower vaccine release in vitro (Figure 5.2.22). 
Both implant formulations released about 30 % of the incorporated vaccine (~ 90 µg 
VLP) within the first three weeks whereas 150 µg were applied with three shots of the 
liquid vaccine. However, after three weeks the antibody titers declined, no long-lasting 
high antibody titers were observed. By contrast, long-lasting high antibody titers were 
obtained for the implant formulation IQ02, here, initially achieved antibody titers 
remained on the same level for 3 months. As formulation IQ02 was the only 
formulation which exhibited a pulsed release of the drug in vitro, it seemed that for a 
long-lasting anti-p33 antibody response this pulsed release with a second burst after 
four weeks was beneficial to the more continuous release observed for formulations 
IQ03 and IQ05. The potential of inducing long-lasting antibody responses by 
sustained release systems which exhibit a pulsed release of the antigen was 
described in literature e.g. for influenza A vaccine, tetanus toxoid and malaria antigen 
[Thomasin et al., 1996; Hilbert et al., 1999]. Formulation IQ04 showed after the 
primary induction of antibody response also long-lasting antibody titers, but on a 
notably low level. The reason for this long-lasting antibody response is not clear as in 
vitro no further release of QbG10p33 was observed. Thus, after clarification of the 
 
Development of Sustained Release Systems for VLP Based Vaccines 
___________________________________________________________________________ 
 
160 
 
reasons for the changed in vitro release behavior further in vivo investigations with 
this implant formulation are necessary.  
It has to be mentioned that the vaccination schedule of the test group (threefold 
application of 50 µg QbG10p33 at day 0, 7 and 14) was different from the observed 
release profiles obtained for the different implant formulations. For example 
formulation IQ02 released about 60 µg QbG10p33 within the first three days, a dose 
similar to a single application of the liquid drug, but then the “second” dose (~ 60 µg) 
was liberated not as a sharp bolus but over a prolonged period of about two weeks 
after a three week latency period (see in vitro release profile - Figure 5.2.21). 
Consequently, the comparison of the implant formulations to the three shot liquid 
vaccine group is problematic. Therefore, for further studies more comparable 
vaccination schedules should be used for the positive controls (multiple application of 
liquid vaccine). Additionally, a more proper investigation of the efficacy of a pulsed vs. 
continuous release of antigen is necessary. This might for example be feasible by 
using implantable mini-pumps as introduced by Walduck et al. [Walduck et al., 1997]. 
 
Induction of p33-specific CD8+ T cells 
The induction of p33-specific CD8+ cells by the four implant formulations as well 
as for the positive and negative controls are illustrated in Figure 5.2.23. 
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Figure 5.2.23 Induction of p33 specific CD8+ cells after single or threefold s.c. administration of a 
liquid QbG10p33 formulation, or s.c. application of QbG10p33 implant formulations IQ02, IQ03, IQ04 and 
IQ05.   
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The ability of QbG10p33 to induce p33 specific CD8+ T cells was previously 
shown by Schwarz et al. [Schwarz et al., 2003]. In comparison to recombinantly 
produced Qbp33 VLP (mainly containing RNA) the application of QbG10p33 VLP 
(RNA substituted by CpG oligonucleotides) substantially increased frequencies of p33 
specific CD8+ T cells. This increased efficacy was explained by the activation of 
dendritic cells by CpGs via stimulation of Toll like receptor 9 allowing a stronger 
induction of T cell responses. In the current study it was investigated whether a 
multiple application of QbG10p33 and a continuous or pulsed release of QbG10p33 
from implants can further increase the T cell response. The results obtained from the 
in vivo study showed that all implant formulations as well as the application of the 
liquid vaccine was capable to induce p33 specific CD8+ T cells within the first week 
which is in good correlation to previous studies [Schwarz et al., 2003]. However, after 
this primary T cell response the amount of p33 specific CD8+ T cells declined for the 
implant test group and the group that received a single shot of the liquid vaccine. A 
further increase of p33 specific CD8+ T cells within the second week was only 
observed for the group of mice which received three times the liquid vaccine. After two 
weeks a decrease of p33 specific CD8+ T cells was observed as well. The reason for 
the inability of the implant formulations to further increase the T cell response upon 
incubation is not clear. Possible reasons for the inhibition of a recall response might 
be: (1) The amount of QbG10p33 delivered per time interval was too low to 
restimulate effector T cells; (2) Clearance of the VLPs by neutralizing antibodies  
[Da Silva et al., 2001] before they could reach lymphoid tissue , which is believed to 
be unique for T cell priming and expansion [Kaufmann, 2004]; and / or (3) Death or 
anergy of effector T cells induced by prolonged stimulation [Iezzi et al., 1998; Kaech 
et al., 2002]. Finally, it can be stated that the achievement of a long-lasting T cell 
response by sustained release devices is extremely challenging due to the high 
complexity of the immune system, and thus, further, extensive investigations are 
necessary. 
 
Summary 
The aim of the current in vivo study was to investigate whether long-lasting 
antibody and / or T cell responses against QbG10p33, as model VLP, can be 
achieved by PLGA and lipid based implants as provisional single dose vaccine 
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formulations. The experiments showed that high antibody titers could be achieved by 
all PLGA based formulations. Long-lasting high antibody levels were obtained by a 
PLGA formulation which exhibited a triphasic release profile whereas for PLGA 
formulations with a continuous release profile the antibody titers leveled off after the 
primary activation. The results obtained for the lipid based formulation were not 
meaningful due to the in comparison to previous in vitro studies altered release profile. 
A primary T cell induction was observed for all implant formulations, but no  
long-lasting effect was observed for any implant formulation. In conclusion, it was 
shown that the development of single dose formulations for VLP based vaccines 
intended to induce antibody-mediated immunity is feasible, and thus, the performance 
of further studies with therapeutic VLP are recommendable. The generation of  
long-lasting T cell responses by sustained release systems with VLP based vaccines 
seemed to be more challenging and requires further fundamental research.   
5.2.4 Evaluation of Biodegradable PLGA Microcapsules Containing an 
Oily Core as an Enhanced Controlled Release System for AngQb  
Previous experiments revealed that the stability of AngQb, a therapeutic VLP 
vaccine intended for the treatment of high blood pressure [Ambuehl et al., 2007], was 
affected by detrimental environmental conditions arising during release from PLGA 
and lipid based implant formulations. Further in vitro and in vivo studies were 
performed with QbG10p33, a model VLP that is far more stable than AngQb. It was 
shown that long-lasting antibody responses against QbG10p33 could be achieved by 
PLGA implants. Encouraged by this “proof of concept” it was now the objective to 
develop a formulation which is on the one hand capable to protect the drug from the 
above mentioned deleterious conditions and on the other hand enables a pulsatile 
release. In 1996 Sanchez et al. introduced biodegradable PLGA microcapsules with 
an oily inner core in which a lyophilized antigen, tetanus toxoid, was entrapped. It was 
considered that the antigen is protected in the oily core from deleterious conditions, 
e.g. moisture, acidic pH and / or degradation products of PLGA, until the polymer shell 
is degraded to such a degree that the drug can be liberated. Sanchez et al. showed 
that depending on the copolymer composition, a pulsed release of immunochemically 
detectable antigen could be achieved after different times, 3 and 7 weeks, 
respectively. It was proposed that a single-step immunization might be feasible by 
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single administration of a composition containing a priming dose and two types of 
antigen loaded microcapsules with different coating composition [Sanchez et al., 
1996]. This seemed to be a very promising approach for VLP, and thus feasibility 
studies were carried out.  
Stability of AngQb in mineral oil 
In a first step the stability of AngQb in lyophilized form suspended in mineral oil 
was assessed as this is the prerequisite for the development of the above described 
microcapsule formulation. Therefore, 1 mL of mineral oil were added to AngQb 
lyophilizates (formulation FA02, Table 5.2.2), sealed under nitrogen atmosphere, and 
stored for 10 weeks at 40 °C to imitate in vivo conditions. For comparison stability of 
pure AngQb lyophilizates was assessed. Right after preparation and after storage for 
4 and 10 weeks, respectively, samples were reconstituted with purified water. To 
allow extraction of AngQb from the lyophilizate / mineral oil suspensions the samples 
were agitated gently for 10 minutes and subsequently centrifuged. The reconstituted 
lyophilizates and the aqueous phase of the extracted samples were analyzed by AF4 
at least in duplicate.   
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Figure 5.2.24 Stability of AngQb in pure lyophilized form and in lyophilizate / mineral oil suspension 
during 10 weeks storage at 40 °C, determined by AF4. 
In Figure 5.2.24 the respective storage stabilities at 40 °C of AngQb in the 
different environments are illustrated. AF4 measurements revealed an increase of the 
aggregation level for both, AngQb lyophilizates and AngQb lyophilizate / mineral oil 
suspensions. Importantly, after 10 weeks storage time almost similar amounts of 
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aggregated species were detected for both sample sets. Hence, it was assumed that 
the stability of AngQb was not affected by mineral oil but depends on the lyophilizate 
composition. Based on these results it is expected that with an enhanced lyophilized 
formulation the stability of AngQb in the lyophilizate / oil suspension might be 
improved as well. However, as the optimization of the lyophilized AngQb formulation 
was beyond the scope of the present work the above presented formulation (FA02) 
was used for further basic experiments.  
Preparation of microcapsules 
Basic principle of microcapsule preparation 
The preparation method proposed by Sanchez et al. is a solid / oil1 / oil2 / water 
emulsion technique. In brief, the lyophilized antigen is first dispersed in mineral oil. 
The resulting suspension is next dispersed in an organic solvent containing PLGA. 
This organic phase is then emulsified in an aqueous PVA solution. Thereby, 
microdroplets are formed which gradually harden by precipitation of the PLGA around 
the oily droplets induced by solvent extraction and evaporation. Finally, the 
microcapsules are collected, washed and lyophilized [Sanchez et al., 1996] (compare 
flow chart depicted in chapter 2).  
The suggested process is highly complex and includes several factors that 
influence the morphology, structure, size distribution and encapsulation efficiency of 
the final microcapsules. Thus, in the following investigations on the diverse processing 
steps were carried out. 
 
Homogenization of AngQb lyophilizate in mineral oil 
First, homogeneous dispersion of the AngQb lyophilizate in mineral oil had to be 
achieved. For this purpose the centrifugal mixer SpeedMixerTM DAC 150 FVZ 
(Hauschild Engineering, Hamm, Germany) was evaluated. This device is described to 
enable extremely fast homogenization (seconds to minutes) of low sample volumes in 
disposable cups e.g. reaction tubes#. For suitability testing a suspension with an 
lyophilizate / oil weight ratio of 5 : 95 was produced. First AngQb lyophilizate FA02  
____________________________________________________________________ 
#http://www.speedmixer.co.uk/dac3000.php 
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was levigated in an agate mortar in a dry-nitrogen-purged glove box (to prevent 
moisture uptake from the ambient atmosphere). Then, 25 mg of the powder were 
placed together with 475 mg mineral oil in a 0.5 mL LoBind Eppendorf Cap and 
homogenized with the SpeedmixerTM DAC 150 FVZ at 3500 rpm for 30 s. Then, 3 
samples of the resulting suspension, 50 mg each, were extracted within 10 minutes 
with 1 mL PBS buffer. The aqueous phase was analyzed by SE-HPLC for the 
determination of AngQb content (by calculation from the regression of an AngQb 
standard curve) and for the investigation of VLP integrity. The results showed that 
homogeneous dispersion was feasible, 96.5 ± 4.7 % of the estimated amount of 
AngQb were determined. Furthermore, it was found that the liberated VLP remained 
intact during homogenization and liberation from the oil, in comparison to the starting 
material no increase of VLP fragments or aggregated species was observed.  
 
Selection of organic solvent for PLGA  
For manufacture of the above described microcapsules the organic solvent used 
for PLGA had to possess several features. It had to be volatile, so that it can finally be 
removed from the microcapsule formulation. Furthermore, it needed to be immiscible 
with mineral oil and should not harm VLP stability. Commonly used volatile organic 
solvents for the preparation of PLGA microparticles are methylene chloride [Chattaraj 
et al., 1999; Kim et al., 1999; Feng et al., 2006], ethyl acetate [Lee et al., 1997; Shi et 
al., 2002; Li et al., 2002], acetonitrile [Tobio et al., 1999] and acetone [Coombes et al., 
1998; Zhuang et al., 2002]. Dissolution experiments revealed that methylene chloride 
and ethyl acetate as single solvents for PLGA were not possible because both 
dissolved mineral oil. By contrast mineral oil was not soluble in pure acetone or 
acetonitrile, and in an acetonitrile / ethyl acetate mixture, which was used e.g. by 
Sanchez et al. [Sanchez et al., 1996] and Youan et al. [Youan et al., 2001] for 
microcapsule preparation.  
In order to investigate the stability of AngQb suspended in selected organic 
solvents AngQb lyophilizates were incubated for 10 minutes with 1.0 mL of acetone, 
ethyl acetate or acetonitrile, respectively. Subsequently, the samples were 
centrifuged, the organic solvent was removed and the remaining VLP lyophilizate was 
dissolved in purified water and analyzed by SE-HPLC. The SE-HPLC measurements 
revealed that AngQb remained intact in all samples, no alteration of AngQb 
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composition was observed. Thus, it was concluded that acetone, acetonitrile and a 
acetonitrile / ethyl acetate mixture (1 : 1) were potent solvents for the preparation of 
microcapsules.  
Consequently, three plain microcapsule formulations were prepared with the 
selected solvents to investigate their effect on the microcapsule morphology. In brief, 
50 mg mineral oil were dispersed by vortexing for 3 s in 2 mL of either acetonitrile, 
acetone or an acetonitrile / ethyl acetate mixture (1 : 1), respectively, containing 10 % 
Resomer® RG 503, a PLGA with lactide : glycolide molar ratios of 50 : 50 (inherent 
viscosity in chloroform of 0.42 dL / g). The resulting mixtures were then added through 
a capillary (0.8 mm inner diameter) to 10 mL of an aqueous PVA solution  
(0.75 %) under vigorous magnetic stirring. After 3 minutes light microscopic pictures of 
the initially formed microcapsules were taken. 
The pictures showed that by using acetone as solvent for PLGA large, undefined 
structures were formed (Figure 5.2.25 A and B). A similar observation was made for 
acetonitrile but besides undefined structures intermediate microcapsules were 
obtained (Figure 5.2.25 C and D). It was assumed that the reason for the formation of 
such irregular PLGA structures was the excellent miscibility of acetone and 
acetonitrile with water enabling a very fast diffusion of these solvents from the organic 
droplets into the aqueous phase. Hence, the polymer precipitated before 
microdroplets were formed. In contrast, by using a mixture of acetonitrile and ethyl 
acetate microdroplets were formed (Figure 5.2.25 E and F). As ethyl acetate is not 
miscible with water, precipitation of PLGA might be slowed down, so that the organic 
phase could be emulsified in the surfactant solution before uncontrolled polymer 
precipitation. Then, by diffusion of acetonitrile out of the organic microdroplets a 
polymer film at the water / oil interphase is formed entrapping the mineral oil inside the 
microdroplets and leading to the formation of preliminary microcapsules (Figure 5.2.25 
E and F). Hence, a mixture of ethyl acetate / acetonitrile (1 : 1) was used for further 
studies as solvent for PLGA.  
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Figure 5.2.25 Photomicrographs of PLGA microcapsules with an oily inner core obtained by light 
microscopy during the initial phase of the microencapsulation process by using either acetone (A / B), 
acetonitrile (C / D) or a mixture of acetonitrile / ethyl acetate (1 : 1) as solvent for PLGA.  
PLGA microcapsule formation  
Four microcapsule formulations with an oily inner core were produced. Two 
formulations were prepared with AngQb lyophilizates (formulation FA02, Table 5.2.2) 
and two with QbSAMSA, which is a fluorescein labeled Qb VLP (see chapter 2). Each 
drug was formulated with either Resomer® RG 502H or Resomer® RG 503.  
QbSAMSA was lyophilized according to freeze-drying protocol A (see chapter 2) in a 
formulation containing 1.0 mg / mL QbSAMSA, 2.5 % (w / v) trehalose dihydrate,  
50 mM sodium chloride, 0.005 % (w / v) polysorbate 20 and 20 mM sodium phosphate 
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buffer (pH 7.2). For microcapsule preparation first lyophilizate / mineral oil 
suspensions with a weight ratio of 5 : 95 were produced as described on page 166. 
Then 50 mg of the respective suspensions were dispersed by vortexing for 3 s in 2 mL 
of an acetonitrile / ethyl acetate mixture (1 : 1) containing 10 % polymer. The 
consecutive processing steps were carried out as described in chapter 2.  The 
microencapsulation process was examined by light microscopy. Furthermore, the 
structure of the microcapsules was analyzed by scanning electron microscopy (SEM) 
and confocal laser scanning microscopy (CLSM).  
 
 
Figure 5.2.26 Photomicrographs of PLGA microcapsules with an oily inner core containing AngQb 
prepared with either Resomer® RG 502H (A-C) or Resomer® RG 503 (D-F) observed by light microscopy 
during the initial phase of the microencapsulation process (A / D), after solvent extraction (B / E) and after 
freeze-drying (C / F).  
The photomicrographs in Figure 5.2.26 show the formation of PLGA 
microcapsules with an oily inner core during the various phases of the 
microencapsulation process. As described above intermediate microcapsules with a 
thin polymer film trapping the AngQb loaded oily cores were formed during the initial 
phase of the process. Upon solvent extraction / evaporation induced by further 
addition of aqueous PVA solution and water under continuous stirring the polymer 
shell solidified. After solvent extraction / evaporation the microparticles were first 
washed with hexane, to remove any residual mineral oil from the surface of the 
microparticles, then washed with purified water and lyophilized. The 
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photomicrographs C and F in Figure 5.2.26 indicated that the microcapsules remained 
intact during the washing steps and the subsequent freeze-drying process.  
Further investigation of cross sections of the final microcapsules by SEM (Figure 
5.2.27) showed that true core-wall structures with continuous polymer shells were 
formed.  To examine whether the core really consists of mineral oil with entrapped 
VLP pictures of QbSAMSA microcapsules were taken by CLSM (Figure 5.2.28). The 
pictures showed bright spots inside the microcapsules which correspond to the 
fluorescence labeled VLP whereas the polymer shell showed no fluorescence.  
 
 
Figure 5.2.27 Scanning electron micrographs of a cross-sectional view of PLGA microcapsules with 
an oily inner core containing AngQb prepared with either Resomer® RG 502H (A) or Resomer® RG 503 
(B). 
 
Figure 5.2.28 Confocal laser scanning micrographs of PLGA microcapsules with an oily inner core 
containing QbSAMSA prepared with either Resomer® RG 502H (A) or Resomer® RG 503 (B). 
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Thus, the hypothesis of microcapsule formation was corroborated. Furthermore, it 
was shown that microcapsules with similar appearance were formed for both PLGA 
materials Resomer® RG 502H and Resomer® RG 503. 
 
Excursus – Evaluation of different techniques for the determination of the 
amount of VLP encapsulated in PLGA microcapsules 
A critical issue during development of microparticle formulations is the accurate 
determination of the antigen amount encapsulated into the PLGA microspheres. 
These data are a prerequisite for studying the effects of different preparation 
techniques and formulations on the encapsulation efficiency. Furthermore, knowledge 
of the drug payload is important for calculating the cumulative amount of drug 
released during in vitro studies and for correct dosing of the respective formulation 
during in vivo studies.  
Several techniques have been reported for the determination of antigens 
encapsulated in PLGA microparticles. One common method involves alkaline 
hydrolysis of PLGA microspheres followed by antigen quantification by protein assays 
like Lowry or BCA [Sanchez et al., 1999; Chattaraj et al., 1999; Feng et al., 2006]. 
However, as already highlighted in previous sections the correct determination of VLP 
content in a multicomponent sample by protein assays is very complicated because of 
several possible interferences between excipients and dyes. Hence, it was assumed 
that an extraction method might be more adequate for our purpose. For the extraction 
of antigens from PLGA microparticles acetonitrile [Katare et al., 2006] and methylene 
chloride [Li et al., 2002; Peyre et al., 2003] are commonly used solvents. Thereby, 
PLGA is dissolved in the organic solvent and the antigen is extracted with an aqueous 
phase. Another approach is e.g. to crush the particles and extract the encapsulated 
drug directly with an aqueous phase [Singh et al., 1991; Mohl, 2003].  
For the evaluation of an appropriate extraction method for AngQb from PLGA 
microcapsules a microcapsule formulation was prepared according to the above 
described process (page 168) from 100 mg AngQb  lyophilizate / mineral oil 
suspension (weight ratio 5 : 95) and 2 mL of a 1 : 1 mixture of ethyl acetate and 
acetonitrile containing 10 % Resomer® RG 503. Subsequently, samples of 50 mg 
each were extracted according to the following procedures:  
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(1)  Microcapsules were ground in an agate mortar and VLP were extracted with 
PBST (phosphate buffered saline with 1 % polysorbate 20). 
(2) Microcapsules were incubated with methylene chloride to dissolve PLGA and 
mineral oil. Then, PBS was added to extract the VLP. 
(3) Microcapsules were incubated with acetonitrile to dissolve PLGA. Then, the 
suspension was centrifuged to precipitate the insoluble VLP lyophilizate / mineral oil 
suspension and the supernatant was discarded. The procedure was repeated three 
times. Finally, the VLP were dissolved in PBS. 
(4) Microcapsules were processed as described in (3) with the exception that the 
VLP were finally dissolved in a reducing and denaturing aqueous solution containing  
4 M guanidinium chloride (GuaHCl) and 0.1 M dithiothreitol (DTT).   
 The amount of AngQb in the different samples was determined by RP-HPLC as 
described in chapter 2. 
In Table 5.2.9 the amounts of AngQb found when applying the above described 
extraction methods, calculated per 100 mg microcapsules, are summarized. The 
determined payload of AngQb varied strongly between the different methods used.  
Table 5.2.9:  Actual amounts of AngQb in a microcapsule formulation determined by various 
extraction methods followed by VLP quantification by RP-HPLC. 
Extraction method Amount VLP  [µg / 100 mg microcapsules] 
Grinding  / PBST 10.3 
Methylene chloride / PBS 13.4 
Acetonitrile / PBS 17.4 
Acetonitrile / GuaHCl and DTT 23.7 
 
Extraction method 1 (crushing of the microcapsules and extraction with PBS)   
and extraction method 2 (extraction with methylene chloride / PBS) revealed the 
lowest amounts of AngQb. In the case of method 1 this might be related to an 
incomplete destruction of the microcapsules. The low amounts detected by method 2 
can be a result of drug aggregation at the organic solvent / aqueous solution interface  
[Sah, 1999]. The extraction with acetonitrile / PBS or acetonitrile / GuaHCl and DTT 
revealed about 1.5 fold higher amounts of AngQb. This might be explained by the 
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absence of an organic solvent / water interface (acetonitrile is miscible with water) 
preventing VLP interfacial aggregation. The more complete extraction of AngQb 
achieved by method 4 in comparison to method 4 was possible due to the 
disassembling and the solubilization of the VLP by DTT (disrupture of disulfide bonds) 
and GuaHCl (disrupture of non-covalent interactions).  
Thus, it was assumed that method 4 was the most appropriate method for the 
determination of the amount of AngQb encapsulated in PLGA microcapsules. 
However, as the evaluation was performed with a microcapsule formulation with an 
unknown AngQb payload this method was challenged in a further experiment. To 
investigate the effect of the presence of mineral oil and / or PLGA on the detectable 
amount of VLP, the following AngQb samples were analyzed by method 4: (a) Pure 
AngQb lyophilizate, (b) AngQb lyophilizate with mineral oil – weight ratio 1 : 19, (c) 
AngQb lyophilizate with mineral oil and Resomer® RG 502H – weight ratio 1 : 19 : 40, 
and (d) Temperature stressed AngQb lyophilizate (aggregation of AngQb) with 
mineral oil and Resomer® RG 502H – weight ratio 1 : 19 : 40. All samples were 
prepared in triplicate. The results are shown in Table 5.2.10. 
Table 5.2.10 AngQb recovery determined by RP-HPCL for various AngQb samples after extraction 
with acetonitrile / GuaHCl and DTT. 
Sample Recovery AngQb  [% of applied amount] 
AngQb lyophilizate 96.4 ± 1.8 
AngQb lyophilizate with 
mineral oil 94.0 ± 0.6 
AngQb lyophilizate with  
mineral oil and PLGA 91.4 ± 0.6 
Stressed AngQb lyophilizate with 
mineral oil and PLGA 92.4 ± 2.5 
 
The experiment revealed that even for stressed AngQb samples in the presence 
of mineral oil and PLGA more than 90 % of the applied AngQb amount (calculated 
from the mass of accurately weight AngQb lyophilizate) could be extracted and 
quantified by the above described method. Thus, it was confirmed that the extraction 
procedure with acetonitrile / GuaHCl and DTT followed by AngQb quantification by 
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RP-HPLC is an accurate method for the determination of the AngQb payload in PLGA 
microcapsules with an oily inner core.  
 
Formulation development studies 
To examine the effect of various oil to PLGA ratios and various PLGA materials 
on the encapsulation efficiency of AngQb and the morphology and size distribution of 
the microcapsules six microcapsule formulations (see Table 5.2.11) were prepared as 
described in chapter 2. In brief, 50 to 200 mg AngQb lyophilizate / mineral oil 
suspension with a weight ratio of 5 : 95 were dispersed by vortexing in 2 mL of a 1 : 1 
mixture of acetonitrile and ethyl acetate containing 200 mg of the specific PLGA. 
Then, the respective mixtures were emulsified in an aqueous solution containing  
0.75 % PVA. For solvent extraction / evaporation further PVA solution and water was 
added. Finally, the microcapsules were collected, washed and lyophilized.  
Table 5.2.11:  Compositions PLGA microcapsule formulations containing an oily inner core with 
AngQb.  
Formulation 
AngQb 
lyophilizate 
[mg]* 
Mineral oil 
[mg] 
Resomer® RG 
502H 
[mg] 
Resomer®  
RG 503 
[mg] 
MCAng01 2.5 47.5 200.0 - 
MCAng02 5.0 95.0 200.0 - 
MCAng03 10.0 190.0 200.0 - 
MCAng04 2.5 47.5 - 200.0 
MCAng05 5.0 95.0 - 200.0 
MCAng06 10.0 190.0 - 200.0 
* 2.5 mg lyophilizate contain 300 µg AngQb 
The payload of AngQb in the different formulations was determined by the above 
described extraction method. The encapsulation efficiency was calculated in 
difference of material weighed in and the payload determined after preparation. The 
size distribution and average size of the microcapsule formulations, expressed as 
volume mean diameter, was determined by laser diffraction. The stability of AngQb 
upon processing was investigated by SE-HPLC after extraction of the VLP from the 
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final microcapsule formulations with acetonitrile / PBS (compare, extraction method 3 
described on page 171). 
The influence of different polymers and varying oil suspension / PLGA ratios on 
the characteristics of microcapsule formulations is provided in Table 5.2.12.   
Table 5.2.12:  Characteristics of various AngQb microcapsule formulations.  
Formulation Loading [µg VLP / 100 mg MC] 
Encapsulation 
efficiency  
[% of applied amount] 
Mean diameter / 
diameter range 
d10 – d90 [nm] 
MCAng01 9.6 8.0 
80.1  
 
 27.3 – 146.3 
MCAng02 15.8 7.9 
88.3 
 
20.6 – 183.2 
MCAng03 31.0 10.3 
124.4 
 
28.8 – 333.7 
MCAng04 9.0 7.5 
99.0 
 
28.7 – 196.9 
MCAng05 23.7 11.8 
135.1 
 
45.3 – 243.3 
MCAng06 43.2 14.4 
523.4 
 
53.5 – 1426.8 
 
Microcapsules prepared from Resomer® RG 503 exhibited slightly higher 
encapsulation efficiencies and larger average microcapsule sizes as compared to 
microcapsules produced with Resomer® RG 502H. These differences can be 
explained by a higher viscosity of the organic phase for Resomer® RG 503 in 
comparison to Resomer® RG 502H. At higher viscosities of the organic phase 
migration of the AngQb loaded oily cores out of the embryonic microspheres might be 
slowed down leading to higher encapsulation efficiencies. Further, the more viscous 
organic phase formed larger microdroplets during the initial emulsification step 
resulting in larger microcapsules. Additionally, it was observed that with increasing 
ratios of oil suspension / PLGA increasing levels of AngQb loading were achieved. 
This might be due to the formation of larger microcapsules with larger oily cores and 
thinner PLGA shells as indicated by the increasing mean diameters.  At an oil 
suspension / PLGA ratio of 1 : 1 for both PLGAs extremely large particles up to a few 
mm were detected. Here, probably for some microdroplets the formation of a coherent 
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PLGA shell was unfeasible, so that these large undefined PLGA structures were built. 
The presence of such clusters in formulations MCAng03 and MCAng06 was 
confirmed by light microscopy (photomicrographs not shown).  
For all formulations only a poor encapsulation efficiency of 8 to 14 % was 
achieved. The most likely reasons seemed to be the excellent extractability of the 
hydrophilic VLP from the oily phase with water (see pages 164 - 165) enabling a fast 
leaching of the VLP from the oily microdroplets during the primary emulsification step 
during microcapsule preparation.  
Concerning the stability of AngQb during processing SE-HPLC data revealed for 
all samples in comparison to the starting material higher amounts of VLP aggregates 
and fragments (Table 5.2.13). Interestingly, for the formulations prepared with 
Resomer® RG 502 H fragmentation was the bigger issue whereas in the formulations 
prepared with Resomer® RG 503 aggregation played the major role. The reason for 
VLP aggregation can be the exposure to interfaces between organic and aqueous 
phases and / or VLP-polymer interactions during processing. A reasonable cause for 
VLP fragmentation are shear forces occurring during emulsification [Yeo et al., 2001; 
Perez et al., 2002]. It was assumed that the faster hardening of Resomer® RG 503 in 
comparison to Resomer® RG 502 H was the reason for the divergent VLP stability 
problems. On the one hand the early hardening of the PLGA shell can have led to the 
inclusion of multiple small oil droplets per microcapsule, and thus, to the formation of 
larger interfaces and a more pronounced aggregation. On the other hand due to the 
fast hardening the VLP in the oily inner cores were more protected from mechanical 
stress leading to lower amounts of VLP fragments. Additionally to the preparation 
steps alteration of VLP integrity could have also been provoked by the extraction 
procedure. However, despite several deleterious conditions during processing and 
extraction the proportions of the main peak was for all formulations still 82 – 96 % 
indicating that the major part of the encapsulated VLP remained intact.  
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Table 5.2.13:  Stability of AngQb in various microcapsule formulations, analyzed by SE-HPLC. 
Aggregates Main peak Fragments 
Formulation 
Amount [%] 
AngQb 
lyophilizate FA02 0.1 98.7 1.1 
MCAng01 1.0 82.4 16.6 
MCAng02 2.9 91.1 6.0 
MCAng03 1.5 94.2 4.3 
MCAng04 11.4 86.9 1.8 
MCAng05 9.9 87.7 2.5 
MCAng06 1.5 96.2 2.2 
 
Finally, it was concluded that with respect to highest payload and acceptable size 
distribution the formulations MCAng02 (Resomer® RG 502H) and MCAng05 
(Resomer® RG 503), prepared by applying an oil suspension / PLGA ratio of 1 : 2, 
were the most promising ones. Hence, in a next step it was investigated whether the 
preparation of these formulations is reproducible and the process to a certain extend 
upscalable.  
 
Reproducibility of microcapsule preparation and upscalability 
For the investigation of the reproducibility of the microencapsulation process the 
formulations MCAng02 and MCAng05 were prepared in triplicate with 100 mg AngQb 
lyophilizate / mineral oil suspension (weight ratio 5 : 95) and 200 mg PLGA dissolved 
in 2 mL in acetonitrile / ethyl acetate (initial batch size) as described in chapter 2. For 
upscalability testing the threefold amount e.g. 300 mg of the lyophilizate / mineral oil 
suspension and 600 mg PLGA dissolved in 6 mL acetonitrile / ethyl acetate were 
applied. Furthermore, also the threefold amount of PVA solution and water, 
respectively, was used. The resulting microcapsule formulations were examined for 
AngQb payload and size distribution. The results are summarized in Table 5.2.14. 
The data revealed that the preparation of formulation MCAng02 was reproducible 
and upscalable, only marginal differences for the loading / encapsulation efficiency 
and the size distribution were observed. Concerning the loading / encapsulation 
efficiency of formulation MCAng05 it seemed that the process was also reproducible 
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and upscalable but with respect to the size distribution strong variations between the 
different batches were noticed. This might be related to the higher viscosity of 
formulation MCAng05 in comparison to formulation MCAng02 hindering a 
reproducible, more homogeneous emulsification of the organic phase in the PVA 
solution.  
Table 5.2.14:  Investigation of reproducibility and upscalability of the manufacturing process for the 
AngQb microcapsule formulations MCAng02 and MCAng05.   
Formulation Batch code / composition 
Loading  
[µg VLP /  
100 mg MC] 
Encapsulation 
efficiency  
[% of total AngQb] 
Mean diameter / 
diameter range  
d10 – d90 [µm] 
A  
(100 mg oil susp. and 
200 mg PLGA) 
13.3 6.7 
72.7 
 
27.9 – 127.8 
B  
(100 mg oil susp. and 
200 mg PLGA) 
10.7 5.4 
73.6 
 
28.1 – 131.2 
C  
(100 mg oil susp. and 
200 mg PLGA) 
12.4 6.2 
78.4 
 
26.2 – 149.6 
MCAng02 
D  
(300 mg oil susp. and 
600 mg PLGA) 
14.2 7.1 
72.7 
 
22.8 – 129.5 
A  
(100 mg oil susp. and 
200 mg PLGA) 
21.1 10.5 
328.6 
 
39.5 – 888.9 
B  
(100 mg oil susp. and 
200 mg PLGA) 
26.7 13.4 
405.2 
 
49.4 – 1406.1 
C  
(100 mg oil susp. and 
200 mg PLGA) 
21.3 10.7 
88.4 
 
31.5 – 168.9 
MCAng05 
D  
(300 mg oil susp. and 
600 mg PLGA) 
27.4 13.7 
138.3 
 
33.8 – 332.7 
Summary and outlook 
The aim of these experiments was to investigate the feasibility of PLGA 
microcapsules with an oily inner core as enhanced controlled release system for 
AngQb. Such a system was proposed to enable on the one hand a pulsed release of 
the incorporated drug, controlled by the degradation properties of the polymer, and on 
the other hand drug protection in the oily core until release.  
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It was shown that the preparation of such microcapsules with AngQb embedded 
in the oily core was possible. Furthermore, primary experiments indicated that the 
encapsulated material remained almost stable upon processing. However, by applying 
a solid / oil1 / oil2 / water emulsion technique the loading / encapsulation efficiency has 
not turned out satisfactory, and thus, the performance of in vitro release studies was 
not feasible. The most likely reason for the poor encapsulation efficiency was 
assumed to be the leaching of the VLP from the oily droplets during the emulsification 
step of the microencapsulation process. Thus, to achieve an adequate microcapsule 
loading, enabling in vitro and in vivo studies, the application of other preparation 
methods is necessary.  
A possible approach might be the preparation of drug loaded lipidic microcores 
by spray-congealing as e.g. described by Maschke et al. [Maschke et al., 2007] which 
can subsequently be coated with PLGA. By using lipids with a melting temperature 
around 35 °C two requirements might be achieved: (1) In vivo release should be 
possible because the lipid cores are fluid at body temperature, and (2) Coating of the 
lipidic cores should be feasible by a simple oil / water emulsion technique without 
substantial loss of the incorporated drug when the coating procedure is performed e.g. 
at ambient temperature so that the lipid cores are solid, and thus, leaching of the 
incorporated drug is prevented.   
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5.3 Conclusion 
In the present work primary experiments towards the development of single dose 
formulations for VLP vaccines were described.  
First the release behavior of AngQb and QbG10p33, as model VLP, from PLGA 
and lipid based implants was examined. It was found that depending on the implant 
composition a cumulative release of 50 – 80 % VLP upon several weeks was 
possible. Lipid implants exhibited a biphasic release profile whereas for PLGA 
implants depending on the matrix composition both, triphasic and biphasic release 
profiles were achieved. Supplementary studies indicated that the stability of AngQb 
was affected by environmental conditions arising during incubation of lipid and PLGA 
based implants. In contrast it was shown that QbG10p33 was less susceptible to 
deleterious conditions associated with such devices during incubation.  
Consequently, in vivo studies were carried out with PLGA and lipid based 
QbG10p33 implants. The induction of a long-lasting antibody and / or T cell response 
was examined over a time span of 3 months. It was found that all PLGA based 
implants led to the induction of high antibody titers during the first weeks. After the 
primary activation the antibody titers leveled off for PLGA implant formulations with a 
biphasic release profile whereas long-lasting high antibody levels were obtained for a 
PLGA formulation exhibiting a triphasic release profile. Further, for all formulations a 
primary induction of the T cell response was observed but here, no long-lasting effect 
was achieved for any composition. A meaningful interpretation of the results obtained 
for the lipid implant formulation was not possible due to an altered release profile as 
compared to previous studies. However, the in vivo study performed with the 
provisional implant formulations suggests that the development of single dose VLP 
based formulations aimed for the induction of antibody-induced immunity against is 
possible. 
Next, feasibility studies with PLGA microcapsules with an oily inner core as 
enhanced controlled release system for AngQb were performed. With such a 
formulation two requirements might be achieved, stabilization of the drug in the oily 
core during incubation and pulsed release of the oily core controlled by the 
degradation properties of the PGLA shell. It was shown that the manufacture of such 
microcapsule formulation is possible by applying a solid / oil1 / oil2 / water emulsion 
 
Development of Sustained Release Systems for VLP Based Vaccines 
___________________________________________________________________________ 
 
180 
 
technique. However, with this method only poor payloads were achieved so that in 
vitro or in vivo studies could not be carried out. Consequently, further studies with 
enhanced preparation protocols need to be performed.  
In summary, it can be stated that the preparation of controlled release 
formulations for VLP enabling the induction of long-lasting antibody responses by a 
single application seems to be possible. Due to the high potential of such improved 
vaccine formulations preventing the inconvenient, frequent dosing of a liquid vaccine 
formulation further investigations in this field are worthwhile.   
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6 FINAL CONCLUSION 
 
The present work addresses the development of stable, freeze-dried formulations 
for a specific VLP based vaccine, NicQb, meeting the requirements for large scale 
clinical studies and commercial use, and in vitro as well as in vivo feasibility studies 
for single dose sustained release systems for VLP vaccines.  
 
For the development of VLP based pharmaceutical products the application of 
reliable analytical tools is of great importance. For the assessment of physical 
properties of virus-like particles up to now three main techniques, i.e. TEM, DLS and 
SE-HPLC are established. As all of these techniques have some inherent drawbacks 
there is the strong need for additional, enhanced analytical tools.  
In Chapter 3 asymmetrical flow field-flow fractionation (AF4) is introduced as a 
new, versatile analytical tool for the assessment of VLP compositions. The rational 
development of reliable AF4 methods is presented. It is shown that VLP compositions 
can be classified by AF4 into different fractions, i.e. VLP fragments, monomers, 
dimers, oligomers and aggregates. Furthermore, by coupling AF4 to UV and MALLS 
detectors accurate quantification of the specific fractions and the determination of the 
molecular weight distributions are possible. Comparative experiments revealed that 
AF4 exceeds the capabilities of DLS and SE-HPLC with regard to the analysis of the 
physical properties of VLP compositions, and thus, it can be stated that AF4 is a 
valuable analytical method for the characterization of VLP formulations.  
 
Recently, the VLP based vaccine NicQb was introduced by Cytos Biotechnology 
AG as a new drug for the treatment of nicotine addiction. For large scale clinical trials 
and commercialization the development of stable formulations enabling storage for 
prolonged periods is required. In Chapter 4 the development of stable, freeze-dried 
NicQb formulations is described. Due to the well structured study setup from pH, 
freeze-thaw, freeze-drying and finally long-term stability studies a fast progress 
towards a commercializable product was feasible.  
The primary conducted pH stability study revealed two divergent trends, for the 
preservation of chemical stability (nicotine binding and integrity of VLP shell) pH 
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values below 6.6 were favourable whereas pH values higher than 6.2 were necessary 
to prevent NicQb aggregation. Hence, as a compromise the optimum pH range was 
assessed between 6.2 and 6.6.  
In freeze-thaw studies the effect of sodium chloride, trehalose and polysorbate 20 
on the stability of NicQb was investigated. The study indicated that polysorbate 20 
prevents NicQb aggregation during freeze-thawing whereas trehalose had no 
protective effect. Sodium chloride induced NicQb aggregation but up to a sodium 
chloride concentration of 90 mM NicQb aggregation could be prevented in the 
presence of polysorbate 20.  
In the next step the development of a gentle but robust freeze-drying cycle for 
trehalose based NicQb formulations is described which is on the one hand concerning 
the process parameters easily transferable to large-scale freeze-driers, and on the 
other hand short enough (2 days) to meet the criteria for economically acceptable 
processes. The effect of polysorbate 20, trehalose, different buffer systems, sodium 
chloride and varying NicQb concentrations on the stability of NicQb during  
freeze-drying was investigated. It was found that a formulation composed of trehalose 
as lyoprotectant, polysorbate 20 as cryoprotectant and either sodium or potassium 
phosphate as buffer agents was highly beneficial to preserve the stability of NicQb 
during freeze-drying. Lyophilizates with excellent appearance, low residual moisture 
contents and high glass transition temperatures were achieved.   
The stability of NicQb in four lyophilized formulations was tested  up to six months 
at 2-8 °C, 25 °C / 60 % RH and 40 °C / 75 % RH storage temperature. Thereby, a 
formulation containing trehalose as lyoprotectant and bulking agent is compared to a 
formulation containing mannitol as bulking agent and trehalose as lyoprotectant in a 
weight ratio of 4 : 1. Additionally, the influence of potassium phosphate vs. sodium 
phosphate as buffer agents and the effect of formulation pH values of 5.8 vs. 6.2 on 
the stability of NicQb were tested. All dried formulations showed excellent appearance 
and were easily reconstituted to parenteral applicable liquids. It was shown that all 
formulations were capable of stabilizing NicQb during freeze-drying and upon storage 
at 2-8 °C and 25 °C, physical as well as chemical stability of NicQb was maintained. 
Upon storage at 40 °C a marginal increase of the amount of nicotine derivatives, 
cleaved from the VLP surface, was observed for all formulations, which was related to 
the slightly increasing residual moisture contents upon storage at 40 °C. Concerning 
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the lyophilizate morphology it was found that the trehalose based lyophilizates 
remained amorphous whereas for the formulations containing trehalose and mannitol 
an uncontrolled crystallization of mannitol was observed upon storage at 40 °C. In 
vivo experiments demonstrated that even after long-term storage at accelerated 
temperatures comparable antibody titers to the bulk material and the lyophilized 
starting material were attainable.  
In the last part the optimization of the freeze-drying process applied for the 
preparation of the mannitol / trehalose based formulations and the effect of a pure 
crystalline mannitol on the stability of NicQb is described. The experiments showed 
that by applying an annealing step complete crystallization of mannitol during the 
freeze-drying process could be achieved preventing uncontrolled crystallization of 
mannitol upon storage. Furthermore, it was found that a completely crystalline matrix 
was not capable of stabilizing NicQb during freeze-drying and upon storage.  
Finally, it was concluded that the addition of trehalose as lyoprotectant, leading to 
an amorphous matrix, and polysorbate 20, preventing NicQb aggregation was very 
beneficial for stabilizing NicQb during freeze-drying and upon storage.   
 
Vaccines typically require multiple applications to achieve the desired immune 
response. The frequent dosing is inconvenient with respect to patient’s compliance 
and treatment costs, and thus, the development of single injection formulations is 
highly desirable. In Chapter 5 primary steps towards the development of single dose 
formulations for VLP vaccines are described. For this purpose two VLP vaccines, 
AngQb and QbG10p33 were used.  
First, as provisional sustained release devices, implants composed of PLGA or 
tristearin as matrix materials, lyophilized VLP, and optionally PEG as pore forming 
substance and Mg(OH)2 as basic additive were prepared by simple compression. The 
in vitro release behavior of the two VLP vaccines from different implant compositions 
was studied. Liberation of the VLP from PLGA or lipid implants was observed for 
several weeks. For PLGA implants both, triphasic (initial burst release, lag phase, 
second release period) and biphasic (initial burst release followed a further continuous 
release period) could be achieved by variations of the matrix composition. Lipid 
implants exhibited a biphasic release profile. The cumulative release of VLP ranged 
from 50 % to 80 %, depending on the implant composition. The incomplete release 
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was ascribed for both VLP to moisture induced aggregation, occurring during implant 
incubation and adsorption to the matrix materials. In the case of AngQb PLGA 
implants VLP aggregation induced by an acidic microenvironment arising during 
matrix degradation was deemed to be a further parameter for incomplete release. 
Supplementary experiments revealed that QbG10p33 was less susceptible than 
AngQb to potentially deleterious environmental conditions developing in the matrices 
upon incubation.  
In vivo experiments were performed with PLGA and lipid based QbG10p33 
implants. It was shown that all PLGA based implant formulations induced initially high 
antibody titers. Long-lasting high antibody levels were achieved by a PLGA implant 
formulation which exhibited a triphasic release profile whereas for PLGA formulations 
with a continuous release profile the antibody titers leveled off. Concerning the 
induction of p33-specific CD8+ T cells it was found that all formulations led to a 
primary activation but no further stimulation of the specific T cells was achieved. A 
meaningful discussion of the effect of tristearin implants on antibody and T cell 
response was not possible because of an inexplicably change of the release profile as 
compared to previous in vitro studies. Finally, it was reasoned that the development of 
single dose formulation for VLP based vaccines aimed for the induction of antibody-
mediated immune response is possible.  
In the last part of this chapter basic experiments towards the preparation of an 
enhanced sustained release device, PLGA microcapsules with an oily inner core, are 
described. This formulation was supposed to protect the drug in the oily core and to 
offer, depending on the degradation behavior of PLGA applied, a pulsed release of 
the drug. In preliminary experiments it was shown that the manufacture of such 
microcapsules is feasible and that the integrity of the VLP within the microcapsules 
was almost preserved upon processing, but with the currently used solid / oil1 / oil2 / 
water emulsion only poor encapsulation efficiencies were achieved. Hence, in further 
studies alternate preparation methods e.g. formation of solid lipid cores by spray 
congealing followed by PLGA coating by oil in water emulsion, need to be evaluated.  
In conclusion, these preliminary experiments indicated that the preparation of 
single dose formulations for VLP is feasible and that with such devices a long-lasting 
antibody response can be achieved in vivo.  
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In summary, stable freeze-dried NicQb formulations possible for large scale 
clinical trials and commercialization were developed. The fast progress was promoted 
by the early establishment of AF4, as a sensitive analytical tool for the investigation of 
the physical stability of VLP. Additionally, it was shown that basically the preparation 
of sustained release systems for VLP is possible, and that with such devices  
long-lasting antibody responses can be induced. Based on these preliminary, 
promising results further studies in this field seem to be worthwhile.  
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